var title_f30_56_31616="Chicago Classification stepwise algorithm interpretation of EPT";
var content_f30_56_31616=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F86118&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F86118&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 496px\">",
"   <div class=\"ttl\">",
"    Stepwise algorithm using the Chicago Classification for the interpretation of esophageal pressure topography (EPT)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 476px; height: 500px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     IRP: integrated relaxation pressure; EGJ: esophagogastric junction; DCI: distal contractile integral; DES: distal esophageal spasm; DL: distal latency; GERD: gastroesophageal reflux disease; CFV: contractile front velocity; IBC: isobaric contour.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_56_31616=[""].join("\n");
var outline_f30_56_31616=null;
var title_f30_56_31617="Chorionic villi2";
var content_f30_56_31617=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F61424&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F61424&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Chorionic villi2",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 324px; height: 309px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAE1AUQDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwDLhSRVyxB+nFXhDbtaNK7opTquOtQSTwwq+1evXNZct0pnJKnGO9eg4XYGhaxuxeSJNynjGOlQXN2Eby873x34xVvStWtrWB42iLO+du1uTWXNiS4zIvJyQB1HtQo2eouZFG6UNIpiIJ74NOtm8vCq2GzirTpEyowXafQf1qN7UB8K2NxyCfaqlrsLmQ2SdVny6Ddjr6mnfa9xAKqWHUEdKYU82cCReB8uR3pFjCuVaTp7dKpabg2mD3HlscorFupaoJpQxXcoZs9xVmR4oyC5zjrkU7SYotR1OK3YDMhwuf5VTWlxXJ9OigvVQArDOgOAR972rS020a2uGa5iALjuox1q9rPhybTJoZV+7j5to+6cUulmJ79LbUGdnnUCInuawk7spsr+J7phbpbtb+Xx9/oGqLwbHFqz3NjcMBHt3qM5Oc+lejtodjLp6R6rEs0KgsPN4GB3JFY/hLwdDY3aTI83nmNky/Hyk5Bx/WlzJIixBZaDHaQXCyKpWQ+WQq8AH3rndXFnD4ZMVnJvtkkL9Ocg/wAq9ZXQVayvbaXLQTrghTg8j1rkNB8PLIbm0urUxWTEiKN+fl6HmpjU6gkebaTqMtsAsrOlqzYUE8N7j6ZFeiN4bm17T4Lxtq7F6bceYK6CHStFWWK0ltIZfKU4Q/wjp1/KuntJFWNY0h/clAuCOFH171EqreyGeAeIrN4FaRbOSGBCU8wrkA1hafckXCRJgh2AI7H8q+idf0dtSbyAEa0cbW7bfcV5vpngqfSPGHlPAZLIO/lOxz9Ca1jVTV2KzN6bTNOGlr5NstpJIi7EgHY9ePrzUtlptto+jOIpAwuT94jBBxWzHoV2VlbzJGk+6vtV6z0W4mUQXih12gjnGD61nKoFiHw3ZRpp6QWsRVCSzNu5YnqTUd7avZX8YRY2SQ7WyvB/2a6jTtPNsu0cYHQVYn09ZCjOqYBzkcn8q53O4ndEOnsq2iRjggZO3p9PpRcWAk/1mJUPzbccCpoVkjd0Tbt7Aipo2VmIB2uBgjtUXaBamTPA4fYhKE/xAc1UuJTbxuzqAQfwroDErfNJIOBgcVmXVusts/mgNGG6etXB33JcTnF0+C4k3XDShiMn5uDk0mq6NDNaKtuCNhyB2PtWylr5jjI2qv8Ae7CpDHIZCFfj0AzmrUragkeb6/phgCGSEOdpZQT90+1edeJo7xGTz4JFt4ydjEfqRX0NfQR7UEqbu3IrltehtZtMms0t2FwSfMmYZ3nHAHsK2p1LMZ4Y6qy4wpOOtQ3DKfmcKfZT0roJ9IlivpbcqA6sVK/3R/8AXrN1G28n93NsDA/wjtXYpqQtmUPLZwgwDnpxkU4SCCEkADnBUCrAnCwhQBj19Kr3ChowJeADlT607IbdyOVhIOBwOeRU0EqDCsNxAyQRUUkR3BQ3oatW1r9oaRYyRt5PFNiIJ2R8FhwRnA7VSkYj50wEPGKu30aRlkJG0Dj1rHnjJRfLJwOwqlYhoeb9VOC6g+hNFVPsbNy65b1FFaaCsemSJlgNylmYn8KiW2MhZXK7h0460AyFGcEsSeeOat20Yacbsl/rXJY6ynHbpGwcRfN3I7GrC26FiS3JFTFYovN3AY6Yz0qlPMquEUAgDPtS5WyGrD1hRnVWYDHFSyWJeQASLt7Cs9JRJIDlQjHOavAsclZMkdhUtMSVxDaANt3FT60zULMJEsiglV+6PU1ZDiRVbhW6ZBqC+lk4CkgUtRqJiXKi4cAhg3erNpbyQ3UFxZNsmhbcDjIJHSjYWkDIGD5wfTFWpHKsoThevA7+9bX0Cx6L4QvLrXpJrnUQN0bBWwvBJzkY/CujutCtrm886CEJcpGVV9owB7Dt9awfAYzpIiU7ZN5lZh1Jz3rv9NRXw7giRuGFcM5WYzI0+2kmtEi1R4yy5GW4X/69a1lbLGy7SPLXsOT/APqq9eWqta5AB4PvUGhqptSxUjHduDWLkwLrkGJ1QBQPWs2zQT3D7oMRrkbmHB+lbsUSywEnG8frULQKoC7SDncSDSUmBzS+HYrW7ubqEhmlOADztHU/rU2lWs6bxPKHVnLKijAUelbDKzSBY4yATye7VJHbOs4wvcVXN3AqWdvKlwGc7l3cA1qJaRvKXeNMjJ5HNWmVI2QRgZzyTTZ5Cz7gfmU/mKy577CuhqwQo25jncOg706O32KwHIHPNUrqdjLwNseMZq0s5EABVW+posxgilZAVHyn73sKG+YlUVsHuKhjeaRnix5YHzYB60QPtc8nyzz15BpCZXiV0nZX4JGQWFLFE3mFtoyRnPrWhKkbIzbvn6IfWq+0xuSdxZsfLnpTuK5GU3RH7oI5qvNCGhjUthTycVbLAlSOCXC5PNNSNXcliQQeo70Ba5WEIjJZsMCOp701lCgjjkcY7VamjKAtgMP5Vn3G7eMcEc8UrjZDcCN1CMSMHJbvmuTvcxXs28FoS2QW4NdW8eEJdvmPp3rC1SySS/hmLxrlGjYuOAuOn1raDIsctfQW0txc3FsqPPKQDn27D0rznxRZSS6k0SRsSgyxA612h0lfDokld5p5pGOBKxwiZ7ev1qTT54Lmz+23EZRNxRmI/hHeuqDKR5NcRMCFIXd1x3xToITcTKmQrEYHOc11mtadYy6uwsGLRFc/KKzCLOxAcKTPnap64rq5o2HYV/D8u5Np5zg5rM1WCXSmYQSjew5xWzLq05XajksR6dKxr+CTYHlyWHXPWlF3ZDRjKss6l2PzNmjAhjZiOMYxVy3hkdtsWc9fpWdq5aMAHaW9M81pZtiLDsE27AxBUHg9KKyPMmbG1iMcHmitfZvuB6Skhj3Jk+mR2qMSuJGySCRu3Uy4nRTIQ2Nwz0qpFdF9pK5HTGa5ItmzLlxNJKCpB2dyOoPvWfJa3Bu0yDsxwAeDWpauFfa6kORj2IrSiMcTAlctjj0/Om2Te5y3lSJcFTu3jgAjAWuh0eGNopdz7ZVHO6k1C+s5GURIXP8AEScc/wBantYt0YkKj7oPB5qHJjSMKfzTOyBSVDcDNRvFdwFw0eFU8Ek9a0rzZHvZcqxIPPStrw/qTajdz2LRW7rKDyRyOOuaHe2gMxdM0/Ur6F/ssDSFF3Pj09jWZd2uoIHkVZFdW24k+XivX/CWmzQ6Zd27DcVbaGXnHPc/StK98M22qywGdduzqB/F9azdboIwfDNprFpa2HmwMVnQSKy+mAea9JtQxAZAfMfqD0o0Y5CWirsaFdi7u4Ax+VTWttMlwd7Hy2ORx0Ncs5XYy6NrQqh+VwfzoijBTy9p2k8+xpdpG59uSvOaj+0AEKSQScZNRdAXkIhVSMHPT2qzsyFOAV5Jz1rMk25PzELnCkU95pdiQk7ZdwG7sQahiZa2hZo9rMQf0qO8uUs7aSR2G4gnk0R3W/y5FZJM8Bl6H6etVfFFsZdIuHt1V7kRMYo88Fsd6xqycYtoqnHnaRS/tlbmSNLcMzScfQdzWnA0pDBlzjgEdq5LwPJMbANeR7JhxnHT2rr7geW6MrOu9e1ZYWcpx5pbmtanGMnGI0vFJLiX8OOKq3EixKgVshe9V57xYnZCQ4AyWPeqcV2A4VlzExyC/GK6bmDOgtGxEGkfcG5Hcg0ydkjGFU5HXnNVdO3NAgdwhBPI6Gp5ojLORG2CoBJBzk1QWuTfaugKAgjP0pGmTIZs49agQ7JQkhx7+pqw7h0wFVQDxSvYbikiND5jCMnCjnIHf1q0YhEijcDnBqNHRAVQBi2MnHSpZE5wRk9aVxFOWQSb1QktnpVJlZzkkjscCtLMayZOA1V1dTuC/Lk96EMrsi7QuCTjOax9RhRlUhfu89K2rncHVl3ADg96qXA5AORnvitIuwHK65ZrdQYaMMzLjHU4rMtY0SzjhRRs+6UK/wA67J4jGzO0fmLsOAe5rmLDTniikFxMWyxZAe2a3jNJCvY8312OKDUJkDsCgIKkbR7YrjZ5CszEDhvug16X4w8MXmra3utzshEQLyHoD6Vxmv6YNOlWKJPMZRgvXXSkgM6N5BaiQqCUPJHaodT1czqsYiHuajncqoEZcJ3B4FUZHTJ+bH1raMb6oT2Ks19NAd8TsvPaozK8p3yHcW557ZrZvdIK2e5cnjcQehHqKzIoo1Ayehx9apPUhkptYn+ZVBB7k0VbUIFADBR6YzRVc7A6G3gW4d2QEjGeehpsMSRSH5QPY0+ynmti6iMPkjaPSpbjTrhI5LokEHr7e1c+zNyCSXytxJ4HOAarxpc3iv5Ify8ZxTYIZJHYODs6bT1ra0OeSwguLfy94f7rkdBRewjmo45TKolXbzjaK6/R9QtrSxkjuYGaX+Fweg9xWK8Be5aQDGTzUNxIyDC/KPXrQ3zIaOiuJ7GewkcSLvIOFPeqHhPWo9EkuBJCJjIoETEfc9c+2K54D7RjHDZwDXoHw11Wy0U6jbatZpKt68bK7IGVSueGB5xz2qaisrkvc9A+HekvDBLdvNcRxTgOsEn3WzznnkV0FzJJBMvlhSpOGA9Kw9LvJptTd4rjFtOfMjQD7gzjj1Fb8UBkuWWXlsc4/i964p6gW7Yh35Q+zL2+tXkYxMjPkgcD1ql5XkqSnU+9SGMpEsjPyecHmsQLccyuzLj7x6Vm3ww5cMCc4BxSwzhH5+ds9B6VIsBu54pEcgBsup6GhvUDCutW2wSASSGTGPk4waraTqtzNKsEkzM+MBmPKiuk1q0tZ7Z4IVjS6PVwvSuRs9LuNP1ASXABtxkkg8ketXo9Rbna2FsYbOKMLsjXpjoK1Wj8uxeZk35XisKO6DrGolUAgKqZ6rj/AAq7PLNJbiOPLIq+vSsGrl2sQWGxUcInKdqdOzzMg+UZ5waYkqWXzSITk/Mx6YqxE9u7NJE+8gcHHFCj2AzY7BY5WkmBbJyF64FQz3OlqfLd0DHgKKz/ABXrkmnRiEFhcSjg9gprz9tVgjDSStvc98c03uPlueveWBCqQyDYBzg9qtWzpGi89BgmvPNG1yO9nVYYJEkKdSeK6GO6ZlUKGC9DTbDlsa91coZC28bz19/fFaFsUKK8ibm7Cuc0+bz7kkKSwGC2PvVqRSZfO7G3rU3uJosi4YyMT0B5IGMe1Kb/AHIwAYsOhqrLdRxr1AYjv3rPNwspGSY93Q5pC5TUa4UyIuPmI5HehWSSR1bKgeg61BGQvPU4445NTxArmTHvzSRL3EkLMSgOeeDQ6eW+4jc2P4qeknzcjj6UTjz5GJBQ5ABrRMZmatcR2tm89y/lwqMk54qvBEJ40fG5HGQSMYq9c2QmiMcuGTuOoNOMQCoM4x2qlIloz72082FlXBYjBwOleba3p9p9qluZYo0tY8Zdj1PSvW2iQqSzbT0+tYWr6Pp89pJ9qiiaBTvYP0Ujv+preFToM8C8YarYoGgtY4n7FlGNtcrPHG8QAcbgcgd813vjLw1G1ve6hFAsFs25409h0b8a88ijYqGCnB5zXo0nZAy28lzJFDHNM+3B+XNDQx/KGbBFVppGGwE/Lg5ognJwCRg9M1stDI01gXAw/FFSQxlowd0Y+tFRcZ0qWzLlz0B4rVNxdT2aI0QEKnnI61z8Op7cR9WK9T0q3Bqbx4Dn5R0JrBpmti5Bb5nZsUNI/mOEXaMHJx6VROqbmPk8gdD0NOW++fhiT79KlpgVZJATuBIOM46VVkZUQu3JPbtn0q+XErE45z3HB+lSaVp91fX+2wtVnKKWkDgBFHqSaa2BM0rfwVqEmhx6taSRTk7We0RD5iKe/P4Vmlmt5SXjaMqxU71PBHscGvXfBBu49Nk+0JtvXiaGVD8uzGCmMe361z2vaY016txervt2Uxz7evGcMPf/AArONRydmDNn4fMtz4cjBY+fEG2E9euePzq9qesz2t/prR72LyPE3OM8Z/SszwsiW67rDe8UEZVVbuT61oy2X20q8qlWDhlB/hPesJvUDsXlDQQ+YQfpTluFjDDcCOnrisq1tnuYPLkcrGr5JB6ir5KmB44xkp0OOTWD1AdcLb7FGfm656E1bjgUWh8tmVm+YH0qvZ27CcyTspCjO3Geanv9Tt7OxkuZVKxoMYA5PNSxGNq+nX0mqreRyhYkXAAP32A6VXt4gxlmvWZZWHzBmz5ZPY+1ReI9QuJdIt7mCQeQxDDAww571yT3t2t9NIk43P14zkfSq2Q4xLGs3TK8sLMjPC+5XTvW7oeuubZCzmQKMFQPm/CuZSVRGfNi+U8CXYTVHTJXTUvM3EIjcYPUe4qTSx6rc6tYHTne/lEabD16+w+tYek6iZrXNu5yR/3yPeud1q9huYlh28I+8Ej2qhpt81vNHuLLFja2F4IoTFY67XbOPU7IRkEyBflftn0rg5bWJN0d7FvuY+WO3HHtXa2c6TxqYpPl6queRVXW7cu0V1GoaZflY9jRKSKRg6fazwRiSCUbT2Q4YVY+3XXnhS8q7uPmHU1qQaDqKwm6WzYqRubPAxVaKQTMqTfI6dCe1T0Hc6LT5poLZVzz2Y9OaedQS1PkzSJ5jqWJJzWFPqckaKfmDHGQoziqF5q5mlHmmHyV4JYYYVD0BK5pC8YyD98HYnO3HSrdnerLMYsbuDlhzt+tc1PMYmWZOQOACcjFGnailvdhnDLICflH3TQKSsejQEeQgjYAlf4/6VIZtyeuODisOHUwzpHGB8y9fTNbVqi7QGdi3cmhGVtScAbwcY77c9KWIkyyBh8pPGaHQtnbgHj8BSvMFiJTlugPc07gNnQlhjAx6d6iI2sWOfpS24ZXLEhj160SMTjy8YPXPrVxVwG7BKcn72Rx3FZmsbmidRhIxyRjJ/GtBlbLlQAwxk5qJFV1kDtktkEGrirageR+MdPvtWTy4mRIQCoReMD1J715zrnh260e382Vw0f3Tt6ivVfFutxWmptbWVrIyIAzDIweecVyfiTWNP1PTp7S0uQLkbW/eLtHGeOepr0aUnp2JbsjzGVMbAud+TnNJEpbbuAJHU9BUc8znhcccMT3+lSxSH5e/HNdjMmaSFgoGGP0opFnYKAoBH1orMm7NpbRlyq4/GpkhKxkffcfez0A9K3DYqsfmOuM54/rVBLUwo0hwwydxPepudSKUEcbBmQgvnn6VfsLPznEbHJZqit4wNrDaFIzgjBFTzZRSsT4HUkdamQm7jZF8i7kiUglWwCegrX07VJ4oBaIsMbTNhmUYaT0BNYlvC+Gc5YepPNK7yQzCYFFePBX5e/vULVCPYPD+p6ZqEps5LgRX8eB5b5BPrg9DUmyK41K5iVbmMRfKwkGFkH+ya4HWtJnWGz8RaMJYomRJWUjKq/ciul8P+I49VjS5uZZIApBx1Vsjr7ZrCUftIZ0lhpY02CcQf6pvmUZySav6NKksaRyD5xkt7VagwbZWAIyOncVz1pL5uvCNychsHHGa573A7SOPZJiIlVK/OfWqsUuJmUK2G6471Yvmkt9Ole1i3TOmMF+1chF4heCB0IZrhQRzUWA6ae8aFykmBGi7sZrI8QanbG3aAsrI43FcZIPY1zOqahJNDLLcu3zALt9BWHEwaLdtbAb727qfWnsVynRXl0jeHorcXIAeQuhAxuGetXdEgt3tJUuxGVk+Vm6EAe9czHcQX0P2ac+WqHapx368Gp7u6vLeNLe1lUoME9OR70NjUTRuZopZIYow8eno+35jnPvVHX7VNPvH8tgY2jDIO/1qKyN9qt9bbpA0a5zHEOBRr1x9pvZY0jZ9jCPpjZgdaV9BpWZmbjcBUcE4w2elXpmEO1HyVf1OTTLWNVgO/EhTrzTbwMsJ2EkNy3fFQ2kabsYl39jJMDuCewOa3tIubm+vIkkIWMsDtPeuZ0+FUI+Ys2eTjOK6jSZlivFYDfs+bkVmpa2ZVj0pr66NuqxupTbtK7QOK5S+0w/aHMsSuW5GDWtaapbyQrKJUKkFih61Ytr6C5QyQlGz1BHSrv0OdswF0xJbXy4/kl7A1yetac8jtbSwMcgiUY+96c16DfXMSLvXAYdcfrVG4uIry3KkqU2kqcdCO1RNLuXCTR57pjILKFAGVACpDc55wBSEeRd+SAy5OdpGRXX20FoluhaJXZuckY5+lW4rWKaaJxApdD8rkdPYVmtEXUszO0e3kZoZN20EB8A57110ZJbI4UDn0FVE0+MBdh8vGflAxU8MW0FCd4XnrVpmJYEhCgnqxx07VHuLFg38PQf1pdwAXe3ynoDSvt4EXNVYkWPBfaMgkdDSxjjrx6UzhjyMH1FKCWJ29quLsAruochh8uOlUZQ252hxuB6GrjA9T2pFCozMwDlv73aqjLURyE/hWzuYZW1KMSSs7StIhKc14Z8SrGGK+git4okt1UjdH96Q55J/SvpDVL6C1iYXMmAVySF3cfSvDPGGrWl7fkWEeduVZ5I9pI+ldmHbbE9TzY2pY5kD8d85z9Kn2iKaME8fyrYit4mkHO5MnA9DUV7GjN/Dkdq9LnIa0M55VDnzUUtnr6iikuIwZOg6UU7mdj0EyyOoUsSAOM1WkHDsxO1ucfSrr2UkUahBv46A0ltYieRkupFhjPO8jdz9K4+Y62ZxRgoleQH5c4xitDTtKudQXdbRlyP4uy/WrFtBaW0JnuS9xOhysQHyfjUWoa9dzbIrZxaRIp+WAbQfXNDbsQWE0K9t5Xjmiyyn+Bs5rJvows2ZCynPK46Guo0DxKtwI0vTGPKG1i5wW9810es6Npd9Yh4hnzFBE8JDFRjv7VHM47jH/DWa5Gjvp7qs0Sv5yI/OUPVRn3qCTwxHptzey2M6izuQXSBv+Wbegq74YtZdA09Lm/UTCLeWMZyAhPBz/Stm0WK/RVhdXjk+dXPT6VzzbuBq6a0n9lRLK2Z/KG49mOOtUbTT0a9SVX8uVSd5xncPStWARKvlEhWUdgaZp0ZJYTCJwTuQR5yfrWFwGeIJngsMR7UR+N2eQcV55I2SS7Egcls8n3rqvGL3b3EVuscqIBnG3Icn0rkLqGRcRNHKueoIxVR1LQs586IoXPyrznuPWq8SlLcZUFmGCR2+tQSTETRrKhwD8vbH1q1HGsuY2JyCeRxSkWmivAWysO3zGU8j0NWGiRbhTMxDkYxUzQrHFkZQAAFh1qJHUFnZS6r8oasxmz4WvLWwvSs42RgcslUtSng/tCQxMZAzEqR/Ws15Udy5YhcbWA7nsaaD5SykgliMrimFhSFZA2GRm+YKeg+tQXbSTMqQvglhkZ9qljsb24hMyxyNEBuOfWrvhrRJNSvWaUskKDgFec1DRSaJ7W2+zw5OAxBOPWptPVIpcx53uc8NuH51tXekzWyHy8SqnTAyRVC1sJ3vx+78nP3VIxisJpplwaJ5juP3NqjpjrUmkTNb3gZ5cIFxg9KvJZRRjBy7dyx4qnqUcKoVjUqwYDAPTNTOVtRxincg1fUGnmAidREeAAehrKvtVOm28KxjMsrfImf1NWI025xGWHTisy3tZbjxDfmRtxt0GFIyMEcfSuKdR83qaKnoURqeo6VLI4upC8nLhjuX8Aalg8X6pMctJ8gAAVRg/UVW16xnVBI6NgHGRXKxzzpIHw65PIA6Yrqpy5dGZysz27RNQFxbl2mZ3Kj5W4wfpT9RvCsqNA77Tw2OlcV4Vvg8gkMrNC2QCy42n+tdbBC8lrcFiD3GOhFauVnoYNK5q2UgkjxySDxt5q9GNp27tr+9c5pG8GIqxDHrjtW0LkFlRjkluuK33MXuXVBGc4+opMvyVGQBzSoUZm+bI7UrkLtIOCOlNaMBCQPmYFWPaqd7dJBESCqnPGeatSFpHIRQVIyWPY1yvim3vsgplx1AA7/AOFaU1d2JucP8TNcv9LNnseBvtCeYRG4bYCSAD6NxnFeXz3clxO0rnJY9jV/xxLNdaqRIXKqMAtwN3fisCLdEflGTtr1qUOSJD3LMkjfaFO4gD145oc7pQoQ57kmqsrkusefm61MqSCc5yORg+lbWJk7Im8mU/dxj3oqKRpWckNIg/n70U7MlNHpX9pRMVjKjJGQ3v6Un2uOQEyKoYVyyW88IUF2dQOGNLLIyAAvIWXliOhrldO7Ok3ruTMB/dsy9SyjjPpWJcsxuEhMbmQjO0DDZ7cVr+CNd/s3Vo3vIxcWMpIkDJuK+jD0IOPwr1ixsNP8RNDqHmxT3EfEdxH98L2BqZS9mrAeTWPh7Vb8ReXbLC8h5aYbOPx7V1Wm+DvEWj6o9zYxWzxbArwrIdsowfUflXqMmhJLAEZRJOvMfOOfX61et7OeGGMzkFlXDDb0Nc08RfRAYXhtfttuqXkL20jrtkgY7gh6YPtWr/Y8Wn3KLbIi2w4Cr6+1aQtYJiZVU78EHAx/+ur8sKy2qKp+ZOwFYSkFjDa2QXsTRZ3HghumauRQGzlIliVHKnYwHAJq3BZK0b+cCMdKZfl3iijGSoGOeprO9wKt1cCGJZCN7RAkNnkY9K85vJ7jWr95xGGlZRmNWzwK7i6wYJbSR1SRkwV/iA9apaZ4ftIWVo5C+5fvjBII+lO5V0cDdWaW9wYpR8zDIVu3tVcIibCC2AuNpPINdv430J7i0+12se+SMfvCOCF7muDuJ4wu5VXzOnuR/jSZadyS7lK4jjDMRjcvtTXwYm2EeWDwnc0y2Q26M8rkSuPkyeQPSnxuVt/MZFBxzz1qUnY0Q0yyRLg+X5f+yuePeka3M8KTb8W4PKd6hcfaFHyqoz3auv0e+0u00kvPFulYBfu5C1Sdwk7bG14Yt7eHTlS2cSpjqcnBPY1YkkKSOibQc4yuMZ+lUbHW9HtbDzVnRFCn5FYBmOewrO1HVdEuLZ5Yt6X7DfG4YqR6UnLoZqLk7s3Xn8vJdSuepU8NVNtcguMCOFuTtJYYOa5aw1ea4dbeaYuwXO9j1NPSdtxjlXc27OR/OuWrNvY0hFLcuXctzEzyCQhc/d7AVz+uavcWiJ5CO8pJLZGRXTWVhfapKqAb48dTXUeF9N8q2lju4gJtxQkY6etcvsJ1tL2R2Rr06S5mrnlWh6zJcyr56BS3PXgV1OjxJcapc3sLAwzLsIUdxWX8SfDv9n6be3FlCIY4IzsIOFOOT9OM1l/DrXXudDS2j3S3EbBcBcBQe+a5JKVGfJLU7Z044ij7WmrI7e9to7u2lhYMEcYJxwvXvXi2rpNa37QwSBuSN5PBGa9lS3ebeZZmKjtnjIrgfFVuZL+aaFAVjOAwXp6130lKaPKcVC8Srpd4YnEJ2rEoLbUGdxPWu78Maj9otRA6kKBhAeuT2rzq3kw4YbgRyWxg12Hg52knVGLNITkEjjFdUdNzne51yW4huFMWdhOM4rSiiYZJLBfcCpkAxjeg56ZqwuwDBHQ+tbIzZXhiEYOWyucj1qSb5kIHXrnNPYx5+c4HUVl6pqBto/8ARYjLK3AB6GmtWI1EDJFjOAvPHU1Su2kd32lfLHGT2rCTUL27cM2ICTtUKc5p8t5KiCG7AOf4x0NbKJmcj4w0K2ffNMgli6huA1ec32jxQXBNuMg5wCecV6b4p8u5hJJEpUYUBsAVwc1zAr7c7nBxtHT8676UmlqByjWZWfLABhxitCysjIokY8A42kcmuv0/QrW+spLqVkLHBUKckVx1+7Wt7MsMpKKSB7GtlJ9BNFO7Dx3Dqo3DPeitfTUtrm1El1MiSkkEUVfOyPZo1tQkiSEp03HO7+77YqhDBG8QKuolBzsPcfWsZJXuCSWIK85J6mtOC2fyfML5bIwcVmlbc3TudDomnRzzQxQgB2OCFB57mu702EaPFJJZwz5RgSuMMfoK3fDUenaPoNo8EEal0DPMy53E+56U6/1+3lxHb3NruJwc4OTXNKXM2rDK2keN0fU4oNTItwx+QsvQ+5rt4dY0+VkXz4ZXfJzG/Gc9D715fJZrLqDGS2t3Y9H9P8K3bfSLa6h3tFLaSZPzwPhs4xWU6aFc9CQslwoGCGGVzxxU1tKgYpIf3hJ5HSuet/Nc2u53/dIAC/8AEBWhBJ+9IbaB6iuOUUik7GxOVKFPMUKe/SqeoIYxGxw/biqk5UIiSHKsx4zjpWdq9xqElvF9h8rAYZRv4lxSiPckuUS51RnDAPIgVd2O3WqdxD9lJFkgCA/OV4rJMU+oSv5hMcsRJBUkBT9KvaZdXwO2+hfeOfZhV2J5SzBqzxSvZy7SJF3KGGcr3rzPVreWC9lSSJY2XJViOME8c+tdNf8AiGCw1MwW0iu7sSxK8AelatxJaazaN9siR14bEZG4EVJcVY83vAZ1Qt/CoU4FVricmAJIOF7j9K6nUvDd2Sz6S0lxERkRsRuHsK4rUJXt2a324lB+ZW4cfWpasap6ktt5lzIERTljheOtavjKzbRIIRFI7RzKGYHghvSsvw/LeXF/bLDCXMLgtgcg+hrc+LqqLi0EsxMpiG5B/BxUK6Vx7yscqsiu7NIItm3O0HkUsjQuFDFTyCgzWeeiyIfLYgL74qWaSGPbhyzHgYrO7Zpaz0N/RoZL28jit8qyjJYmu2Hh5oYoJ95kkUgSDuQa8vt9QuLaUGBvLcjBI6gV0vhnxTPoVwyqHuopGG9pJM49TTjy21M6ib1PWPswtYYYbFtp6lj/ACql4jcwzQz2s/lTAfP7ii48QWMdg93ccW6hW3Kc4rCl1qHU7hmWVML90ClWklHQdG7lfoaU11DqUEltq1qlxbyKUZH6Mp68VgaVonhzQ9TuLTR5ntpZFDPbCQsoAHAGfY1eYnfgdeuaw/EunRqJdQhBjvExtcHH1GO9efUlLlulex6FPS8VKyfToa97cfZrd0Qg9sVgSESQNGyHa/U015mnRW3YEqZBxjLVWu75FBhjIL4xXZQmnC5wVo2lcZ9kgiLO4YZGE9K67wjZLDbeaxGTjHHSsW2tvtFrDJhWHTaT+tdjp0BgswXCgr1AroXc55MtpaqjysyMcfdx2p0RcooQFz6elTwb8fMeD71JGgU/KpFaIyW4wqWXLgDHFVvswjl3ysAf4SPStEKDkBfzqOePcmMZPvVrTUo52WNjdjy0O3OWPpVXU4HktHj537sgsOa6SaE7N358ViapcNBnMRZz7ZxW0GKx5t4jvYbCXyF/1zAhsnhfeuILKkm/JBOQT611PxAiQ3qSLw7rznowrifKYyEBsJ2zz+Fd9HVXZlJ2NOxvTCeCc+o4pZ4lmZnzuDcnA71Wt4lWTcwOM/dJ6itIQPCokCt5Z5wtaSdnoC2uYrWo3Girlx5LSkjaM8/MeaKLsXMXILJoYiwA3cDHtWzHbu8edvy9OlZVzqluoYxr5nOOa2/Bxude1WDTrd2WN+pA4jUdSal6LmZqtzcTV86P9gSeVn2+XFEi/MfapNL0LV90cq6aAYiGHmOACO457118mg2mlXDy6daqTtyzytyCB1GfpXO6p4sTTrkRiJrmRiNpVvlwT046n2rlc7aoo7aPw5os89ndyjyrlDvljjf5WJHINXrrwdp9zI09q80C4BHlynDfhUmn2BmETzyrGxwWiWPBxjuSeDXT2223gVIk2r1x1x+NclST2BK5kx6TK8mZJWZOAEH8qs2ukrBKxVyOfuvyK0o54hEDlQM88/zqmLWZ9Sin89vKjyTEDwP/ANdZc1x2Fmt4oiHMWdmTntXG+NriS20wyacji4EgUlBkr+Fdner54kHzkkHAB+771zc1tcW6K6h7hWHLsMH8R3oRRwula5HbyyrqlwytKMiU9jVnxRrcqWiDTL4OCArSDrj2rD8QxFdUnDxmPHzgbcYPqK5u4ui5cZZs8gH1ok2aRjoEyu9wXL/vGOdzEk1Pp2oulx8rPA2QN5fCk+tVjZzvbPcl5Ngbb06H/Cs55ZYJo5md2IIO3qKycrFKDZ6VqN5rmiqs7xx6lZsgdZYAcj64rC8aiXUJNKe208/a7xgiSkj58j7uemfrU+l/FLUNKdUms7W4gIIxkq+PT0/CqHj7xPp+uaLZHS5ZbSZZPMNun3c+tVzJoErM7b4a6DdaFpE8+q2vlXTS5ZN27jsc1xHjnS7w6jd6tcyebazSYjwSdox0rf8ADnjUarp0ducC9jU+ZA52l+eCp9Kk1HWtPs/Dc8UsG+2kbOxm6uOpp8ytYUU1K7PJXmZboAKVBH3jnj0q1YxpLJ5szYXA69zVfUHBYrGxC78hSc4Hbmq8NzPZZKSKMHlOx+tYXOg07yVTv4IIO0Y7YqOCZcsu4ibnB7ciqBu1IJ2kEsS3PUH0pNv2m4IU43DIZaylLWwep6/4KDz+FmWUs4ZsAMMgDvWjb+HyrkwyxeQWAwV5zXm2j69fadZi1tLgrEeJADVYa1dJMAss8Tkld6OeBVOat7xlyu+h7dHpAGI7hlIwRheprndYmWG58maIDy+fm7r71yUXjDUsC3acfKco/RvTFdp4TY6npFzPfOZJ5EMOCBu2VLtPSJSutziPELNFZTTafF++i/fR4OQR3H5Vl2msWRhtXub3y5ZG3N+7J2Z4Irfi06b7Vs0+IvFGxQb2zn61e0XwaILiR74Rm3YgLBsU7DnPXHrxWNSnUUlybDc1azOi8MaUqRpN5qTwkboyv8VdKtqURiWBDe+cYrn2ZreONNPJgdDnPY1f0WwmtnnlkneUzyF23dOewrqVRp8phKN1c21WNVUjlevFPfoOcgck0REBfu8dqc4z90jpit07nPaw5egx1PamyZC5BxTScMu7k9M+lRTk7CNxx61ohlLU9SNvF8qls157rXie6jdlljJjOQSP0rovFReyt2uZrhIbeJdxJ5z7AeteQeIPF8DSkW0abRyM9wa7aMLiY3xdrH2+7j2qRhMbuzfSua8uTzNy5J7VFf6v9oKnywpbv2FEV2p2kliT6V3RjymTVyyGm80LJ97HX0FXtQ1QT2qRIm1wu0laxZNUVWX5SXY4wfSqD3waVucD0q+W4ttx107mXkvwMcGiomnlUkB8jqMDNFXyMWh2UdkoVIztzgfPXofhC6/4RrQry8eFofMYRwuU5kPPT+tcwlltgKAKfl5X+Va2pXst1plnbmWWQQHdljwp9MVyTd9zciN1fandSNNeTSISSVdztUk+ldDoOoW2j2j79Kt7nUMlo7l1BZD6c9BXOIGPLMvze2KsNcqi7XYn2BqGl0GeoeGtebVLy2hETNcBSbplH7tPoe9dnNOYYj1dycY6cfSvO/hfLa3D3CwoEuOrEfxDtXoF8zLHtjRWk3hwDzhMVwV/iHEbFp9tPOt0gZLnuM8fl0q9G6wo/mMQT1PepLIeYm8ReUOm2pJUXk4AI5Ge9YFWIllSLaMqrScKc9ahurdyyOXCgDBxzViFhKMuij1FFxGpTnoOaV7Dsch4j8PnVXlwmGVcKR3+teXjwXqj3N3DOog8kZTJ+99K97bfkuHO3+7jrXI+K9D1q7uI59I1K1tFwTK7xNIzHsPahO7Gro8u0/SmsJvsuqSo9jdI3myq2DHj1qrf+BLuKyuLu0vbae0TBV/N6j8utdjf6BLe2clnqE8X9qkMyhPlWU9s+1Wfhz4cms7MRaqQzwyiVEjbIHPCnNKWuhoqljxWUIfL+0DfFnnA71UupC5ZlGGU9PavQfixaGz8SSzSjyxffvdhwdvbjH0rz6WEM0gJZVVuPesW+XQ1XvaiWZkSZnJYblG3DfMPpXp/ifRY4/h3EkkplkWNWDDgkt1Bry1QzOu5d2edpP3a7e/1K0u9K0mKa5Lzx5WRFXj2JxUxna45xdjgmfaI42YkE7eTwPpRJaNKRJ8xRskgg5OPavS4/C3gjWrUQ2muvp96hzLLMQVZj0UBv6c1rL8O9Js4zNean50EUW5lV1Cscdu9NJt3b0E6iurI8d8vZEGQF0xnJ449qkspBGDJtccZGPStTUH0+fUCNPQi03HAJ/pQLCaaEmLYVOQvz4bA56elc0372jLsU4tx3/dKkZwBjNa2m6Jq16iywWUzKOV24G6sq2aVpw0pXAPIPp9a9S0jxLa2kMcVpbs7kABQ+MVVJKekmEm4q8US/Dvwgy6hJea/YkLED5MMgBVj13CuoutKuri/ItZobWwIIMUYw7fQ9q4vxb4iu9QEduqyRQqAXAYqCfTjmrVhqUiWa2ulRXFmMjzHdi4bjkA10pRhpE55uT1ZvpY2egW85gDPcyDlGfcxB74otS8qBrggN2Udqz7O2D3IlYgSsCWZgcmtS0QiVDIuP4unWpkTY0YIo1KsUJY+orRt4yWA3DafTpSRKJP3gAK44yMcVYTaG+Re3U04iHMnzbQchal2FSCMYxTAI88cknn2p3BB2nCjsa2RmxWICsTjA/WsrVLtbZPvYJ9avyvheYyfpXLeMZZhYyPbIHuFBCAjgGt4LmZCOb8fTPPoFyX5JQlVPc9sV8/xW7eYwkB3Nk5ruNUvNa1eU/2hPsjiBj8sLwK5wwOu8swBXjJ716dCPLEGZjRoiMTkA9uwqpA7K5Yv8i+hrWaLzAyEdcHjtWbLZbZcgE59K6UybELyKJBncSOajXy94dzwBj681HLBJ5xAbjr+FVZCUfDGtUtDCUnfUmmcxyFUY7eoorW0rQpL6xjuM5380VOvcd0etDiEkqAT2FJKW80bBtRjyPWqVnLczOVYAHpgnpVbVrpradkkByB1FcDuzpNoxSywHdjhuxrPmt5EJYggHqetJp2tpMm1hsAPXFbmm39iFlaaZd2CApHIpx0Aq6Hqd7pscksMjr84B2YBwOetdX8N/Fl/JrSWV8I5Eu5GZC33lYjk7vTjpXCLqCTM0dvE5DNhcDIrf0zRrxmiuHYWkSncCv3gR0IrKpGLV2NH0BHeKhw8qbgPuj1qSKRn/wBYPmPauWtJPtFrbTO0bSFBucDoKs2WsWyXAjaRUcnCBnHzH6V50otFbnSIxB9MdMUjHdnIqva3UUgXLEHpU7OoPByKhopDWx04Ue1ZOtahFpto0hSSQHKhU7njr7VfvdwtpJVONozXJSG51JZUht94GD5krlFXnp75pIY/RTNqNtcXGrosLxMQsic7VPTtVmyNpYXAgs5i52Etg7t4OeSaztb1y7tIFgtLMTxodr7OAT6DH9ah0661i2tDd3UlsUlJDW4TLRexqtxXPNviRf3Gr+IZVuYlEFtiGJghBK9ev1JrkZ7dEkZV3HA+UdT9cV3XjfxPc6lcNa2LKLRF2MVQfvD35rkRpF2NGk1aFokh87yMbwJC+OgH9a557nRTWmpiyKpkfapcuQm4jbj14qwoEMbGA7ZCMY+ldl4W8GR60GfUr5rWZceXHs5kUjJbPT2rc1P4bRTaXPNpGoSSSqDIkcirhscYyOe1RyPcbmlueVMZJHcyKjNjso6f4+9Vn3MiRq0m4vgLvJ/Pmr5iKTS2s8ckUsZOcjB//VS28ADBjCFJ9D196wle+ppFLc7XRNE0LRdOuLu7L3szQ8qx2rznoPxrKguvDMqET28tsrbhuIZjnPTPYU60sproIGkBUqcgnIYelVl0cFxbgjDttxz19K0dR9EHKras6CLTtImmU2KWkh643dj+lX5PBUZlklt7homfBQZ+4e4rA0bTJ7bCRWsjAD77RkDr2zXrGggppkLyxk+WMuSM44rWMnJao55txdrnA2ul/Yr5pL2Oe5ZCSysOoz1+teiWE9ndRxG0h2jbkBk2hT6Yovc3Sp9nUSQNzux3rQsrMooynzAD8aFFp3FJpoWLToZVPmwqWfksOuaifTohEWK5A+XJrQuCUCFWCnvVdlO4lmyO9U2rEXK8SAEgE46BSeKs4CnAPbpVeJW8w7SMdeasAdSTlqExERBAIVh81OXcRg0MwXOQOOaq3F4sah2XA64reCM2yR5kljdfmG3r2zXE+PtXOkWUU1vbGZd2JFL/AHfQ11MlyJrfzDhUUc9ua4T4gwm70i5ZHQoVwQe5rpox1EjyPV9XuZLuT5gVbnI4rHWdnYlhjB5zS3TDeUfh04wO5qGOCeSN3WMlBkkj2r046ITkWBcAnhjlugpYLuGORvtEWV28EdjWfpsf9o3HlRsAx5/LqBSatE1lMUZwewq0S3ZlTUrhWvC0TZUdapn96SzISFPHvU8cfmFtvJxyO5q5Z2DqCwz83OTXReyM2rmnokUyaegWQhckgDtRVNZXjG1GZR7UVjzC5Dv7zUrm2vmu4EUs/bbkCqdzLc6ndxSzkb2+TIXGPwrqBp0Rm+b5kzwF9amFmlooIKhmOSAPu1zc3kdBztxpElpEgCMpIypxwaz5bOWVxHywJw2eMk9s1299J9phSJpyWXkH0pujf2PA07asV885ZN4JGPTFJyEatvHpsKGG3DRC1VQCqglj7+tT6nrdxpG+O2sorycrvAmfCqM9SBz+FYWpeILI6fNDpsHl7+DIwx+IFYNtB590kksu5nxl9xyKytzbjR1kPjjVJZYRLHaRWm8b4oVOWHcZJqLQNNbXddll029t7S4gl8+KK4cksM8hfXjtUeu6PHZWlrLZO0u5dzv2B962PhxpjSi6u1mVZVcRK5wCo9vzrOcUloUeuWlu7oG3ADg4q/I+zAzisewmmhdQUBA4yT1960pSsspG44IwDXFJgKr/ACMsnzKe1Me3QQlYxgsM1KIsJjNRtKFIHocHmp2LRmDThd2zrEAjh1Y54DYPTNYHiKHZpuoW+nqDPKdjFScqSOSDXWJMYpCrLlCc1nGyVbueYEqZMfePAxTTEtzzm10RbDwlrRv3j3Q25dNkbbA/OMnufpXN2s9nf6PZQWNlqF9eRMXkZUBjRj0Xp616jbaVbXt5NdPNOxBEXlk4jP1XoelZHi3V7HQNLfR9Dhjt7kkFvKXasWTuLE9zzUOKZanKWiOV1uyjtr3SXkkkcrHvkLDaN3TaBXSJ4n0m21lJWjuDFDaqibMKpkPByO/esHSVuNT0wJPdKywsdp2gsc8n8Kke1hiiCxB3Y5BcjFQ5cruaNJqz3NDUtb0LxAslpf2/2WRxuhuVxv8AT+lck+lRxX08MKtcRrIdkgZTwO9dJp0EU8kkFxZYt5nyrrh3A6/gK2bjw5GNLeSK48wkb1OwL8v4Vlze0V2Hwu6MLTdCtZlSeYy5hJdFVsBSeoNENlHNctLAEkw3XqSff3q5YxzrZNbJKQpbO09gewPerdpp8MEheJZN4HBxgZ70lZBd9zVtUZynkqobHII4X8K2LNZHtpDKu0v8u0dDWdYxvA6vKWYn0rUjnV2KE7SPUdRVRdhS1J7OGKPKKuCO3atFAdrIOD0rNLkOdvzHvTlmb5TvxnoPSr50kZlmbEo2vhgOOOtQ+UoBGdy+9RciQsrE5609WZV/285HtTXvARlQg6EZPegn5SR1FPkXgh/vAZpityM9CMGqSJbCQq0dc3dq017jdgx8georfMhC4A+Udfas24ggLtKZAuRXRAixka+QNCvShw6Rl+DjGO/4V5/r2qb/AAu1wiPLGoBGw/f9W+netn4hPcJoF01vMfuEOPVD1/pXj1n4vn0+yFtEqSrGMKJBkY9/8K7aVNt6EvQz767M00k6RYikw2Qcj86amrzQWP2Py025JVhnPPrWRPqJmYl3IjJJ2IAME/0qOC6VMhiG4yD6V2qNrXJuXoA6OJ4l2spySO1Vr2WWe4Zi29j93vitG01S2Fi0LRsXJxnHWqqxock/Ip6ZGK0jZMmSvsQWDhZCGHzdvpWxayJJEWLHOcFR3rMCKFzG+XxjI7VNphZM5JYscU5Qe4oqxdZeTsXiirUESFOh6+tFRco7yG/MMYaRgG6YJqle6szttjLBtvbvSTLK8hbYDjgjHanNaDBkaJUyMAN6Vz8qLH2M7mSOW5BwnWovFd6l/IpsvlG3DDHWnXEyKNmcY/WmxqkqnauVPGKaaiEkjCtornAVnIx0U9DWvCJ1i3xqdo/iqxcxKiplV4/hq9pOoxJatbvENzZw2OBRKdwikanhvxY5eHTtSSN4WxGJG6ZPQH/Gux0NdIh1CVNIuo45bhsTrHJuLEHHyg/jXj1/HtmKrjnJq34Vkt7DXNOubpWNvBOrSFD8wGeSPU+1YSi5J2LPpYTR2lrHLdsSu5YxnqzHgCq8d5cyTbjHGLb+9u5B9MeteT+LfF15rMS/YobhrSOYvC4U7lCnh/8AerX8J6hNqUby3F5qAXI3oyAeYB0z/jXI6Vlcadj0cahIcAptJOBzV+2j8xgxU9Op9a5Sw/eyi4ZXKt0HpXVQTgR+XnaAcn1rCSKJjxGxKrkdBiqMsRmOWdgeuBVti8nJx0zxULg78LkjvntUNBYypRJE3BDsTkAcfjXL6z4XN3dtczwrLI5z8xx+frXdtbRpIGIw/wBetQvA/m/vMYas23cNtjhLLwu0DF2kMTA4GOg4qXUrGeSJbaJ1CsCvmY6Gus1CylMeFZwMfwjmoo7EpGhkbDY6gfMfrWVRX0NYStqctoOirp4Y3AaSSP5TkkAnvXTyuiwtHHGyxqgz9PSrltbRKFExyxPO7r+NOvoI1YMpJYHp2NKMeVWQSlzMy4tOEiK6bo1B4+UYNTrDDcB4xx5bYDCrv2fdDtDEZqxBaRpFtZgu484pxTZFyrFAqRDIzzjmkuLdUbBx04z3rQZEBCjGR0z3qC6jyo3Y4O7HaqlCyC6KkSbY12jPqPWjysyK7dh0qUyASDavammTI5H4VMI3ESJtx04AwKY/BB4/Ooi7N0QDHqarSyqZSGbHcVqn0QF7zQ+GfhjxmoJ2UEhhjb3FVJbgKCSw8tfmYnsKwLjxfosfm41C3IVSTl+a2hFvZCtc2pJnVs5O1uCPWqWrGU2z+W6Z6/N0xWHpvia21qV0sbndFGVDMo6AjINYvjO+vLaODyzLPAP3khjHOOwx6VvCN3Ymxi+LNQlks9QtY5EzLEVJHb6V4jDptzcNIsO5lQfMa9E1DxFZXkaSxjBAIKD+tcWNRuLOS6NmPkkABAI9a9KlHlRD1ObmRrfzEkO1lPYVULkgbc5HWr94JJpZJHYlj1+tUljO47mJ+grqimtTKRp6VaSsn2kIWRGyR61fu7wXJO2DYBgVV0vUZ7K1eJcNFknkUy12yyEjgvk+9CE3pobvh63tppWW5YRJ2NWLmGK3d/IIYdQRVG0ZUGRlyMc1o6TJbTXg+2sypk59KjVMEUEumUEAMMHvRXQ6laadHc4tmMisoYnbnmilzIvlXc7qWFDJx8owelVtQkWKMndvYcVbddwDF8N6VVurYSPtA6989ayTLOb1EyXW1Y12MOSR0cVUS6MA4yWX+HPQ10dzbCNlKkDA6VjahEm1l2YdmycDnNae69GIb9vSRQ0mU/2Sc81Gt+YEJ37Qp4wOtVZ4xEVQbvM6HAps4IjwVyQcA+tJ049h3ND7WJW35355OKWaV1h8xI8RkjB7A1QSPZEmflcHnnpW1p0uIBBPGstsWDcioa5XYF5nT+GNVS7062s7dcTfxZPX3z/Su1s2MYaErsiXoUAyTWLZz6Lp9tamGCAS4BYqMkVvx6hYyyHy2jj3DczOM8e1c00Wlc1dNjurdo02lk+9gd/rXR6dCscsk4DLK4Gd/wA2K5TTNSuZrhjaARWX8LOuS3uPat7SrzKbJ5cuvPzcbvYVxyRSOhjl5JkBCdmI6ik/dlmbOWas+O5cXWwfcZeHHQD3q0kwlZfIUDPQ1g0wJGiZmDDNP8rDc4JNScooUvnPXNDOFRsJ83Yk1NgGTIDG2ckqOM1RXLbvNB7Ae1XppCF+UD3qBnjQZ6+tS1cd7EXloU5+8KmWIiHdgEnjaw60+LbIp4UCklYhkRTle59KWi3Dcjhzvw+OOgFPYqMOcDPbHX2pjyqg2ggEc5qjLKyyffDHHArN6P3SlEsTzl8DAGOMelRMcgq5PrSR/wCsWPgk85qSTB3BsfL096qKb1JY2NFZgzMFPUk8imbOvzZx/FT41yOvBOODUSgLOxbJGfve1WoPoIjmXGM8k5rIupJYIc4Lgttyoztq5d30TTFYs7BwXx3qlc7iI3U5jHGF7574rWNMDm/EV/b3enTWzzPsZdr7DjH+FfP3iPS1iu5/sF8rxKDkZwWz/npXu2r3Fq6MktlEQxIZtgwf/r1zqfD/AMO65BJcvatp94wcpLDMwXdjhmU9h1rrpR5VYDxltcmsdTsLvSop7I20EUTKz5EjL1bHfn1rZm8d+Ib2C5d5QQUMe7bgqM9sVyeqm5h1W6tNQJE9nI0EnbkcZpE1Bo9PMOATnhz1xXfGlGyZk2X7SdvKAAK9/fmtPSmsmguDdALJj5Qe9c7Y3saqo6n1/wAatNMDkrj5s5J6VrbXQCKRRJNIsa4Vjj3NR/ZSqO2AB2WmRSbWYqFA28Y71IbgvAoPscelbRMJMqrFuUBQRzzUsELoRJjgZGM1YiuEB+bbknGcVasbd9QuVtbc/MQSzDkj8KJE2bIrNm8tju2gdzV223R5Y4NVJYDYXXlnJBGTnrTDcu4IRgBngmla5rzKxsR3IYZ3kc9hRXOi6lUsB60U/ZIm8j2U3yI2WyccN9fale/UkAAgeprGludqt5g+cjHHQ1VufMCh8lmzyu7tXPys2ukdAxE+AnXGeeuKqyWqtJtCs3G7GcHP1qhBqAjGRwTxk9anfUA4GCOORRaxTabGS27PGpZvm3ZPGD9DTZdCeS2E6u2R93nqaX7XsILkuSepq8l9ttQgPD5wpP54pOQuUxLbTXEimbcxdsAV0Uun/YbcSEggkfLnpUMrKFWRTkLjG3t9aga4+1XMMMx2RscZLVDdx2Q2W9G0jOGz2qTTr26nnhWJ3dWfZtjySPrUXiDTYLO+hS1naRXxu5zjitfQ9R0/SY3ZgDPjnjrUPYux6Y8wstGgG4FtvJJxVTRLsPqT3I3vFIAFGehrmbq51fVbW3Vjb22lzRmTzDhsc/4V1WlW9qRHPZSF7cDC7DkEiuZoV7M3tU1CUQC2gUjzAAMdqv8Ah6eZY5GuEKsr7Rk5wKwr6SSNVYISp6E9RVex8R29lK6NMk0xwWVfm68VzTiy9LHoE9zHGkeG3MTwcdaS4mLJgyKeeorPtlMsu7d8pAZAewx2p92r+WCEwc85rB6biWpOlyilgTl8VLBIpVtyhhnGKxJkd5I2UggjnHByO1W4CUhDfMp27iD9ax59S3Y1opwFf5ULKcAGql1f24YfvEW4Iwsecc+tUZrpVR3LdRu3d/yqubiBwjlPnIyHIo52CjqSXEkkhQSEeYh+cg8Ypwnit7Z5rg7VX+Ic1myXYNwdtT3kYu7ZUeV1jcchcVFNty1NJWQWV6bmRWjOATnk9RWpLG3kuzHJ7Y7Cufhg+yX0ZiDPCRgN02n3qPXvF9hoN3aQalcpCbsER5HHHXntW8FZWMWzWtn8gbHyMHu2evSpLxsFkLfL6g1iQXguY4Zo2EkL4YOOQwNWNYuVjVIxhQSGYjqa2j2JaKz3BDPH5eFHORXnvxU1+bStKjexlcF5U3SI2GT/ADiu3knMiM7OBtGML3+teS/ESVbqJ7UxeXICWWRjnefTntzXRTgETYsPG2m3FlHc6uky3SfMRCm4SjHB9M1j+J/ifDDamXw9b+Zaxgw30N0vlThm+4VIOCvBz+FeT6HfXNlcS2tyxYZOMj9KTxQ6fbY5BjAycfU10xgD3KmqXNxqep3F5dgedcS+Y5XpzVeZAvmFQ2en3utBlxnY2FIJ+hqtn5uQMevrXVCWljGSNvw21nG05um/ffwbunTvVWKcEyMqjyiTsNQWsS4BY9+KsGL5SRjb71aJbLkEKmJSCvJweeakNoHDbOoHOOarW0giX1bNalpcRbCXIGTj6VqtFcViHTLOMRv5zgN1HHWm2drNBdiW3kZDk98E1tLBEsG4fN3wKv6Jp9ndafNPPOFkQHCDrUuQ+U56e3eQM8jAnp15xTII0PyccVLPNEjssbljkjmoFdY25UsO2K0RNh4trbJySDn0opgnUdSufcUVoFjtp4nj4TLJJztI70lpYPfXLhiEPr61c+05AcjLKMge1QfaQZx5XytjHTp71yamjMzU7aS3uGjQmQKe3SpbZJSu14tqkZGa0olSVmLfLyWJ3Z3Ut5MkQBSIbsDDZzgHtSd2JKxjXUpiXCnr0xTbF5HjYuA657jpSzKZHYMwUKcg+tJCxiIAXlfvMv8AFU8rL5jVadhANuTzg57VastInvrQTx4GwMcntxWQ1+JIzGowDwTinf2rdQRvGjMqN1A70vZtjuSO0kRBB5XJyfWsyS+LuRISQeuRVs3LSJtQ7Qwwxx0rNu1Ebbm+Y9scZqOXdFc2hajurgWYgWSVIuyb/lP4VseGvFGq6ZGLayY8ttXJ4H0rknvgZExHgZwTnpW14Wmgl1WOO8bZEnOT69awlBoF72p6brOpahFpyRC8ke4PzE9+aueCvDsCXTSJdicnBI7rnkg+tULgWyu13LcRiIxgpk8geoHpUGg6/Jo+knVBNGXaUjJTgjBArGUR2PT5vEmi2l8Le61C2iuUBXZI2CMVY/tuO6WE28infkjnOVFfP9pqsep+Jhd3m55bmQux7ZPt2q7Nrl9beJooLHy8hjEu88LmsZU7lJHvEkyKyHcobORk8j3qW+uzBboVZiASWPYrWNptk88SzXjM1wAFOOmfWrWqxtc6XNFHPIm8FV28EGsPZWC9xbe8tL+3+0WkyTRSd4+fauH1Txl/Z/xBstBD20MD/JM82Q2WA2bfqSBWxDC+jabGkalptpwg/iavmzxFrd7rurz6leylJ2fKMAAU2n5cfTAp+zsjanqz6mW0uBKQT847dq0NzxW4MuC4+79PSuF+Ffjx/E2jS/2hCy3tgESWUY2yZBAP14rpby6kuJQEO0Dpg9amnT1uZyepvQO0sTbSpJGMH868y+LWnrrui2zzW266spTL9z/lmeG5/Kuxk1MaVY3N3clVhgjMj5OM4BwPxPFfLeq/EvXNR8RR3er3cwjjPlGKEBFWHn5COjcN1PpW6hYSVze8Q3eq+Cbazv8ARtXuY7aYAG280smTyMKen4VUX42+Il2i6trG4fu+wjPoKyp/GFnrunywavAIthDxLngkdhXCGWBL8kKfKEgPB5I71rGC6jm+x6v4i+NN3cacsWnaZ9hvmYeZI0u9QAckAYHBrl/FPxQ1nxDpJsLmC0jiYAlokw2RjHNc74nurG5mj+wxbIwMj1A96yERSu4g+gxxWnJpoQzUs7if7QspbzG5I7ZrrGksdR8Phpji8Bb5cVwkEjxbirE5wAB2rXtZ2RPvbvqK0jFolu6CKxcfO2ScYxmpltdoHmg7eSDSRzSSTEk8mrG+WUYXlxwBXXBHNKWpXgUJAS55/n7VZVhIG2njAIHpQLWSRWLLk5wB71BJDJCPu7Gzj8K6FEnmsPdWUEhck+9bdiLNdKLyYM2csCelY8f3d4XBPY02QblwCQw5Pp+VJxdx8xpWd0RPsLkKx6jsK0rgqwP2Z8b0IYKe3vWPpMKT3axzuUU9T7VYuwltdMIpFZTx0pON2UpdyzFahAWILE9c9qiOEJGME+tSR3G8bgSPftVdt5V3X5z12kVUbg/IruoZict+Aopd7LjEjDPJA7GitiOaXY9JuLSKFP3YAyfmbfwKqKiHywq8bTzn8qhaeW6GCu1GPUdxWlplvFHdRiRhtYE5YgLWOqWprcQeXEzMABv7noKoXSea+dpKDhtnek8Q3MS3RFu4Zf0qCxuiMYPz4wQOlRdoalcnW3HlgHeFHrVny4/K8teQTniql24cABmJJ5A7VqWExsolE8G5myA/t71Emy7eRnSwLtG3CnOMCnTmEIu0cnjB9akuYfkdlJDMcgCs+6QpMgc/vcfw9KncZowpHFg4U8ZxVHVHiaIthSenHY1Ayzb2I6kYHPB/wrOktriWdlAb5eNo71m1ZiepmtJHv2spXHGa0rEqGRgJJNuNxHQVVayO90ccjkn0rW0O/g0i2nFzbmQuQc8ZAH1pPYqLtoXNb1Maj9ljQAQx/KuDz9KlivxBosllKPMVj8mTgJiudtZzO7HON7lsACrN/IIo8vkhOVH+NYyRaKct2YZRJHMVKHdweRivV9BgsZLGz1jUVVLsoHUseM9jivHbOxuNQvbNY4iUmkCs4Xrk16L8QfP0zQ4oGUpGjLHEwbHSsld7jOw8CeMLqbxJqUOpy+f5rDyVzt3AdlFWLn4gSQeMJdMuYtlt9oNsiIdxzjOTXil/eLLFaXllM0V9B1kDbSD6j3FaWkvFB4i0u9uLxp7l5/MaSU7zI5HU1LSKSR7p4g1ux0+ykury7jVcbVyQM8cDr1r5W1PUobrVbuWFfKtmlZoo8dBngVueL1B8RagGcyxmQlRu49c1yk0IJwDlhz9KzbRa02PU/g/4n07S7XXF1C7+yxYSYgrkuORtVQMs2T0r3bRprG4tIp1EkAdA6iddrYPPzDtXxxo16lhqtncRjeIJg7bujDIJGe9ew+KPjrbGze38M6VNDO6Y+0Xm07D3wo6/UmiO9iJROi/aO1iG38KWmkW1yUlu7hZJUU/fjUcg+2cflXzdcKqjmReM5I5A9qm1bV73VbyW91C5e4uJPmLOf5DsPaqNvPB9rga4y0IbLADp+HetUmK/KVp5CS2DkfnTbdhznGfer3iGWxe6B00ERFRke9ZIzVIzctbk8jc9T7E1ZicEYbFWPDVra3epRxX5CwlW5zjpUd9DCl9stnBixwR3qorUG9BBtwcDocginwyAZCluepxTEQDgE89c1YhRFRudxx2rdJEblm0kDHBOfeteKVOEC/N1HbBFUF0i6tbMXjRhYjyGNPgmUAMy5y2a3hqZSVja03UEguVk8veF5KkZyaZ4gvo9SmDxIIvbGKi/s+VLVbjkIecimYUJnduPTkdK6IrqQ30KyhvLwGG4c5NQSOWGEGecVam+UfyqKKNDIzEc56VSYp6WsNjlIHOcg9RTRIxjZlb5wcZb0qwqhcljgntSxxJIhH3SRQkQ2yO0lZGYAn3rotHsftt0E80IMZyaw4fkAGMtnNa1rPhSEJVh74xUtNPQuDIdSsWt7jy1fOBzgd6KjnlUyne4Dd+TRS981ujuVhWAbYiDcDjdniqd04wsce3ceOe9dDHoGpFYm/s2+VJSDHIIjiQnoAfepdS8P3ml3CLqNjNBNInmIrryQT/9ap9rF6XHKLt5HHSWDE7Sv8OcZ6U4WjgqVUgYxx1rrrjwzqsFpBqFxp9wtlM+yOYj7x7DHXnBxVqHw5rHmwxnR7uN5pFjj86MplmBIBJ+lRKpFdQhBt6HKQQsk0ZkUsR/Biur1S9tpbKHy4wsie1Utb0zVdJmEF9ptzBI7DG5eD9D0qTV/Dl+LbTZLWeG/ubpWZ7WHIa2AGRkng56VKlzK5b2Mq7mEnmKByDjj0rMngdQJfmZW4APY+9dba/D7xX9lu7+5tbaxjtkErpdTqpYYzlcZB4+lS2/gnxXe20Tw6R5kc6+ZCxmjAkHqPm6Y55o9pHa4WucTK7RgM2fLPB+v+FXdF1eKxvZZ5IxKTwBjgGr0HgPxXrzXH9j6YZlhk8iXM8aBHzz1bOKZd+FbPQ/DV5Lf6gqeIIbvyRZxyB1CDGWJHf0rCpUilds1hCUpcsFdmLdzG81CWZkCqzZGBWbqVvLIFCj5tx3ZrrdL8J63qpuf7Jt7e8a3iM0mydQdo4PLYGfakm8DeIjoSaxcJp62TrG6Rfa1M0ivjBCjvz0zn2qYyQn1ucVp9qwDybW+Toe1Q6hJIMxlgeM46/hXUeMdOfRJY7ByY9SAUtbOMFQwyM9ulZM/gjxRceHm1lLCJtOWTy2mFzHnOcY25z+NRKabsmXOjKlBSkt9ilo2uaxZbI7W5URR8qrRKeT70mr6rqesPu1K6lmAwEQngY7getbXhj4feJdQ0uW/ttND2iZVC06BpTnGEUnJOazrnQNbTW10j7GFvmlEAiZwpLE4xnp171hKfJrJijCU9IrYwJI5NhCk7RxtI5P1NW/DayS6zEHJxCd5PoBXZ6d8LfE11fFNVitdIsbefyLm7mukZYu/QElvw/HFVLn4X+MIdSvF0q3jns9jyw3T3EcIuIVbbvALcZ64NOVm7sVmjidZ1EzateSRyNt3Eqcc1jzTOI2kw2TxzxWpLo11uZvLQlQNxMq/wBK1vD3h/TbiZYdf1WPTg5I8/y2mCAf7I/xrNTjLVFzpypu0lY4VrmQElTgencU2WYkAMMnrXceJPhzeaPFa3Q1PSr20uQTE8E5LqvbeuBtJ9Oabp3w1vdWi0prXWdESa9leF4bi58o2xXOC/B4OOo7kVXNFOxKpzknJLRHAO+T6U0k11lz4F1KDxDd6OLiwkntnZGkjnBjbHdWOM0l74G1extrOe+SKCG8Gbdy4IlAODjHp3q7O1yIpydkcnjJpyox6fXrXX6f4A1K+0m/1GC4sfIsgplR5gshBOMqvcVv3Hg7wrLqk0dp4kmgtEtFMcl1asXkuiOYyo6J/tUoSUldO4VKU6cuWaszzhI5JJAqjLN2759Kvz6VdWjx/bITDvGQG/lXplr8H9QsJBep4o8KGCBz85vCckY4xt9TgVffw0vijw/FqV5rNlHqdxefYrOyRsAv3Mh/gGOc81pCajJRYeym4c6Wh5KYFEmMOMjjnOa2ZtDuodPWd49sbDkdx/8AXr0/SfBHhvwreadP4o1iy1WRllW6sYVJSN9pCMHB55wegrA1uFZtAtZP7SWW8Zys1vtP7tB907u5IFbqau2xQpznLlitTnZtSvrnTY7CVwYUUbdq4OB2JrNji8sEuTj0rotJ0SW4vLeH7RbxeadokkfagHqTWlp/gu/1ePVHt7vTIxYJvYTT7TN14j4+b9K6aUoWu2YTjKMmpdDGstRlksPs5xsT5ckdc1Zls7ddKEnmAyHJIB6U7SNDM+rWlpcana6fDO+xriYFo0OM849+PxrpJvhrdfa7i1Pibw8vk2/2jzPtJxKcn5FGPvfypQrU5S5b7FTpTpxUmtzgkQFc87R0NSbAoBGcY7nvV6y0qaYxxtNGqtkN83SmXOnmS7EFrIo64JPBx71tUrU6drvcmnQq1k3FXtqUIjh8EZJ6CrFvt80BkAx1zTv7Ln3HM8KsvXc/+c1qyeFLtvCp1o6jphXzvKFosx889fmC45XinzRfUyal2MyVYmViowc/L9KpSTlGwhrXm0r7JLFDHfWs8rQ+YTGSQM9smn2+gT3TbogroOGx2ohWjK9maVqFSm1zK1zBBzkkBie9Fb0mjRI7LuUYOOaKftEY8kj03xf4k1e50SzQ38yx6fOkkAU4IYZwc+1bepa1e6yttcX8xklESgsfpn8OtFFeNQSliqifQ+px1OKwVFpau5S1LxBqIt4NMNw5t4HWRfmPUHIql428Ya7rFnbCfUZ44xMsoWNsYbHHPtRRTzFKFFuJhkcIzxUVJX3/ACMjVvE+sazZwJqV/NMsIOwE8DtWZNPKJQEkZeSByTjmiiuukv3cfQ4Knxv1J9d1W/1HTfLvLuaSJCkewscEA8A1dj1rUzDbRrf3KCzBWHbIRtB6j9BRRXDBt4po9PGRSwdNpdTOt9a1G1edbW8mhYspZlbljnv61mahK93BvnO5t249snNFFXjtKLt5GmQxUsXZ9jQ03V73TopFspTGsqbHGM5H40XiyWtvavFcT8FJgC+QGX7p/DHHpRRV0EvZr0PPxjtVkl3KfiHxJqGsrbJqLpOYlZ/MZQXYn1bqabYC5k0OeNLyaO33j90vTI5BzRRXHhkvazPazR2w1G39aFCw1XUoBEsOo3ipauXhUTNtQ5zwM+vNS3N5cXV6L64ld7uV2cy5wd3qPfiiissdpTXqRk8VKVS/b/IbPPcXKXC3FxLIshDyAsfnNK2tagVhRrydhFD5SAucBc9AKKK6pL3PkeTOTVVW7mdqIAUOO7AEEdaxGkZ5ZFOMY9PeiiuTBr3X6nfmr/fL0X5Ggmo3ElsLd3LRxHCg8gVJqJMKpPESsocMHB5Bx1oooxGlWNi8I2sPUSM9p289pCWZ853Mctk9TnrTzcSzT2/nSPJ5TKqbmJCjIPH50UV1y/hs8zDO2Ij6ljUpXg8vyjtWUbWHqBVd9RknsrW1McSrAXO5VAZ9xycnqelFFYYJfujpzqTWLfoiTTXaS4CSMWRlJI96nkL+bG6SMhWMkYPvRRRL/eInRSk/7Lk/MZbSu2ZCeW+Yj1NWbWQyRS5HHbnoc0UV3Y1WpOxw5NJyxkU/60H+cyMRHlcnB5roLWO2bwbfXbwsbyO4Eay+YQNn90jvRRWuFV6MbnNjvdxE7dzny7SKpbG4P1A69DTY53jkdVJGc8g470UVjhF/tEz0cxk3h6KZLY3DW8yOgG5eeehNSXMgbWDhcBoy+AcYOKKKnH7wM8sbhGry/wApVkysisTkE42/jW74oktn1yZ9Ps47G3ZVP2eNiVDbRkjPTNFFejTXuI8WU5cz1L3w88MQeKdZvILi4lt1gsnnUxgEkqQMHPaqOgXckEzwrjY/yEf1ooriwWvtL9z1Mzm7w9C1d2cTXDbwSfXpRRRXZY8vnl3P/9k=);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Errol R Norwitz, MD, PhD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_56_31617=[""].join("\n");
var outline_f30_56_31617=null;
var title_f30_56_31618="Pyoderma gangrenosum 2";
var content_f30_56_31618=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ALLRG%2F55967&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ALLRG%2F55967&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Bullous pyoderma gangrenosum",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 264px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Three large hemorrhagic bullae on the dorsum of the hand and fingers. The bulla on the index finger has ruptured, resulting in a large erosion with an irregular, raised, pustular border and a purulent hemorrhagic exudate.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Fitzpatrick TB, Johnson RA, Wolff K, et al. Color atlas and synopsis of clinical dermatology, 3rd ed, McGraw-Hill, New York 1997. Copyright &copy; 1997 McGraw-Hill.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_56_31618=[""].join("\n");
var outline_f30_56_31618=null;
var title_f30_56_31619="Digoxin immune Fab: Patient drug information";
var content_f30_56_31619=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Digoxin immune Fab: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/15/27895?source=see_link\">",
"     see \"Digoxin immune Fab: Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?1/11/1207?source=see_link\">",
"     see \"Digoxin immune Fab: Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F160237\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      DigiFab&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F160238\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      DigiFab&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10205400\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2749559",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat digoxin overdose.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10205337\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2749558",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to digoxin immune Fab, sheep products, or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10205340\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697282",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have kidney disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10205341\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698217",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of low potassium levels like muscle pain or weakness, muscle cramps, or a heartbeat that does not feel normal.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698296",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Pain and irritation where this drug goes into the body.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697859",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Allergic side effects may rarely happen.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10205343\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698640",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Trouble breathing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699024",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad dizziness.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698655",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       A fast heartbeat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699050",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad swelling or pain of hands or feet.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699062",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       A big weight gain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10205339\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695989",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is given as a shot into a vein over a period of time.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10205344\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699596",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug will be given to you in a hospital or doctor's office. You will not store it at home.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10205345\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 15551 Version 32.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-202.43.93.2-77D3A94D3A-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_56_31619=[""].join("\n");
var outline_f30_56_31619=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F160237\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F160238\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10205400\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10205337\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10205340\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10205341\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10205343\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10205339\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10205344\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10205345\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?27/15/27895?source=related_link\">",
"      Digoxin immune Fab: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?1/11/1207?source=related_link\">",
"      Digoxin immune Fab: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f30_56_31620="Grade IV HTN retinopathy I";
var content_f30_56_31620=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F78225%7ENEPH%2F57183&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F78225%7ENEPH%2F57183&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Grade IV hypertensive retinopathy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 385px; height: 307px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Retinal examination in a patient with papilledema due to malignant hypertension. There is blurring of the margins of the optic disc, distension of the retinal veins, two cotton wool spots inferior to the disc, and a flame-shaped hemorrhage at a venous bifurcation (arrow).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced by permission from: Gallasch G, Ritz E, Nephrol Dial Transplant 1997; 12:1518.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Grade IV hypertensive retinopathy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 397px; height: 334px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAFOAY0DASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD5UooooAKUYxyTSUUAFFFFABRS9iMfjSUAFLSUUAFFFFABRRRQAUUUtACUppKKACiirumaVqGqzeVpllc3cn92CIuR9cUbAUqK9I0b4M+MtSwZbCKwjIzuu5Qp/wC+Rk/mK7bSv2eXJB1XxBGvHKW0BPP+8T/SueeKow3kaxozlsjwGlr6ktPgN4TgiXz7rU7l+5aVVH5BarTfCbwhZvtfT7iUryd1y/zD8DWP9oUelzelgatTY+Y6K+uLL4aeBpI9yaEhQrwWmc/ruqy/wp8CzIA2hqh9VnkX/wBmqP7Tpdn/AF8xywNSOjPj6ivra6+CPgiYN5VpeW56Dy7pjj/vrNYV7+z1oMgP2HW9Qhb0kVHA/ICqjmVB7u3yMnhaiPmaivbdW/Z/1SB2XTtasrg8lRMjRfhxmuQ1j4SeM9LyzaS1zGBnfausg/Lr+lbxxVGe0kTKhUjujgaKs3tldWMxhvbaa3lHVJUKH8jVaujcxasFFFFABRRRQAUUtJQAUUUUAFFFLQAlFFFABRRRQAvGO+fpSUUvagBKKKKACiiigAooooAKKKKAFpKKKACiiigAooooAKKKKACipIY3mlSKFGkkc7VVRksfQCvVvAvwZ1PV3W48RO2mWnXysZmcfTov48+1RUqxpq8mXCnKbtFHlVvFNPKsVukkkrcKiAkn2AFej+F/g54i1gLJf+VpNuRkG5yXI9lH9SK9/wDDXhPQ/DCmPRdPiicgZuH+aVvqxrRYu07MeT1rzKuYt6U1Y9Kll6SvUZw/h74R+FtFEUt1C+q3CkFmuT8n02DjH1zXo9rHBZRiGxghtoQOEiQIB+AqlIp+zuCTyvA+hqYggIdxyR05rz6lSdT4nc6o04RXuonMzdW3HPXvVmCXczDiqWPk2nJwOuKegwh6k45NYGkoplxnO3ngjNZ+sQmSAyw48xOR704MxOGJySetL8x784wRjFNXQQfI00YmlXKwXATkJLkjdxtb0rpUz154rktWtmhuC0ZK+Zxj0b1rp9FP2qBC7fPs5x6irlHm1R0YmS5VURc8xOSCOOop0LfMSPypGspBvYcEAUEFY8sdhB+77VDptanCpxew+aJSme/vVRLhmOxgQyj16ipQ5kVhngDOc1Uu28kIU+YEc+9S1cuDvoLfWllqMBh1G0trqE8lZowwrzzxJ8GvCmrqz2EculXBHDQnKZ/3T/TFd9vYYz0K+lKr/PtJJJAINaU6tSl8DsOVGE9Gj5l8V/BjxJou+WwWPVbVed1vw4Huh/pmvNbiCa2maK5ikhlU4ZJFKsPqDX3OQVbg+5Fct468L6R4htN2p6fG8o4WVRtkUf7w5r0qGZtu1RfNHLPLlL4HY+PKK9X8T/B7ULdZrnw9KL6BefJbAlH9DXl11bTWlw8F1E8MyHDI64Kn3FepTqwqK8Hc82rQnRdpohooorQyCiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKAFFdR4H8Eat4wvDHp8YjtUP726kGI4x/U+wrrvhl8Kp9cVNT8QCS10z70cXSSf/4lffqa9+s7WGwtEtdPiit7SIBUijXCgD6VwYnGqn7sNWd2Hwcp+9NaGF4J8AaJ4MhS4s4xeajtAe7mHzA99o/hFdbEwaZpAQd3IqrmTO5SOeDVi2jmWTClRx6V486kpu8ndnqKmoKyWwXBWNh0BY8UsX3yOMU542PEm05wR2qEJJv2lMLnJasrmqldEsjqI414wWwQKldgepyM8YqtMjKI3ZcqGGcVMoJ25Q+nPP0pNoht2RYULjOO3akVAeQ3ammNgo2gjAPFJCGYZAOAMHNK5N3uTtwucD1p643EcepqtnCkeWRninj5ZPukZ5NTcWpU1mHzEAGOucH86vaKBbEF+ARnpxVWRxIrbkbAyBkVBDPtgS33O0jPhVx0BNXGTsayTlDkO5gKSR9jmmT2wlU8fTii0gKqAwYYFWY02lOuTnNdShdanj8/LLQwbmHyFPyDk1Su4d5iVFAUYrpLuFXL7h2+WsK/kWDcOjAjFYThyK510avM9EU5owmVx07DvVUcMPUjAp6Ss5Yk/LkZIpMfdxnjOOaxVzui7bgsoVcN+RqOdw0bBkO3byAM02RMjLNxn8qrtO5kC5yMYBxVpFXvqjN2tY3pww+Y5/wqt4t8I6P4wswup26faQvyXMYxIn49/oas6kpa6jMjDepH5ZrXsGUoy8hgeuMZrbnlC04uzHWjGaXN1R8t/ED4bar4Skadf9N0wn5bmNeVH+0O316VwlfbMuMSC4Tep+TY3IYV418QfhC08E2q+F4wJBlpbEf+yf4V62Gxyl7tTfuePiMC4rnht2PC6KfJG8UjJKjI6nDKwwQfcUyvRPNCiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigBQCSABkmvevhL8K44I4Nc8VQlpTh7exccAHkNIPX0Hbv7RfBz4biCOLxB4igHmMA9nbOPu/9NHHr6D8fp7On7wneQWNeTjcb/wAu6b9Werg8HtUqIZOQzHywQoOAAOB7VEgYS5GQO49asPEVG7p2OaauSwbPTjNeXdHrXdhqs5QGM7Gz0PPGasRz7G4Pyjqehpy2x+Vwy1A9uWLgEgPz+NZyaFfmNCVt0g29MdMUkbfK/BPTqKRBtRNxwSMYFNjVgWC4+9U3MbOxLIivATnOD0HNPh2yAupBUjP0psanvx83FS28WwyRoRj730qbkuTtqKXU5PI/HrTVIXd8px60yVGALMQOMYFMQspYLyCMc1N0JXJWlQJjK7h15oUp8zoCcjsKiKHsAB71NGrKuOM44ApXKEaNmTKkD19RWXobZ1whh0bBz2reRj5RLLyAM/8A6q5PRJHn8RTMMgF8kfQ1tCxrScpU56dD1OJxgAtnPvUvmLwM1ljfvXahILcnPSntvD8r/Fn8K6lPQ8TlL0rL5bHt61yV+BNO+4nZnPpmuicnywSPlyeK5q8/1u2MDG4k+1Y1mm9zqwl02RhMk44HYCmq4dVJI44wKcjiOAhlww9KxZd75Mv7sds1ilc9GEXLc05wAWyBtx061ScqewAA6mqpNyJGMbLJHzx3/CqssV/NkKqqrDg1ag+5vCC2bJ4T9rvyxyyRnG4HitoDao3D6YrN0y0+xqVBy/DN7mrksq4Jxz3qnvZBNqcrR2QTAbWLnGPWsybVT92BTuHGRT7iNrrqTsBPAp8VmiL8qZ+tWkuoPlgve1Z5h8QfAC+KI5r6xhjg1Yc/LwJuOh9+OtfP97az2V3LbXcTwzxNteNxgqfQ19pSQhXVlAHfjtXnvxV8BweJrJr2wVI9aiGd3adR/Cff0NelhMZytQnseZjcIqv7ymtT5ooqW4hkt5nhnRo5UJVlYYII7VFXrnh7BRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFetfBXwCNXnGu6vGf7Pgb/R4iP9fIO5/2R+p+lcd8O/Cc/i/xDHZRkx2sf7y5mA+4mf5noP8A61fVdpDBZ28FtZxrFb2yCKJB0VR0rz8difZrkjuz0MDhnUlzvZEcs8jPnA4OCDUsTFcnkduavwwx3Y6Dd/Okl0nBG2QqM9K8V2se1zrZ6FZrgyFYyuWPWpoWxhSpG4UyG1+zyZdmLE9cVMYtowM9PpzUNpCk+iCxn5kjOeDlecYqbgqWUHIPpWfaRE6gqszLkfMPU1qhdqnBY81Dd0RK6lcrRzq8qI64xnirB+Xa2Diqt1GhhDZG5T/OrTEm2QZyelToyZc26HSMNhOSCD09RSRy8s+SPmC09EVlO8jJFQJGYpGDOMA5xipdiFfUmkYN3I7miPJ3AdB14qEyYdyHyhHOBU0Dbg+0/Iw9KlWY5c0REmAIU5BzjJGM1Mkod1IyOaiSA+YC3qRzUsNu525II7D0oW4pMW4nWG3kkPQAnJrlvDp/4mc0pBYKu7IPrWv4qlkg0/ySdrSnqOwrM0FRFE24/NIu4/TsavRK510U1Rk+51EGqeXKqvyT0FaZuNwxnqMmuR0cNd3wkXdtRupHfFdVChU44IzwcUQ11ZwV4KEkkRXMhEX3sDGRWVJACxYuSTxWrcQuYSnB54NVGRkGCqlc4zVaDpza2M67nMa4DdOcUmmWsd5AZ5Tukc9zxiqcqyPr92rPm3VBgeh4qodQktJGhjTcpYspJxwarl7HeoTcbR30Na4sES4U5IOODnpVZZpY2CHlR0bvVL+2rlyoe3VxjGVbmkOuJER5lnKOORjmq5ZdUWqVa2quXyzLkoQN3X2qIsATzn196yr7xDGyqlpbsHYc7qyhe6hcyHy8jA6BeKtU5PY6KWHm1eSsdfFIrOF4VR/DUyyId2AcL+VcfDeXUTbZ1OR7VbGrfOckkdxT9nJEVcLK/um1cXHyYIA5yDWbNdqZ8KDgd8f1rLv9SZ1UMx+U8AVQkubmfBjBVT3PGa1jSZUMLJK7OI+MfhaC+jOsaav+nIcTxov+sX+9x3FeJ19T2emSPKGlO4k5PHUV5D8YPBZ0G+XVLFD/AGddthh/zzk6kfQ9q9bC11/Cb1PDzXBxg/a0/n/mebUUUV3HiBRRRQAUUUoGelACUUUUAFFFFABS0lFABRRRQAU5FZ2VVUsxOAAMkmm16J8G/DL6zrMuoyIGttPwQGGd0hztH4Yz+VRUmqcXJmtCk61RQXU9f+G3h9fCfhiK3ZQL+5AmumPPzEcJ9AK7OxHnyZLD8a52O9Iby7gEMDw5/wAa6PT3TerY5x6/1r5yrJyk5S3Z9S8P7CCjE0rcGKXPVc9asSzhiCCOOKgUqzlgCPWiSPHzIO/Q1zuRyOPM7kMrtuIJ5zgDFKNzcsOfyqUbXBBX5s81JBBu3Aggjp70tGiruO5VnjKNFKoBA65q6rl9rYBD8jFTi3Ro9sigrjmqtun2aZYWO6FvuHrikiJS51puiG5G2QyOOgyfSnQyCSPPo2Aa0HtlJO8MeKqxW6ossZUgb8jNRJakqd0RghAzIDu4NSzAORlcg9O1OiiU+2Tg1JtXy9uSCvfPSpugbZWliChZFG0Bfu+tOtBkOVHYGiYELkZI7DNSWBCxsgTODzU8yY/eS1LAQYGecE0xWCAFgdxJGKkWRSwUocL1OaJNihSDyTkYrSMbGLncwPEkpeYjaSFjB9ep5rn7SedppEQZaQgAk4AHpXS67sJEm1mAGGOO9VtKigWQzDgAdDxk1TWmx6VGuo0joNDs2tbTGcs3JNaEEoyODgdsYyags7xCpG3GO3TFEsyNb/ushw2c9KqEU9Dyas225MsPKo/hOT2ArG1jUbOxhEk7kHqF7mrmq3sGn2QuJXy235V6lieleZXSXWr6kpB8yaTn2Qeh9KHDWx24Gh7b3puyRMdWuL/VS1qrL5p4AGf1rpIYEjuY1nXd2yR/n0o0rR10ae2kt3t2j2N9oeQEuW42hewHXJNXWCNKvzK3cY7VUrLRHTVxcZu1NWSH3Gj2ksfKKhOAGXg1Tfw4gi+a4k5PGTWmXVHAdwFxnrTfOY3QUHgc88VMZM5/rFWK0kUdO8P2SyZcNMxbGSMAfhWvJp8UKhVjRExwoWmM4hxLvGc5IHapWvluol8shvcdqpzuRKpVnK8mc9qmnrPKSOPQAVhT6cY3JwOMDFdksTGWTzjkDpWZexFGWQjcM9QaqEmtDpp4txWhhR2UKD94hLk8Uhh8s52cjgc1tzxADJwG61SljLyqyYIB6HoatVLm3tW1dspwu6FQVxx2qDXNNt9c0K4029QmCZcH1VuxHuK6BNJ3RKwI3dcCqMsRU7HOSPaqUrO6MXONVWPkbxDpFxoWs3WnXikSwtjOPvDsR9RWbXvXx08Nfb9Ji1y2Gbm0GycD+KP1/A/zrwWvoKFVVYKR83iaPsajj0ClFJRWxgKTk+lJRSkEHBBB96AEooooAKKXtSUAFFFLQAlFFFAEkMbzSpFErPI7BVVRkknoBX094D0P/hF/DFpp5C/bHbzbpgP+WhHT8BgfhXkPwS0RtS8V/wBotEZLfTAJmHq5yFH5gn8K+gi6SzhwCHJ5z2rycxraqmvVnt5Xh9Pasgns0vFAkBLrzuIqFIruwYEEsg6A1tRuFAxnnirSqsoBPevKc+h66rOGj1Rl2mqhlOHKknoeK0Le8LkjcCM1BPp0Mp4+T1AHFRjRZHciGUhuwH+FZuz2JtSlrextRTAjqoyelOhmKsSHyAcY61kSaZqUbhQwkTNWLdXtWxdZIY87u1JabmFSnF/DK5vK3nchxz71XDYTyweVyRmp4gsUayIQQ1IdrsJcAY9qUnY40mmSpJJJAG3c8A1FcbwXwfTPalhkClkbIB5FWjErHp2596baZGsWZsDZl2n5c8Y/CpSM5BwAaeY9s/T8KdtLnPY8Vi1fRGt7alO4LKq7cFccZ7VPbZ2bh0PWpkgLRYcA4zVyG2REG4df50Qj1JnPQzHJJlY5BHA4609MyPFkYCnkY7VpvChBGCDTo4whJ9a3TMDLngjdp8njBrHu7CRbcGJjtDfQiuucLzjafQetV5YVAO4HHpTTtoVCbjszl7S6mS6WOVTIhypk9OD1rZjnEFizuQBuzz9KZd2qAkqnHpjv61g6rfyTxJBtGEPOP4jRzW2OlYd4h3XzM/WrqfVtQRYsZJAiUHOPc10eg6OmmacysA8zHLv3+lO8OaQttB9pmUGZvuAdhWyq7V3ScDPHpWkWkrsnFVf+XNPZFG5VUEBbAyMmqtjF515JIRiMZwBxmr8kRmcY4HQcdKkSJbeFgvLAcCockZRTivMyL5WklCA4CYOT6VUlBN8dzu4x24zWvLC7fMBkY5FZmpTx24Yw/MwHQHJqJSSdjeipSdole8KFSgdkcHGAataftM0axIduOWrDgs5rq5Mrt8pO4CulsEWNyM8qOtUpJKxviKbSte7JYoiHlL4IPUntWXeXClXRE+TPFbVwUETdifesia3QjcTgd+armV7nNTg3uZ1wrvMGPCgc4FQxyeSWxjBIOBVx1Mk5UcJxyB2prLGrNGI96561aasb67WLsN2AIyOD1x61lXIMkkjn5jz+FPd1jbLA4HQVE8w+chWAbsKaaJhQlHVDZLJNQs3t7pA8EylHU9wQRXyv458PTeF/E95pc2SsbBomP8SMMqf6fUV9XW9/Cdgc7cHAzXm/7SuhLd6Zpuv2qAtbf6NcMByVJ+Qn6HI/4FXdga/LU5Hszgx9KfxSWx89UUUV7R5QUUUUAFFFFABRRRQAUUUtACUUVZ0+1a9v7a0jIDzyrEpPqxAH86BpXdkfRPwP08aX4KjmZCJ79zO3+70UfkM/jXa3loHHnW/DZyR61UhghtLeC2t/kSCJY0C9toxVyKaSM4YBh2x1NfL1qjnNz7n1tCmqUVGPQr2l0RuSVdjBvWtWJ8KMDjPaqe62ulZSADxkHg1LDbtuYQylQDWDZdSMX5F3lSoxlTxW7oahjuCrjGKwIN/3XIPY5rpdOcLAoQA8c+1KO5w1/dgaEypuU4xjNcr4jmWMBZRkOCM+lbF5ftHHkrx3Oelc9rtwslqGkK4U5DdadSp0MsLSbmmXNLlLWSIWyD90mr0ZxuUAk56Vn6I6G1Xd07H0rdgEZ+ZCPapUkyqy5ZMzF3CYZyDnpirsL4fcxPTBFOuUBkBXb0zxUcM8U7TRxyxu8J2yKjAlG2htrDscMp+hB70PTYyeurFuDidCgzkfnWbpV7c6xdJc2TiPR4ySjgAm9JGNwz0iGchhy5AIIQAyZsYPim62N/yL6rkemof/AGj/ANGf9c/9Z2duqhckD86Iqzd9/wCv6/4OyqbIrJl5M54JwQKsKCUXOQcnnNSw42scDOT2obBYAjrVRtFXMndsarEqCRlulP4x/wDXpflRwFHPpTmUheRjFNrqJMqpIMOApyG4/pT3ClvmB2j1qKKTDsAOc/gKp6xei3iCR43NU3uawg21FFLVLlpphFEBsUks56AVn6Nbi8u/O2k2qk446471Xw+pXa2VtyoOZmH8s11EaR20McFuoCqMUaI7pt0Yckd3+RYeVUCYwRjoKRYzL+8lHy9QpNR2ka+YWkUjBwPerTsrHamS9O99Th+F2KcrbCTHgDsDREcJ85ZmPNXFs0b5n6n0NRyqqAHG30FKS0BSRkzGe4ucIrKnTrjNU49MWAuZE3Ock85yK31w/Uc9B7VFdRIcE5z0xnrWdkbxrSXux0Rj28WHIHygMCOac7+TdEdM81ZePnI459etQ3MZlbPCnHBqm7m0H72o2ZnlTgdOpNUhv3bAQWP44qxIs8a/KMn+dFrGySZYDd1OKpaDemwxoxAM7+ehFVmKAkpyD19qlvWYzDKnk9qgBPzAKOmPpVJjUXa7ZVkPOSMqT+VV5ZCEG1cj1zVyXo2RnPcHIqsI97Z6Y9+taJo1V+pQliDPhgASeDVPxBpzat4cvtMmO9JomCjPRhyp/MVu3NuwRSABg1AgCsCeAK1hOzTQpvnjZnx/IjRuyOMMpwQexptdV8TtKXSPGuowxj9zI/nx8Y4fn+ea5Wvo4yUoqS6nys48knF9AoooqiQooooAKKKKACiiigArsvhHp/8AaHjzTgybooC07+wUcf8AjxWuNr1n9n20Darq98xIMNusSnpne2Tz/wABrDEy5KUn5HTg4c9eK8z2pRlwSAMg85/rSpGVJCnOAPzqO3++M8qc53VaV+Djv7V81K59S7AsK5DbQr9eO/1qaJJAXKvgE+nSnISQzZI4qYMpY7upOOnArnlclyRBA1xEwZwHTdzgc1qQXR2fuSd3eqpUqhZeT15NIuxsnBU8k/Ws22RLlkrMkubl/LKuxz3yayruI3FsyqpORng1ZlWPcMtljxV+zhSOJd3cUJtoFy01dGFo1+ttbtHOCApP4e1bFvekxq8WSmOcdDWJrkEcN6O0chyTjjNZ8d/JYlo24hY9euPcVok90dMqEK65onTeJfEcPh3w7f6zcDfFax7xHkje5wEXIBxliBnHGc187fCyPxjrfii7v9MsZNRs7+cnVhMfJtbgFwzq7DAz8+dqgnaSNrKWU+8y6ZpHiSwtYtWt4ruGGdLlI3JxvUEAkA8jBPByDnpXb6WIre3itbeNIoIUCRxxgBUUcAADoAO1dmHxSpU3Hlu39x4mLwz597JC/Z0W4R8cNhasmIxOygHHQU4ATKRgjHQ+lWQ/9/AwOCTzWKRjJ7FZQUnYNyDRIuW74wcY9amaRWOMdD60+Nl7gZzQnfQBkKYcFgd2KdcH58H09aeZR2HFV2IefHQ465p31JtcZMFSORhwowSR6VwWoXUs88jgsQX2oa7fXZfLsSg4MmEABrA0jTt+pASncIwHI681Ld2ehhOWEHUkXNB082lqz8+dIcs1aCRFRvdjgdq0COAOM1G7KgPendHLKcptyfUq/eZOSoParIGxVKnscn1qs0gG0qOc4waGumYbYxyKSmkDg2WhIQvDA8Z+lULmYkHcccZNSDKg7h19Kikg8yU7ulTKVwjBJ7jBdCILgjbnqT0qGa8WdhswzKfvVM1nG3BGQDmo54YlVcADHXA6VFzZRiQx73PIOCetWNihTnGBVVZxCQrHB9anaQMu5T1HaldGvLIkAG0jjH0qjKAGIUHIPrVmWUDgHkjvVKSRM4yNvfmqUgUG9SC6GEySc5x61QlyjEEkDsTV+aaIY3OpAPY5qCS4hlyrlWA45NaJm0IyKgO70INWIU/eFioA9ar21xbtKSuBg8ZNbYuLSKJj8oOOSTT5gq80dLGZfTJv2gDpWRdyIxwBgrzjFLqd9HLK4AOB3H+FZbSq6nkYFbwizSNFpXZ5R8dbMfa9MvwNpkRomH0OR/M15VXuvxmhW58HRygHNtcqwPswI/rXhVe9hJc1JHz2YQ5a78wooorpOIKKKKACiiigAooooAK92+AdqB4W1S4YcyXYQe4VAf8A2Y14TX0D8FI/K8EJJziW5kJx9AM/pXDmDtR+Z6OVxvX+R3yqVbbn8u9SwRSO4VeFx6f0pmMt8oJI65NT2rmNQCTtFfPtn0TVy8kTDvlfTHSpWQ7+wHX9Kbbs8u0bSAexq2LZiu6VeB71jLmZzScU9WRlCwzgH0qNwDIuMDHWpFXymG3o1P8AlU/MO/bvWMroV76lQW7m4ibIxksferLOcDHJ3euKtM6BM+/GKrSXIiZVZce2KfQm/MUdRtxNCwkAPf6Vzb28rwMpRnVP5V2rCKWL5hwRyKSDTrZlKqCCexq4SZ0U66pLU4rRbt7G5VXLGM8V6LaOSiyAArjGQa5u/wBCUXBKjAPQrmtjw/BNap5M53xdVb0q76k4yVKrHni9Tat5JAxPr6mnzSlt2ARkYFEZjjOCMZ/WnymM4VeDV81jymosZHuYbsZHBGKnVSSwGQvUfWqsM4ikMZPPvVwSBR15NCbJmrMag4wQQenNIyhmyAcBT2zT/NBGeOOxqleXPlbVB+8aXM73CMOb3UZXiGQ5td2SwOfpVzw9APs8twwO9+M1k+K7hY7m2C43CPLA1taJIV0y3DEEsM46VUXrc7KkLYdW6mnHtU5wQCO/rVS5K7wig5Pf0q0yyv0Xr60kEIB3MvzdCarc4tIlOCD7uQScZqa3t1IAAZWA5q85VcYA60hkGBgZB4NJCcmynKNqAjI6DFRMQTx94Hj6VovtYY/SqjkJztz2zUSZUSoxctjJHODmoioCEMTknrV7GV6YPrUMi4xjPrms7mqM6SMGVUC4yc1HJaswIhba3XrVx2QMGPr61EGyWKDjGKhvU6qbkkZk0U53KxOarR2eRmQkt1254rak6NuGSaqzlDyCM+oq4ysbe0kzHngQeXhFHJzx1qCS1jkRCU5bqQf61qXaruyN3Xg5pqoNy46Z7Vop9jRSaV7mBJp6x/6pirYIwe9RvBIoPmMSF7etdBOilh8oyAQBVKRDJkc9M1qqly41H1Zh3MZYMMHOO3FUYMhnVuSD0Nbt4R5Khh0HNY97FsdZFGR3HXNbwldWNE77mH8QbQXHgzWOv7uPePQFTmvnavpnxCyz+F9VXgBreQH8q+Zq9fAtuDTPns2X7xPyCiiiu48oKKKKACiiigAooooAK+ifg+q/8K9suTkzSnHr8xr52r334PTFvAsSgf6ueUZz9Dj9a4MxX7pep6uUK9d+n6o9EtZArMGXJHOKmtyGlRG2gZJI/Gs+As8mQVIGDg1MQwkaQrkLjGBXzz3PoWkdFEu3DBge/Wuis41kgUvyTzXGLMTxwNuOa14NRkSAKuM9AahTtqebXpOWxo3VoiHk7RWZOnJQPx1zT/tTypmUnn3quq78BWK5HUGsJy5mOEeRWY/DqCpPfd0q99mDqhz1xximwWzy4LOMelWBkQY5znqDThF2InNLYbJbow2AYbsah+xFFXynOVOetX+AoAGdvWmy7mHycfpVqJHtB8duTs3noPSpUt3jxkjAGBViFiuAyk9s0gf94V5PNbtNK7Ofmu7EZQsmDtzjFKI2BCnBXikBAGQCTk8VKk6nqpUVF2LfYrXcO9HC5Dt0I7VVhvJRmOZQJEXIyfvVp7/3YJ5BznIrMvAJZIyE4U8euKaiyoyXwyJRcCSDdtAPao4IXubnz5+I1Hf0qSWBPJYAH2+tU9VnkSyMMQKluD64ppamtOzdomBr8jX+rfulJBbYAO6/Wu1srTyBDuBJRQOa5/w3p7/aBdzptC5VAR1966kXO3ZkDpk5FaWa0KxlaLtThsi6i85xxUflkRnIxzmoxN5jqOgDY/Sla5baxIJwCSBVcrSPOvqNZAEI77s4pig7vlXAJzUc0rAnK9CKYbsueAe/es3KRokiRc+Z86/N61HK/wA+OwxURnbjJ+9VR5WAJ6krxisnds0VkaRIYZ6VRmOZFAU7cU9J8KFY4OKjkuFA4UMBgZrLqbLYo7HaZeO5FTwKY2wwyufxppumMmUCgZ4pXulZRv4J9Oe9J66mylZWFlIDN3APes24Qb2IA/Crbyx5JO444OelQLKEZ94O3oKuNyuZIz922YZDYI4yajTcGXrjpn3rQnZZGUjI71QnZQx8tsDrinfoaxkmI6OzdPyqFtyoRHjPTGavQMshAc8n2qmyAzvjlVbCnFUmNSS3M2/y0S4UHHXFZty3yjOcZ6ZrYvACp2kZ561lyEZbcckLgkDNdNORspJmJqwzZ38RwFktnPXH8NfODxIsEbiaNmbOYwG3J9cjH5E19I680Z0q9kLbTHbyE5HotfNNe5gH7rPGzdpygFFFFdx5AUUUUAFFFFABRRRQAV7t8C5Fk8JX0bKCY7s4PsVX/wCvXhNeu/Aa5+TWrXJ6RygD/gQJ/lXFj43os9DK5cuIXmeuxJEpyF571e3KYwqoOvOeayVkJI+bPQ9KsoTtJO4V83NM+mkkWIy63EpLBozggY5B7/hWjGwwFwfrWdA4Unr2NWiXMhyxIbnrWM0zKVtrF9H/AHZXAz0p0YUcBuenWoYzjAXPNRiUgnHIBOeKxe5k0jZt2KfKSciplAKEMTis+FxjOMmpluHAYn24xVxbOecUXxkkFST2xShXMmQRg1WhlZnzkD5sYq3GWOGyuM1olIwlyouxyHHzjHvTV2GTKnB61BI7cD5Tlc9aSMMpO7HTPFaSlJmKjFalpIiuPmHXPSnqhVgrMGP0qEzNjAGMYp0cm1yGzkHApO4iaRBsCYyOvSmG3VmJwM4xSTXARQXIGDjmm29wJ5witn6dKerYKN0PeIAElefpTby2EoVgoLdBVlryGK7W3f7x4FPt8yTHPQDIrphFCd4a2JEs9kSqcA8Y9qGtFJHAqfeXwGJxjPFKSDg4xVTVjnTuQiAeg65pEt+DnBBGMU4hiHJLbVOMUQ5LEK5K9s81neUR2TIpoRsPBz1zVA23JJJ6YrSnkZVyR7VReUhuh9655tm0EVniA2r6DFOS3DDco2nocHimXMhyDz164p9vcoRhuB3+tRGbvY25Fa6FltgkZLcdMdqoOqg8MTk9KtXl6jR4AJGe4rMe5JO0Rkgj7xHSpnPXQunC+5FI2wjH5VE2WlyCTgVNKDKQFwcj0psqmHODknFYts64KI6O3DR7tzHFMkjkGcDH9aQSSAFs45+lO+1Bev4D1q4zZLplWeNmiA3bWHHpVdbdkRh1yOp7VeaZG+WZQMjjmsnU/D+g3s7T3ej6Zc3UgG6Wa1jd2wMDJIyeAB+FXGSb94dmlZHFaF8T/DOrSLH9tOnzMxVVvl8sYAzncCUA6jlgc9ume/tpIntIp43ilhmw6SRncrAjIIPcEd68y0n4K6BaXEkuoXV3fqsjFISRGmwjhW2/MWHXIKg8cdj3Wm6Lpeh2jQ6XYW1mm1VZoowGcKPlLN1YjJ5JJ5PrXXiHh7/uGznpKrPSqkVdcuJEcFItyNkCqaL5kauuQx6rjpWt9viaTZJjeTx70jlXVhHhQeM46GpjNpJWO9xUY2scf4yTyfCOtMTtJtX5xntj+tfNlfSHxbuUtvAuoDGPO2RD67hn+VfN9e/lrbptvueFmT/eJeQUUUV6B5wUUUUAFFLSUAFFFFABXe/Be+Fp40SFzhbuB4euOcbh/wCg1wVX9Dvm0zWbK+TrBMsn1API/Ksq0PaU5R7m2Hqezqxn2Z9So2xQOmePWralWUncQcZrMeRXVJIzlGAZWxnIIz1oWbCsT29TXys0fZqNzQjK727E8CrqMofk/QVyN1qm1gkYO5jywpEa+lcnDhDz1xmplSdrst0L6t2O1SYEfLgZ6VJtUohPB9hXFRw6jjIypxxzVpbLVZQIy7bSM4zWTpa7mboxWrkjuLY4GSVIFOEq+biUZFcpDo+oCMSPITxnAc1AuoXtlOqXAkaPpzyR9DS9lJrQxeGU/hkmd3GYy4OOatqQDwep71zljdpLFuVjwM5ok1ORjshG89c+pqYp7HG6LbtY3/NxIFJAz6VoJhlxyeOxrl7dblyPNIQkZxitONpccMSQMkVvGLMatNdDZRVxjJFJK8cYY5Bbrj0qj5s5Q7QAR7U62hcyl5G5yODV8rMOVLVj4rKS8k8y4YhM5VR3rStIEt5QVwRzTFcquM4wcAU0ykrlTz0HtVW5SXJz06FW8KSasWX+A8Y55q4J1WQZJGeqjv8ASkghEALjG9uOaztQ1FoN32UIzgkFm6L9PWqi2aaVGorodCjhsMqnGMYqUOMkkH0ArltButQnut05/dNkA9B+Vb8RY55BOT2qtbanPVp+zlylgbvm55Y0qqFBAPJqo00i7iVzj0pGnd1GVxyKlK5DViadd47+tVWjxls1K1yO4wM4NMeQEdO+OtQ4Nlp2KcykryOM5qg6Efx49Bir805PCxkn2rOndy42r0GTWMoO500xUQbMM+cHPtUTsCWyRtqBmllAVRsBGc0z7IuEDBmOMk5rFxkdCjHqzUsYPMblxwKq6iAlwVAzxyahXzoOE+cdRzzVdjJK7tIxHsaUm7WY4U/ebvoSXE8YiBUfMOSTVBFZx5j/ACseQOwFSG2QEtkleuM02RsnK8AnpU3Oi0UrIVgDGVyM47VDuc/KwLcdal3qByOp7UquM8Gi7JskERO5juBqORDIHxUypG+cON574xUSIzhhG53KO9NSJdjMuLISTb3xkNgYpzW53KF5GKvOkicsufc0gKbODhs/lWvtGOUro8c+Pdw8Gi6ZaMcNNM0hX1AGOn414jXpXx71E3XjJLUPuW0gVSPRm5P9K80r6zAxcaEb+p89i581VhRSnikrrOYKKKKACiiigAooooAKKKKAPevh3rceoeErQOw8+zHkSc84H3T+VaV1fiZkiiGR3x1NeWfCcy3OvS6dHJtW4jLgZ6svPHvgmvZtO0uO2lUlS75614GKpwo1Hf1PtctxKnhoye60+4s6Rp6hVlmU7nGPpXRJaRKckjI5AzWfC7IqqOqrjH9a0UkYoQRlieOK82fvasitVnJ3LcNpGNoGwt1NSEqr4wv/ANaq8ckiq4IwTg4AyagYzmXKjk85xWGiZj7zWpuQSRhQF2k/nVPULaK6jCNhWPQ1SHnozknjtUqTESJlTjGDW7qK2hlaUXdFGHR5YmYRtlW9Ditmw05YyTJyaI3zwoOCOBmrkQLE7o2wDUvUVTEzasywIAGB49PoKuRgDACgg9eKpBCzIRnKjmpi5XONxGccdquKOOUrouFkABx7VIvljuM9T9ay/MPQggBqe28PjGAOfrVX1Jtoao8p4gRkHselSR26Iu4Hg84rOgnBRQcgc/nUvmEIm5iFwc/WrumZarQfqDv5aQocFurHsKy7K2hvZHlAzBGdsYP8RHVqiurp5UbEhAYhBzV+0HkQxxxZyM5qfQ6eZ0o+bL5MZtGQ/KeoPpSWkwB8tuGHr3rPRyJQC+4HH86fduVuVkBxggZFPXqYaPQ1Jl+9tPJ9ahVX6hwAMfLmqscz7+u4nv7VLv3bm37cngmnYi+pYOf4hyfSl8sEcE9c1U85mAO7vjHr71MwYIzxtjb1FPldtB3Q4xLg8nIqpMqq2XHGOKJJn2tjhiemO1QyzHa7MwwMALWck2XBiw26uwUH2HNXU0uN8HJ4GCfWsy3ufL3SI4IBxtrUhvty5TAJP5cUQinuFWUlsV7qySBSVOccHmsi4AYEjHA6Hg1szSFlbodx5NZlxCDllIFZ1YK50Yeo7XZj3LyDd5YHT7tIgaRAQPcjFWZIckjcc81AylCFQnGMkdqwcbHbzJjGQkcgZBqEgnjIxnqKlkd8gn/GoGl55BqdR2shysy5KZ600u6ybl4NKbgDhl257560jvGp3Kcj0p28hWuWItSQoyXKjgccVmajf28KPPjEcYLNk4wBzVa7mRnBRsHPSuG+K2rDTvCM6q2Li8PkLjg46t+n866MPhlOaS6mdTlpwc2eIeJNRbV9fv79+txMzjnOBngflis2lGT2PA5x6UO245wB24FfYpJKyPmW7u7G0pBHWgHBzxQPrTEJRRRQAUUUUAFFFFABRRSqCzAAcngUAaHh/U5dG1qz1CDO+3kD8HGR0I/EZFfUVvLBPFDc20geKdFkQj0IyMV8mV7Z8GNeN1pEmlTP++sm8yLJ5MZ7Y74P8xXl5lQ54qouh6+U4hwk6Xf8z0+Ebjg4yO5FTyXnlIEj+aTHBHaqvLKGJ/i4APJ/CtfRdLkciabqRwDXhctz2qkuSN5ENqW8tS789yalYqpyzkg9s1oXVmwcOgAAGKpG2clcKSMk59ea55wVzGNZy1sCbGZSfunqe9ShlLfKDtPrSi3dSu5cH0JqdLWQICw4HBxxSUDOVXUS3XZKfmGMcDNaKuwVeRyOmelUVjMZyFHzNkZ7U0GYKoEZbGenNUkkRNuRsi4VehGccUiSrv8ALyT9DWSqkJna25hjOeBVyBGEkkgUknAX2rSHdmElZF9XRnIA3AdSaV0Uks3GOlVY02sNysRnPHemanOYraQqDliAD6VTaREU5OxeiZeowKfduEgfHzfKcYrJiEmGwhPQfpzS3SkwHcGy2ckA0ulx6c1iC0mjaaFNoZQ2etdKCAuQAOPSvOLe4aG9VpFwEOOa7WImW3jJLYCk0R941xUXFpllgrssq9vapJlEgU4OD7VW8lliyxYDZgVBuKMVZnHHH1rRRaOXmuXrdgUYMMFafJhcEsOeBxWW7+VOGBbk461ejCv5RLE5bP0pxi9gm+qJGKoAzDB6dKsrIiJufGw9abOqNHg5z7VTEgSNlLYTk81cYtLchtNll1SVC0bK3bI7VSvIRtxgFu5rFIniuPNtZcKzZKHpitH7QZIwzMAehXvWLm27dTfkUEmtUMlhj3DaFBIyfertrPGq7GUA+orPlZdmA3OM5qopl8zAfjAPPFR7yd0aLlmrM1ru+RMCIDNZjXDPIWLYBHAHeoJSXlbB4U44FQbmLbSD9axnN31OujSjy6Fzz/kYYBHqKrFlYAqSOMVSnmWPCsSCx4qKJsgr8wxzySKL3Rt7G2poElQQTkAYqvKFJJLc1XWQsccg84yc1HJMWO1h16c04xdxcqHT4XlmBNU5JDyFzycUlzKoJzktn8qqST7RkEjJxwK3hA0jFWGuXYDHXJrwv4raydT8RtbIT5FkPJXnq38R/p+Feq+MNdGh6HdXRJE2CsQx1Y9Pyr54mkaWR5JCWdmLMT3J6mvcy6jq6jPHzSsklSRHS0lLXrHiiUtJRQAUUUUAFFFFABRRRQAUUUUAFa/hXWpvD+vWuowZPlN86D+NDwR+VZFFTKKmnGWzKhJwkpR3R9b+G57bVPIvLU77aUBlY89R0rtlcbUWE45xXzZ8FPFZtZhoNy4VZHMls7HgN3T8ev517pY30yuPMCgK2Tz6181iKXsZuDPoueWLgqkToJYshSzEk9PpU6tCkeMAN0HHJqC1nW4K4IB7A/Wpp4vKUyPsz1wa53GNjmbmpWZBO0QcszLwetMvb5IbVnHzBSFwByxNQOySssaBDzyfSqt/F5kkSRMCIzuYDua552WxvCMm1zIWK5eYgy7Fz1HoafDc9UJxgnkdKrx28m8k5IJycU820irnHQ8DNYWTRrJ67FsyKqhzjAOOa0IZIxGAXG/vz0rFMTyZaUjHUYNWI97pnGW6sQec1VN6WM5o0zKvUHJ7VT1SUqsULbdztwB3qKU/Z4XeTGABznpVG3aW91AzYJjXhM9KqTWwqcX8T2Rv20mGk3BdqgDg9aZPcAgx44Xvmq9mjyRyM6nBbt3GKjMblSQD16eop1Je7cziveMrXYVWeN0yMjn0q/oeqhY40nYFV4BNVbmEvICFcbjknsKzlt2hdeDtzg5FRTlZna2qkOSR6GJlli+8u08ZFQXCZKBHG7tn0rmNNuHWVkBcLyetakbF5UVt3IyPY966ea6see6bhImluWJ2Sx5PqBUVvexIwRSyh+RuPT8KYzFZQHB28mo5VSWNQwwMZX60l6l3XVGxbzqeHYZqyVR1BKgisGEfKASdwXg1etg5YKGb7obg962ic899B9/YRtFvjbaQc7cVnyyx+YVOFkTrx1rVUEFZGJG5hwTWPr9s63ImtTg98d6mrDqXQnfRj5CjphD25AFVnICgAAL06VmPduCdxZWyOac8qiPIkKseCCa5btnYly9CxcAICY+nXFVfMA3P1JPAzTHl2q6h9zHrk1AUldPM3YT+EZrJ76nZSS5RzoJ5lLqAB3pxREmyM5YY5NQTPKsHQdeuOar3F04iQSJtIGd3c1pGLLbu7F6WNRFvj4xVOXCgYPTn3qi9+XhZQ2wDBGeKjjuXz87AkKPxraMZLcFALogsSznJGCBULOpG3IAz+nWorh2ZiFIwCMmuG+JmvDTNJazglxe3Q24U8pH3PsTXbQoupJRQq9SNCDnI4r4l+ITrWtGGB82VplI8dGb+Jq46iivpacFTiorofIVajqzc5dQoooqzMKKKKACiiigAooooAKKKKACiiigAooooAkhleGZJYmKSIwZWB5BHQivoz4d+L08TaKGnkRdVtRi4Uj747OPr+hr5vrU8Pa1d6BqkV9YOVkThlzw691PtXJi8Mq8NN1sdeExLoT12e59VQai8LAxBgw53VcivZ7t/3zsFPT3rntA1PT/EGhw6nYy4jIAkjyN0b/3TXXeHbZJEDOQQRjHpXzThq0z6OpNcnPFDFW4ckRny0xyxHOKPtCIpCE4Hfu1dM1srryF4GBXPX1tsmbawK44x61hUgkjmp13UdrWJIbldmVB3elI9152eDgdTWYz/AL1RyBjk+9EcmHkAPX171zOKN/Zu5owOzEkAYHfNWorhFGDhSc/jWZZyKqlWYDn1qeUNvDx/NgcVV1EzlGXUr6xKZWjizhXYEj1rStNttAxIwoGPpWLdK3221d253YxWxfHNg6dzg/SnZPUclKyj/W5owSAW0QGcH5hUVw5WVWHIILVXncRwxAHGFAqOR2kG5hxs2gA0OS2Zg4u90SJIjBSc5POKzddlRLdj0PtUshZVB2HfjA56Vh+IZ2e4iiX5f73PrUwjFux0UIyc0a2k3g+0xlhnsQK6JJ4pWOMr6E1yWkRvIkh6qejL3IrbhLqgUD5s55+tbXSVjPEJuZfuX8xQFIyDzUBnEgVQDzkFh2pG+ZCzkfe5we1QKpUIACASc+1FtbmN2tC/FIqphWyR3NadlOpt/MOC1cxKGRWDM20jg+9NjuJYIxCGJ3DP0zVRqcjuDpe0jY6qeWNG+917E9KqeYJCclSfQ1nJueNgSxBAOfSk3Ou0D7nfJ5rTm53cw5ORWCW3iEzM4Ur1HFZ91FFKv3CMHg9OlabANGMscsRisq4kCSlCx4YgVhOFjppVG2YbpMZ2CHfGTznqBVtZduEYcAY9hSQgqcjgHmlk3EneQR61nJ62PTjPmSuSNggHj2qpcxtsG4KSv65prXBQlcdMgVFLc7mABJB5wRWkEyHZPUp3EaSSkbcggDGeKqSwGJhySpXtUpZlL8gnqO9V9Ru4Le3luLuby4YVJd2+ldML7I3uo+hT1fVbXRtIuL66J8uMfKhPMjZ4UV8/65qk+s6nNe3Z/eSHgDoo7AVoeMfEU3iDUmcZSzjJEMXoPU+5rn6+kwWF9jHmluz5fMMZ9Ynyx+FfiFFFFdp5wUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAHQeDvE934Z1DzYCXtZcCeAniRf8a+n/DOuwanpFvf6Y4ltpeAo6oe4I9RXyBXS+B/F194U1LzrY+ZaycT27H5XHr7H3rzsbgvbLnh8X5noYTGOn+7n8P5H1uuslIiHJ3c9KoyX/mEbeCVzzXM6Hq9j4k00X2lThkOd6N9+Ins1X0VlwykZIwOP1r52a3TPbp0o25omjM4ABYjJ56VRnugT5cHLd2x0qC7uGity24MSNqjvk1Lp9uy2+4EGRxkn0NY8qSudSTjG7ARFWDGQ7gMk+tWtO1I7/JkY5HcijyXJPzAccf/AF6X7GHLEcHoD1rKTVtSOZy0kO1VpCqGMjOd2avNPm2eNlBOMZHrWfBbP5iec5ZQPu1akZPkQsBnjANJNWsZzvdRLcs2baP5R93HWoPPbaoGFIbGM9qsOoO4AZAHXrVZoju5Axn1rNtN3MtR01ypww+lcdc3fmahL0bGQB2rp54iVfIVeOFz3rjZojHdu5I+VuBW9CKuzvwabudxpBaCCEMNpKlsfWrst5kHnGMHNU7RRLbxOXAwuQMetQXh8qQHcSjjaBjvUXucU03Nm7a3CbDgF81ZDK/BOOM1y+n3vllg6FVACjjqe1by/OynGPlHatYWejOatGUGTTMuF5yPpVCFEaZ5JTzuJwewqzcCCGPdcOsaGRUDOcAlmCqM+pJAA7kgVg69O1rtigiM19OXEEAON2MZZjztQZGWx3AALFVLlS5vhClU0sy/qGsmyZIIYxcXs/EEAbG7GMsxwdqLkZbB6gAFiqnRskuIrSNbq4+0T4JeURhASSTgKOijoASTgDJJyTwekz/2fPi+3yXsxHnTkEZAztUD+FBk4XPckksWJ7u2mBVehQjFF+S0fx/roXWoSWrQ64Z4oty8n1IqjNIkwMhGD/WrU0m2QLknJxjrUMsQFq2MjBJAo5bmUZWKcsRDDIwOo461Wnyo6jHfmr4cygB/4cAGs+6ys5QAkHJyeMVi1ZndSldalG5UBshunNVHBHOfujHTGfwqe8Yc+pGBWLrmpWukWct1qMxht0wATyWPoBXRSi5aI1corWRPdzQ2sM1xdSrHDGuXZ+AK8M8e+L5fEF0YLYtFpsZ+ROhkP95v6CovG/i+58R3OxN8Onof3cOevu3qa5Wvo8DgfZfvKnxfkeFj8w9r+7pfD+YUUUV6h5IUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAaeg63qGg3y3el3DQyjqB91h6EdxXvHgrxtY+KY1hbba6oF+aEnAc+qev0r50p8UjxSLJE7JIpyGU4IPsa48Vg4YhX2fc7MLjJ4d912PqAvLe6lHFHu2RAlzjAJrciEilY1JC4ySRXivgT4oGxhSw1+MyQZ4u0Hzj/eHcV7PYXdtf2Qn0+5iuYH6PE24f/Wr5zFYedCXLJafmfR08XDEQXs3sSvclVAA3MT2q1BICpXgHBI9qq6dEGfMpUuM4B9KluYAX3owDHgAdBXHJLYlq2g7dwMEZOM/SooA0uoF02+VEMc9M1C8U6oAXUH1P9KsWcqQW7IxQE/eJPSlZLVD5Wle9y9ZNvh3AjJyKWR0AHzAH0qBJlRF2c4PGKq3LyD7irtY8nPOKycdbCUZDrtyxO3B45rkdcLx3D4xg84x0rroVaQhl4JPIPcVS1yw82JiFwwPPfIranaLVzfDVHCdmO0C9NzYxdAYxtIFaE7CdYy4xzgHriuR0Oc2WpohJ8mQ7Wz2rrxGwOAOQ2cDtRUgosWKg4VLrYzboMwdSwBB6g9a1dF1HfGoYg4AwSetQS2u47yAHBPcc5rGaQ6ffFW+aJegHQ1nGN9EFvbR5EedftA+J5dY1aw8L6ejyC3dZZURdzSTuMIoG3OQrdiQfMxjIr0P4Vx+IF8PyTeLLPZfv5YSeWUtcTRBPlEinO3bk8ZBJLEqGLM9rTtG0rTprrUNKsoY7y8dppZiNzsWILDceQMgHaOM9q67SkFxEHYEhsE16MsVGdFUIR0XV736nkSw86M3Vk/kY1zaRXDZ2jcc59RRZu0GF3HaMnFdM2lRNFlEIYsegrC1O2e1jErK3fIx2rjnScVqdNPFe09xD4rxWO8ggdeRU5vRIhT26+lZCTRz2hWMNjbkEjHNFqnlhi2/OAO9Z7FSj3RcldRLjcevHpVeVDK3X5u2Kr6lqNlpkLXOq3UVpbqMlpG2n8B3rx7x18XnuY5LDwtEYIDlWu5B+8Yf7I/h+vWtqGFq4mVqa+fQU8RChG8mdj4z8WaV4ZiYXMhnvWGUtozk+2T2FeB+I9fv/ABBfNc6hMW/uRj7qD0ArLkd5HZ5GZ3bksxyT+NMr6rB4CGGV95d/8jxcVjZ4h22QUUUV3HGFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFauga9qWhXQm0u7kgJI3LnKN9R3rKoqZQjNcsldFRnKD5ouzPbfDfxXsruKOHXVNncjA8+JNyHn0HI/WvUtN1CC/sYrmyniuIXbIeNt3H4V8gVoaRrGoaNcCfS7ya2lHeNuD9R0P415OIymE9aTt5dD06WaTty1Vc+uZ7gSMm44444qsYkkO58Kc5PH3q8T8P/GC/tyia5aR3sY4MkXySf4H9K9A0P4heGdV2Kb/7JIT/AKu6GzB+vSvHrYCtRd3HTutT0aOKpz+CR6Dp9qGXGflB44q82l7VOCck07w+8c9sfs0sMyNyrRuCK3pUZgFOMcZP9KyhThKJz1a04T0OGuU8ieMKCPm9DinykMvz8gg85rX121xEGGAyksOaxEBlgX0Gec1lKKWh10puaUjidSUR306KSApDDHau506bzrGGUuu6RRk9Ca4rWUKXd0epHJPaug8OPv01AwACpgVtUV4Jnp4tN0os2ZCAAcjv1PNZWqwiaKJwoLDg/Srqj+JlzlQMVXkYrhADlieB2rmSszjpOUWmjJ+2sm2GE/KDkDP866Xw1qRjd96nGeR6VysttErM7SxwNGDvLuFGPxqrB4r0LTpNlxq9lGyH5j5wcn8BmtlFyXuK7NMV7OcWpHtcMsbBChHP86yNfkWSLB9OQOa8nvvjL4b01T9ilub9t2dsUZQH8WxXn/in42a5qkbw6XBDpsR/jX55f++jx+ldaweIxEbKNvXT/g/geBGdOhK/Me06jqWm6FA0mp3VvaRKON74J+g6mvL/ABf8Z0jcweFrYMRwbu4Xv/sr/jXjF7e3N9O097cS3Ezcl5HLH9arV6WHyWlB81V8z7dP+CRWzKc9IaGhrOr3+s3j3Wp3UtxM5yS54H0HQVn0UV7MYqKtFWR50pOTu3qFFFFMQUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAXdO1O/02Tfp17c2r5zmGVkP6Guy034veNbErnWHuUXotwiv+uM/rXAUVjUw9KrrOKfyLjVnHRM9aT45+IJAgvbLT5wvXCsuf1NWLT42zRy/vtCgaMgghZyD/KvHaK53luGf2fxf+Z0RxtaKsn+CPVr34qw3Us7/wBkMvmjGPPz/Sp9O+LyafD5R0YSMuRkT4B/Q15FRQ8uw7VuX8WbPNcS1yuWnoj0/UvjLr05kWwtbCyibOMRmRh+LHH6VyGo+MfEOof8fOr3ePSN/LH5LiuforWng6FP4YI5ZYqtLeTHyyySuzyuzuerMck0juzsWdizHuTk02iukwuFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAH//Z);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Retinal examination in a patient with malignant hypertension and grade IV hypertensive retinopathy. The optic disc is swollen with indistinct borders. There is venous tortuosity with multiple cotton wool spots and numerous flame-shaped (large arrows) and punctate hemorrhages (small arrow).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced by permission from: Gallasch G, Ritz E, Nephrol Dial Trans 1997; 12:1518.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_56_31620=[""].join("\n");
var outline_f30_56_31620=null;
var title_f30_56_31621="Shoulder anat anterior PI";
var content_f30_56_31621=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F60661&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F60661&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 613px\">",
"   <div class=\"ttl\">",
"    Anterior view of shoulder anatomy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 593px; height: 462px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_56_31621=[""].join("\n");
var outline_f30_56_31621=null;
var title_f30_56_31622="Remifentanil: Pediatric drug information";
var content_f30_56_31622=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Remifentanil: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"mobipreview.htm?5/50/5927?source=see_link\">",
"    see \"Remifentanil: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?37/41/38547?source=see_link\">",
"    see \"Remifentanil: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F217521\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Ultiva&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F217522\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Ultiva&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F2734185\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Analgesic, Narcotic",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       General Anesthetic",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block don drugH1Div\" id=\"F11444952\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Neonatal",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Anesthesia, maintenance of anesthesia with nitrous oxide (70%): Continuous I.V. infusion: 0.4 mcg/kg/minute (range: 0.4-1 mcg/kg/minute); supplemental bolus dose of 1 mcg/kg may be administered; smaller bolus dose may be required with potent inhalation agents, potent neuraxial anesthesia, significant comorbidities, significant fluid shifts, or without atropine pretreatment. Clearance in neonates is highly variable; dose should be carefully titrated.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Endotracheal intubation, nonemergent: I.V.: 1-3 mcg/kg/dose; may repeat dose in 2-3 minutes if needed (Kumar, 2010)",
"    </p>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F2734196\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?5/50/5927?source=see_link\">",
"      see \"Remifentanil: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     I.V. continuous infusion: Dose should be based on ideal body weight (IBW) in obese patients (&gt;30% over IBW).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Infants 1-2 months: Maintenance of anesthesia with nitrous oxide (70%): 0.4 mcg/kg/minute (range: 0.4-1 mcg/kg/minute); supplemental bolus dose of 1 mcg/kg may be administered, smaller bolus dose may be required with potent inhalation agents, potent neuraxial anesthesia, significant comorbidities, significant fluid shifts, or without atropine pretreatment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Children 1-12 years: Maintenance of anesthesia with halothane, sevoflurane, or isoflurane: 0.25 mcg/kg/minute (range: 0.05-1.3 mcg/kg/minute); supplemental bolus dose of 1 mcg/kg may be administered every 2-5 minutes. Consider increasing concomitant anesthetics with infusion rate &gt;1 mcg/kg/minute. Infusion rate can be titrated upward in increments up to 50% or titrated downward in decrements of 25% to 50%. May titrate every 2-5 minutes.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Adults:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Induction of anesthesia: 0.5-1 mcg/kg/minute; if endotracheal intubation is to occur in &lt;8 minutes, an initial dose of 1 mcg/kg may be given over 30-60 seconds; in coronary bypass surgery: 1 mcg/kg/minute",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Maintenance of anesthesia:",
"     <b>",
"      Note:",
"     </b>",
"     Supplemental bolus dose of 1 mcg/kg may be administered every 2-5 minutes. Consider increasing concomitant anesthetics with infusion rate &gt;1 mcg/kg/minute. Infusion rate can be titrated upward in increments of 25% to 100% or downward in decrements of 25% to 50%. May titrate every 2-5 minutes.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     With nitrous oxide (66%): 0.4 mcg/kg/minute (range: 0.1-2 mcg/kg/minute)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     With isoflurane: 0.25 mcg/kg/minute (range: 0.05-2 mcg/kg/minute)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     With propofol: 0.25 mcg/kg/minute (range: 0.05-2 mcg/kg/minute)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Coronary bypass surgery: 1 mcg/kg/minute (range: 0.125-4 mcg/kg/minute); supplemental dose: 0.5-1 mcg/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Continuation as an analgesic in immediate postoperative period: 0.1 mcg/kg/minute (range: 0.025-0.2 mcg/kg/minute). Infusion rate may be adjusted every 5 minutes in increments of 0.025 mcg/kg/minute. Bolus doses are not recommended. Infusion rates &gt;0.2 mcg/kg/minute are associated with respiratory depression.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Coronary bypass surgery, continuation as an analgesic into the ICU: 1 mcg/kg/minute (range: 0.05-1 mcg/kg/minute)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Analgesic component of monitored anesthesia care:",
"     <b>",
"      Note:",
"     </b>",
"     Supplemental oxygen is recommended:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Single I.V. dose given 90 seconds prior to local anesthetic:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Remifentanil alone: 1 mcg/kg over 30-60 seconds",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     With midazolam: 0.5 mcg/kg over 30-60 seconds",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Continuous infusion beginning 5 minutes prior to local anesthetic:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Remifentanil alone: 0.1 mcg/kg/minute",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     With midazolam: 0.05 mcg/kg/minute",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Continuous infusion given after local anesthetic:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Remifentanil alone: 0.05 mcg/kg/minute (range: 0.025-0.2 mcg/kg/minute)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     With midazolam: 0.025 mcg/kg/minute (range: 0.025-0.2 mcg/kg/minute)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     <b>",
"      Note:",
"     </b>",
"     Following local or anesthetic block, infusion rate should be decreased to 0.05 mcg/kg/minute; rate adjustments of 0.025 mcg/kg/minute may be done at 5-minute intervals",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Critically-ill patients: 0.01-0.25 mcg/kg/minute (",
"     <b>",
"      or",
"     </b>",
"     0.6-15 mcg/kg/",
"     <b>",
"      hour",
"     </b>",
"     ) (Jacobi, 2002)",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F217497\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, powder for reconstitution:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Ultiva&reg;: 1 mg, 2 mg, 5 mg [contains glycine 15 mg]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F217482\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block csi drugH1Div\" id=\"F217553\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Controlled Substance",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C-II",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F2734197\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     I.V.: Prepare solution by adding 1 mL of diluent per 1 mg of remifentanil. Shake well. Further dilute to a final concentration of 20, 25, 50, or 250 mcg/mL in compatible I.V. solution. An infusion device should be used to administer continuous infusions. During the maintenance of general anesthesia, I.V. boluses &le;1 mcg/kg may be administered over 30-60 seconds; for doses &gt;1 mcg/kg, administer over &gt;60 seconds (to reduce the potential to develop skeletal muscle and chest wall rigidity). Injections should be given into I.V. tubing close to the venous cannula; tubing should be cleared after treatment to prevent residual effects when other fluids are administered through the same I.V. line.",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F217558\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Stable in D",
"     <sub>",
"      5",
"     </sub>",
"     LR, D",
"     <sub>",
"      5",
"     </sub>",
"     NS, D",
"     <sub>",
"      5",
"     </sub>",
"     W,",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      2",
"     </sub>",
"     NS, NS, sterile water for injection;",
"     <b>",
"      variable stability (consult detailed reference)",
"     </b>",
"     in LR.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Incompatible",
"     </b>",
"     with blood products.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Y-site administration: Compatible:",
"     </b>",
"     Acyclovir, alfentanil, amikacin, aminophylline, ampicillin, ampicillin/sulbactam, aztreonam, bumetanide, buprenorphine, butorphanol, calcium gluconate, cefazolin, cefepime, cefotaxime, cefotetan, cefoxitin, ceftazidime, ceftriaxone, cefuroxime, cimetidine, ciprofloxacin, cisatracurium, clindamycin, dexamethasone sodium phosphate, dexmedetomidine, digoxin, diphenhydramine, dobutamine, dopamine, doxycycline, droperidol, enalaprilat, epinephrine, esmolol, famotidine, fenoldopam, fentanyl, fluconazole, furosemide, ganciclovir, gentamicin, haloperidol, heparin, hydrocortisone sodium succinate, hydromorphone, hydroxyzine, imipenem/cilastatin, inamrinone, isoproterenol, ketorolac, lidocaine, linezolid, lorazepam, magnesium sulfate, mannitol, meperidine, methylprednisolone sodium succinate, metoclopramide, metronidazole, midazolam, minocycline, morphine, nalbuphine, nitroglycerin, norepinephrine, ofloxacin, ondansetron, phenylephrine, piperacillin, piperacillin/tazobactam, potassium chloride, procainamide, prochlorperazine edisylate, promethazine, ranitidine, sodium bicarbonate, sufentanil, theophylline, thiopental, ticarcillin/clavulanate potassium, tobramycin, trimethoprim/sulfamethoxazole, vancomycin, zidovudine.",
"     <b>",
"      Incompatible:",
"     </b>",
"     Amphotericin B cholesteryl sulfate complex.",
"     <b>",
"      Variable (consult detailed reference):",
"     </b>",
"     Amphotericin B, chlorpromazine, diazepam.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Compatibility in syringe: Incompatible:",
"     </b>",
"     Ceftriaxone.",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F2734193\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Prior to reconstitution, store at 2&deg;C to 25&deg;C (36&deg;F to 77&deg;F). Stable for 24 hours at room temperature after reconstitution and further dilution to concentrations of 20-250 mcg/mL in D",
"     <sub>",
"      5",
"     </sub>",
"     LR, D",
"     <sub>",
"      5",
"     </sub>",
"     NS, D",
"     <sub>",
"      5",
"     </sub>",
"     W, 1/2NS, NS, (4 hours if diluted with LR).",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     <b>",
"      Y-site administration: Compatible:",
"     </b>",
"     Acyclovir, alfentanil, amikacin, aminophylline, ampicillin, ampicillin/sulbactam, aztreonam, bretylium, bumetanide, buprenorphine, butorphanol, calcium gluconate, cefazolin, cefotaxime, cefotetan, cefoxitin, ceftazidime, ceftizoxime, ceftriaxone, cefuroxime, cimetidine, ciprofloxacin, cisatracurium, clindamycin, dexamethasone sodium phosphate, digoxin, diphenhydramine, dobutamine, dopamine, doxycycline, droperidol, enalaprilat, epinephrine, esmolol, famotidine, fentanyl, fluconazole, furosemide, ganciclovir gatifloxacin, gentamicin, haloperidol, heparin, hydrocortisone sodium succinate, hydromorphone, hydroxyzine, imipenem/cilastatin, inamrinone, isoproterenol, ketorolac, lidocaine, linezolid, lorazepam, magnesium sulfate, mannitol, meperidine, methylprednisolone sodium succinate, metoclopramide, metronidazole, midazolam, minocycline, morphine, nalbuphine, netilmicin, nitroglycerin, norepinephrine, ofloxacin, ondansetron, phenylephrine, piperacillin, piperacillin/tazobactam, potassium chloride, procainamide, prochlorperazine, propofol, promethazine, ranitidine, sodium bicarbonate, sufentanil, theophylline, thiopental, ticarcillin, ticarcillin/clavulanate potassium, tobramycin, trimethoprim/sulfamethoxazole, vancomycin, zidovudine.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F2734186\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Analgesic for use during the induction and maintenance of general anesthesia; for continued analgesia into the immediate postoperative period; as the analgesic component of monitored anesthesia",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F217560\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Remifentanil may be confused with alfentanil",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      High alert medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       The Institute for Safe Medication Practices (ISMP) includes this medication among its list of drug classes which have a heightened risk of causing significant patient harm when used in error.",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F217557\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Bradycardia (dose dependent), flushing, hypertension (dose dependent), hypotension, tachycardia (dose dependent)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Agitation, chills, dizziness, fever, headache, postoperative pain",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Pruritus",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Nausea, vomiting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Local: Pain at injection site",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Muscle rigidity",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Respiratory: Apnea, hypoxia, respiratory depression",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Diaphoresis, shivering, warm sensation",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Rare but important or life-threatening: Abdominal discomfort, amnesia, anaphylaxis,  anxiety, arrhythmias, awareness under anesthesia without pain, bronchitis, bronchospasm, chest pain, confusion, constipation, cough, CPK increased, diarrhea, disorientation, dysphagia, dysphoria, dyspnea, dysuria, ECG changes, electrolyte disorders, erythema, gastroesophageal reflux, hallucinations, heart block, heartburn, hiccups, hyperglycemia, ileus, incontinence, involuntary movement, laryngospasm, leukocytosis, liver dysfunction, lymphopenia, nasal congestion, nightmares, nystagmus, oliguria, paresthesia,  pharyngitis, pleural effusion, prolonged emergence from anesthesia, pulmonary edema, rales, rapid awakening from anesthesia, rash, rhinorrhea, rhonchi, seizure, sleep disturbance, stridor, syncope, temperature regulation impaired, thrombocytopenia, tremors, twitching, urine retention, urticaria, xerostomia",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F2734189\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to remifentanil, fentanyl or fentanyl analogs, or any component;",
"     <b>",
"      not for intrathecal or epidural administration,",
"     </b>",
"     due to the presence of glycine in the formulation",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F2757155\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use with caution in the morbidly obese",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F2734190\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Remifentanil is not recommended as the sole agent in general anesthesia, because the loss of consciousness cannot be assured and due to the high incidence of apnea, hypotension, tachycardia, and muscle rigidity; it should be administered by individuals specifically trained in the use of anesthetic agents and should not be used in diagnostic or therapeutic procedures outside the monitored anesthesia setting; resuscitative and intubation equipment should be readily available; monitor vital signs and oxygenation continuously during administration.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     Rapid I.V. infusion (single doses of &gt;1mcg/kg administered over 30-60 seconds or infusion rates &gt;0.1mcg/kg/minute) may result in skeletal muscle and chest wall rigidity; administer slowly. Interruption of an infusion will result in offset of effects within 5-10 minutes; the discontinuation of remifentanil infusion should be preceded by the establishment of adequate postoperative analgesia orders, especially for patients in whom postoperative pain is anticipated",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299990\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F217491\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alcohol (Ethyl): CNS Depressants may enhance the CNS depressant effect of Alcohol (Ethyl).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alvimopan: Analgesics (Opioid) may enhance the adverse/toxic effect of Alvimopan. This is most notable for patients receiving long-term (i.e., more than 7 days) opiates prior to alvimopan initiation.  Management: Alvimopan is contraindicated in patients receiving therapeutic doses of opioids for more than 7 consecutive days immediately prior to alvimopan initiation.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ammonium Chloride: May increase the excretion of Analgesics (Opioid).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amphetamines: May enhance the analgesic effect of Analgesics (Opioid).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antipsychotic Agents (Phenothiazines): May enhance the hypotensive effect of Analgesics (Opioid).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Azelastine (Nasal): CNS Depressants may enhance the CNS depressant effect of Azelastine (Nasal).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Beta-Blockers: Anilidopiperidine Opioids may enhance the bradycardic effect of Beta-Blockers. Anilidopiperidine Opioids may enhance the hypotensive effect of Beta-Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Calcium Channel Blockers (Nondihydropyridine): Anilidopiperidine Opioids may enhance the bradycardic effect of Calcium Channel Blockers (Nondihydropyridine). Anilidopiperidine Opioids may enhance the hypotensive effect of Calcium Channel Blockers (Nondihydropyridine).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CNS Depressants: May enhance the adverse/toxic effect of other CNS Depressants.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Levocabastine (Nasal).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Desmopressin: Analgesics (Opioid) may enhance the adverse/toxic effect of Desmopressin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Droperidol: May enhance the CNS depressant effect of CNS Depressants. Management: Consider dose reductions of droperidol or of other CNS agents (e.g., opioids, barbiturates) with concomitant use.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     HydrOXYzine: May enhance the CNS depressant effect of CNS Depressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Magnesium Sulfate: May enhance the CNS depressant effect of CNS Depressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MAO Inhibitors: Anilidopiperidine Opioids may enhance the serotonergic effect of MAO Inhibitors. This could result in serotonin syndrome.  Management: Avoid use of fentanyl (and other anilidopiperidine opioids when possible) in patients who have used a monoamine oxidase inhibitor within the past 14 days due to reports of unpredictable but severe adverse effects.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metyrosine: CNS Depressants may enhance the sedative effect of Metyrosine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mirtazapine: CNS Depressants may enhance the CNS depressant effect of Mirtazapine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mixed Agonist / Antagonist Opioids: May diminish the analgesic effect of Analgesics (Opioid). Management: Seek alternatives to mixed agonist/antagonist opioids in patients receiving pure opioid agonists, and monitor for symptoms of therapeutic failure/high dose requirements (or withdrawal in opioid-dependent patients) if patients receive these combinations.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Paraldehyde: CNS Depressants may enhance the CNS depressant effect of Paraldehyde.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pegvisomant: Analgesics (Opioid) may diminish the therapeutic effect of Pegvisomant.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Perampanel: May enhance the CNS depressant effect of CNS Depressants. Management: Patients taking perampanel with any other drug that has CNS depressant activities should avoid complex and high-risk activities, particularly those such as driving that require alertness and coordination, until they have experience using the combination.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pramipexole: CNS Depressants may enhance the sedative effect of Pramipexole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ROPINIRole: CNS Depressants may enhance the sedative effect of ROPINIRole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rotigotine: CNS Depressants may enhance the sedative effect of Rotigotine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Selective Serotonin Reuptake Inhibitors: Analgesics (Opioid) may enhance the serotonergic effect of Selective Serotonin Reuptake Inhibitors. This may cause serotonin syndrome.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Oxybate: May enhance the CNS depressant effect of CNS Depressants. Management: Consider alternatives to combined use. When combined use is needed, consider minimizing doses of one or more drugs. Use of sodium oxybate with alcohol or sedative hypnotics is contraindicated.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Succinylcholine: May enhance the bradycardic effect of Analgesics (Opioid).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thiazide Diuretics: Analgesics (Opioid) may enhance the orthostatic hypotensive effect of Thiazide Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Zolpidem: CNS Depressants may enhance the CNS depressant effect of Zolpidem.  Management: Reduce the Intermezzo brand sublingual zolpidem dose to 1.75 mg for men who are also receiving other CNS depressants.  No such dose change is recommended for women.  Avoid use with other CNS depressants at bedtime; avoid use with alcohol.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F217493\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F217507\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse events were not observed in animal reproduction studies. Remifentanil has been shown to cross the placenta; fetal and maternal concentrations may be similar. Maternal apnea, as well as neonatal respiratory depression and sedation, may occur (Montgomery, 2006).",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F2734198\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Respiratory and cardiovascular status, blood pressure, heart rate",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F2734194\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Binds with stereospecific mu-opioid receptors at many sites within the CNS, increases pain threshold, alters pain reception, inhibits ascending pain pathways",
"    </p>",
"   </div>",
"   <div class=\"block phd drugH1Div\" id=\"F2734370\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Onset of action: 1-3 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Maximum effect: 3-5 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Duration: 3-10 minutes",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F2734195\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: V",
"     <sub>",
"      d",
"     </sub>",
"     :",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Neonates &lt;2 months: 452 &plusmn; 144 mL/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Children 2-6 years:  240 mL/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Children 7-12 years: 249 mL/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Adolescents: 223 &plusmn; 30.6 mL/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Adults: 100-176 mL/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: &sim;70% (primarily alpha",
"     <sub>",
"      1",
"     </sub>",
"     acid glycoprotein)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Rapid via blood and tissue esterases; not metabolized by plasma cholinesterase (pseudocholinesterase) and is not appreciably metabolized by the liver",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life (dose dependent): Terminal: 10-20 minutes; effective: 3-10 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Elimination: Clearance:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Neonates &lt;2 months of age: 90.5 &plusmn; 36.8 mL/minute/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Adolescents:  57.2 &plusmn; 21.2 mL/minute/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Adults:  41.2 mL/minute/kg",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      &ldquo;Clinical Practice Guidelines for the Sustained Use of Sedatives and Analgesics in the Critically Ill Adult. Task Force of the American College of Critical Care Medicine (ACCM) of the Society of Critical Care Medicine (SCCM), American Society of Health-System Pharmacists (ASHP), American College of Chest Physicians,&rdquo;",
"      <i>",
"       Am J Health Syst Pharm",
"      </i>",
"      , 2002, 59(2):150-78.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?30/56/31622/abstract-text/11826570 /pubmed\" id=\"11826570 \" target=\"_blank\">",
"        11826570",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Jacobi J, Fraser GL, Coursin DB, et al, \"Clinical Practice Guidelines for the Sustained Use of Sedatives and Analgesics in the Critically Ill Adult,\"",
"      <i>",
"       Crit Care Med",
"      </i>",
"      , 2002, 30(1):119-41.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?30/56/31622/abstract-text/11902253/pubmed\" id=\"11902253\" target=\"_blank\">",
"        11902253",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kumar P, Denson SE, Mancuso TJ, et al, \"Premedication for Nonemergency Endotracheal Intubation in the Neonate,\"",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 2010, 125(3):608-15.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?30/56/31622/abstract-text/20176672/pubmed\" id=\"20176672\" target=\"_blank\">",
"        20176672",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Scott LJ and Perry CM, \"Remifentanil: A Review of Its Use During the Induction and Maintenance of General Anaesthesia,\"",
"      <i>",
"       Drugs",
"      </i>",
"      , 2005, 65(13):1793-823.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?30/56/31622/abstract-text/16114980/pubmed\" id=\"16114980\" target=\"_blank\">",
"        16114980",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12998 Version 36.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-110.137.129.113-F7CC41E664-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_56_31622=[""].join("\n");
var outline_f30_56_31622=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F217521\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F217522\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2734185\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11444952\">",
"      Dosing: Neonatal",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2734196\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F217497\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F217482\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F217553\">",
"      Controlled Substance",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2734197\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F217558\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2734193\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2734186\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F217560\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F217557\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2734189\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2757155\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2734190\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299990\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F217491\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F217493\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F217507\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2734198\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2734194\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2734370\">",
"      Pharmacodynamics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2734195\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12998\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12998|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?5/50/5927?source=related_link\">",
"      Remifentanil: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?37/41/38547?source=related_link\">",
"      Remifentanil: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f30_56_31623="Adynamic bone disease";
var content_f30_56_31623=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F75592&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F75592&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic2\" style=\"width: 1040px;\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Micrograph showing adynamic or aplastic bone disease in end-stage renal disease",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 378px; height: 258px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Bone biopsy showing adynamic or aplastic bone disease in end-stage renal failure. This disorder is characterized by reductions in bone formation and bone resorption that are manifested histologically by thin osteoid seams (red lines at the bone surface; arrows) and little or no evidence of cellular activity.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of L Darryl Quarles, MD.",
"    </div>",
"   </div>",
"  </div>",
"  <div class=\"figure\" style=\"width: 450px\">",
"   <div class=\"ttl\">",
"    Micrograph showing normal bone histology",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 382px; height: 269px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Histologic appearance of normal bone.",
"    <br>",
"     (Left panel) Goldner Masson trichrome stain shows mineralized lamellar bone in blue and adjacent nonmineralized osteoid in red-brown. Osteoid usually comprises less than 25 percent of bone surfaces. The cellular area between the osseous structures is the marrow space.",
"     <br>",
"      (Right panel) Villanueva-stained section viewed under polarized light following time-spaced tetracycline labeling. Osteoid appears orange, mineralized bone is green, and tetracycline markers appear as luminescent yellow-green bands within bone and beneath osteoid (arrow). The distinct dual bands represent active mineralized bone formation.",
"      <div class=\"footnotes\">",
"      </div>",
"      <div class=\"reference\">",
"       Courtesy of L Darryl Quarles, MD.",
"      </div>",
"     </br>",
"    </br>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_56_31623=[""].join("\n");
var outline_f30_56_31623=null;
var title_f30_56_31624="Nerves of the abdominal wall";
var content_f30_56_31624=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F71423&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F71423&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 562px\">",
"   <div class=\"ttl\">",
"    Nerves of the abdominal wall",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 542px; height: 572px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_56_31624=[""].join("\n");
var outline_f30_56_31624=null;
var title_f30_56_31625="Clinical use of minimal residual disease detection in acute lymphoblastic leukemia";
var content_f30_56_31625=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Clinical use of minimal residual disease detection in acute lymphoblastic leukemia",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?30/56/31625/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/56/31625/contributors\">",
"     Wendy Stock, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/56/31625/contributors\">",
"     Zeev Estrov, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?30/56/31625/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/56/31625/contributors\">",
"     Richard A Larson, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?30/56/31625/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/56/31625/contributors\">",
"     Rebecca F Connor, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?30/56/31625/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 3, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The large majority of patients with newly diagnosed acute lymphoblastic leukemia (ALL) attain a morphologic and cytogenetic complete remission after induction chemotherapy. While most children and up to one-half of adults experience prolonged disease-free survival, many adults and some children will relapse and die of leukemia. Relapse is thought to result from residual leukemic cells that remain following the achievement of \"complete\" remission, but are below the limits of detection using conventional morphologic assessment. These subclinical levels of residual leukemia are termed minimal residual disease (MRD) and can be evaluated using more sensitive assays. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/32/15880?source=see_link\">",
"     \"Detection of minimal residual disease in acute lymphoblastic leukemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    MRD status is one of the most powerful predictors of disease-free and overall survival for children with ALL. The impact of MRD status on the prognosis of adults with ALL is less well studied, but appears to be strong. This topic review will focus on the clinical relevance of MRD monitoring in ALL. The methods for MRD monitoring in ALL and the use of MRD testing in acute myeloid leukemia and chronic myeloid leukemia are covered separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/32/15880?source=see_link\">",
"     \"Detection of minimal residual disease in acute lymphoblastic leukemia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/50/12073?source=see_link\">",
"     \"Remission criteria in acute myeloid leukemia and monitoring for residual disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/18/33066?source=see_link&amp;anchor=H20#H20\">",
"     \"Hematopoietic cell transplantation in chronic myeloid leukemia\", section on 'MRD and relapse after allo-HCT'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    As discussed further below, the immunophenotypic or genetic markers identified at diagnosis on the bulk of malignant cells may not be identical to those expressed by the more primitive \"leukemia stem cells.\" Thus, recurrent disease may arise from occult malignant progenitor cells that lack the markers assayed on their more populous progeny. Alternatively, some ALL cells with abnormal markers may persist for some time after treatment but lack the malignant stem cell's ability to recapitulate the disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     MRD IN CHILDREN",
"    </span>",
"    &nbsp;&mdash;&nbsp;Testing for minimal residual disease (MRD) has become a common part of the management of children with ALL. While it is clear that MRD status at various time points during and after treatment has prognostic value, it is less certain whether altering therapy based on the results of MRD testing will improve morbidity and mortality.",
"   </p>",
"   <p>",
"    Ongoing clinical trials are examining the use of MRD both as a prognostic factor and as a factor in decision making to determine whether therapy intensity should be escalated or reduced in a given patient. Specific questions regarding MRD testing that remain include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      What is the best test to measure MRD?",
"     </li>",
"     <li>",
"      What number of abnormal cells should be used to define MRD status?",
"     </li>",
"     <li>",
"      At what time in the",
"      <span class=\"nowrap\">",
"       disease/treatment",
"      </span>",
"      course should MRD be measured?",
"     </li>",
"     <li>",
"      Should treatment be intensified for patients with MRD positivity?",
"     </li>",
"     <li>",
"      Can treatment intensity be reduced for patients with no detectable MRD?",
"     </li>",
"     <li>",
"      Is there value in long-term MRD surveillance after the completion of therapy?",
"     </li>",
"     <li>",
"      How does the information gained from MRD testing differ among various ALL subtypes (eg, T-cell versus B-cell ALL, Philadelphia chromosome positive ALL)?",
"     </li>",
"     <li>",
"      Must the leukemic clone be completely eliminated (ie, not detected by these sensitive assays) in order to achieve long-term survival?",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Prognostic value",
"    </span>",
"    &nbsp;&mdash;&nbsp;Depending upon the method used, up to 70 percent of children with ALL will have MRD detectable immediately following the completion of induction therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/56/31625/abstract/1,2\">",
"     1,2",
"    </a>",
"    ], with levels declining in most patients during the first six months of treatment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/56/31625/abstract/3\">",
"     3",
"    </a>",
"    ]. Multiple studies have shown that patients with detectable MRD have significantly higher relapse rates [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/56/31625/abstract/3-11\">",
"     3-11",
"    </a>",
"    ]. The timing of MRD disappearance and reappearance appears to affect its prognostic value.",
"   </p>",
"   <p>",
"    MRD can be detected by polymerase chain reaction (PCR), reverse transcriptase PCR (RT-PCR), or multicolor flow cytometry. The ideal test is unknown and likely differs depending upon the ALL subtype and the clinical scenario. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/32/15880?source=see_link\">",
"     \"Detection of minimal residual disease in acute lymphoblastic leukemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Most of the published studies of MRD testing in children have used PCR. Variability in the results of these studies may be ascribed to a number of factors:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      PCR testing at different times during the treatment cycle",
"     </li>",
"     <li>",
"      Differences in PCR methodologies",
"     </li>",
"     <li>",
"      Differing sample sources (eg, fresh bone marrow versus archival material)",
"     </li>",
"     <li>",
"      Considerable variation in treatment regimens",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Large, prospective studies of MRD in pediatric ALL have conclusively demonstrated that the probability of long-term relapse-free survival is directly related to the level of residual disease, both early in the course of treatment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/56/31625/abstract/4,6,10,12-18\">",
"     4,6,10,12-18",
"    </a>",
"    ], and at later time points [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/56/31625/abstract/12,13,17\">",
"     12,13,17",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h3\">",
"     With conventional therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Children with detectable MRD demonstrate decreased disease-free and overall survival. Three large, independent prospective studies conclusively demonstrated the prognostic value of MRD in childhood ALL and set the stage for its use in determining treatment intensity in this population [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/56/31625/abstract/13,14,19\">",
"     13,14,19",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A prospective study of 246 children with ALL used semi-quantitative PCR to assess MRD status in the 178 patients for whom appropriate probes could be made [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/56/31625/abstract/13\">",
"       13",
"      </a>",
"      ]. MRD was detected in 42 and 25 percent of standard risk patients after induction and consolidation therapy, respectively. Detection of more than one ALL cell in 100 (&gt;0.01) following induction or &gt;0.001 tumor cells at later time points was associated with significantly higher relapse rates.",
"     </li>",
"     <li>",
"      Another study of 240 children with ALL evaluated MRD by semi-quantitative PCR on bone marrow samples from several time points during treatment [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/56/31625/abstract/14,20\">",
"       14,20",
"      </a>",
"      ]. MRD status at day 33 (end of induction) and day 78 (start of consolidation) were used to identify three risk groups with significantly different rates of relapse at three years:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Low-risk (43 percent): Those with no MRD detectable at either time point had a relapse rate of 2 percent.",
"     </li>",
"     <li>",
"      Intermediate-risk (43 percent): Those that were neither low nor high risk by MRD assays had a relapse rate of 23 percent.",
"     </li>",
"     <li>",
"      High-risk (15 percent): Those with &ge;10",
"      <sup>",
"       -3",
"      </sup>",
"      blasts detected at both time points had a relapse rate of 75 percent.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A third study used flow cytometry of bone marrow samples to evaluate MRD in 158 children with ALL [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/56/31625/abstract/19\">",
"       19",
"      </a>",
"      ]. Samples were collected after induction therapy and during weeks 14, 32, and 56 of continuation therapy, and again at 120 weeks (end of therapy). Leukemia cells were detectable in 23, 17, 5, and 4 percent of patients after remission induction and at weeks 14, 32, and 56, respectively. None of the 65 samples examined at the completion of therapy (week 120) showed evidence of disease. At all time points, MRD detection was associated with a significantly higher rate of relapse.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These and other studies have demonstrated that either semi-quantitative PCR or flow cytometry may be used to assess MRD in childhood ALL [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/56/31625/abstract/21\">",
"     21",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/32/15880?source=see_link\">",
"     \"Detection of minimal residual disease in acute lymphoblastic leukemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     In the setting of transplantation",
"    </span>",
"    &nbsp;&mdash;&nbsp;MRD studies have demonstrated prognostic value when measured before and after allogeneic hematopoietic cell transplantation (HCT).",
"   </p>",
"   <p>",
"    Patients with MRD prior to allogeneic HCT are more likely to relapse than those without detectable MRD [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/56/31625/abstract/22,23\">",
"     22,23",
"    </a>",
"    ]. As an example, a study of 64 children and adolescents with ALL in morphologic remission reported two-year event-free survival rates of 17 and 73 percent for those with and without MRD prior to allogeneic HCT, respectively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/56/31625/abstract/22\">",
"     22",
"    </a>",
"    ]. While prognostic, some patients with MRD prior to HCT will have long-term disease-free survival and some patients without detectable MRD prior to HCT may ultimately relapse. A study of children undergoing allogeneic HCT for ALL (64 patients) or acute myeloid leukemia (58 patients) confirmed that MRD status prior to HCT is associated with relapse-free and overall survival after HCT [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/56/31625/abstract/24\">",
"     24",
"    </a>",
"    ]. Five-year survival rates increased as pre-HCT MRD levels decreased being 29, 52, and 68 percent for patients with high, low, and no MRD. These results suggest that more than half of patients with low levels of MRD prior to HCT will have long-term survival after the procedure and that detection of MRD alone should not eliminate HCT as a treatment option.",
"   </p>",
"   <p>",
"    Several studies have also demonstrated an increased rate of relapse among those found to be MRD positive after allogeneic HCT [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/56/31625/abstract/25-28\">",
"     25-28",
"    </a>",
"    ]. As an example, a study of 71 children reported that those who exhibited MRD during the first three months following allogeneic HCT had a ninefold higher relapse rate when compared with MRD-negative patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/56/31625/abstract/25\">",
"     25",
"    </a>",
"    ]. Only 1 of 35 patients in complete remission had MRD detectable more than 6 months following transplant.",
"   </p>",
"   <p>",
"    It is not yet known how MRD status may be used to facilitate treatment decisions in patients who have undergone or are about to undergo allogeneic HCT for ALL. Potential uses include using these levels to determine the best timing of HCT, to modulate immunosuppressive therapy after HCT, or guide the use of donor lymphocyte infusions after HCT.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     In E2A/PBX1",
"    </span>",
"    &nbsp;&mdash;&nbsp;The",
"    <span class=\"nowrap\">",
"     E2A/PBX1",
"    </span>",
"    fusion gene resulting from t(1;19)(q23;p13) is a marker of poor prognosis in children with ALL. Several small studies have noted that MRD monitoring for",
"    <span class=\"nowrap\">",
"     E2A/PBX1",
"    </span>",
"    by qualitative RT-PCR at the end of consolidation therapy was not predictive of treatment outcome [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/56/31625/abstract/29-31\">",
"     29-31",
"    </a>",
"    ]. Discordance between matched blood and bone marrow samples was noted in a number of these cases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/56/31625/abstract/29\">",
"     29",
"    </a>",
"    ], emphasizing the need for careful comparison of these tissues in future MRD studies. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/25/22938?source=see_link&amp;anchor=H7#H7\">",
"     \"Cytogenetics in acute lymphoblastic leukemia\", section on '1;19 translocation in pre-B cell ALL'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Using MRD to escalate therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;As described above, patients with detectable MRD have an increased risk of relapse after conventional therapy. The absolute risk varies depending upon a number of factors including the timing of MRD evaluation, the sensitivity of the method used to evaluate MRD, and baseline characteristics of the patient and tumor. Given this increased rate of relapse, prospective trials have attempted to decrease this risk by escalating therapy in those demonstrating MRD.",
"   </p>",
"   <p>",
"    A prospective trial in precursor B ALL used two tumor-specific PCR probes with sensitivities to detect at least 10(-4) tumor cells to measure residual disease at treatment days 33 and 78 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/56/31625/abstract/32\">",
"     32",
"    </a>",
"    ]. MRD assessment was able to categorize 3184 children with ALL who were alive and failure-free at day 78 of therapy into three risk categories:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Standard risk (42 percent) &mdash; Neither PCR probe detected MRD at day 33.",
"     </li>",
"     <li>",
"      High risk (6 percent) &mdash; At least one PCR probe detected MRD at day 78 with a quantitative MRD level of 10",
"      <sup>",
"       -3",
"      </sup>",
"      or greater.",
"     </li>",
"     <li>",
"      Intermediate risk (52 percent) &mdash; MRD detected at one or both time points, but at a quantitative level less than 10",
"      <sup>",
"       -3",
"      </sup>",
"      .",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    All patients with high risk disease underwent a more intensive consolidation regimen the specifics of which were randomly assigned. Patients with the following clinical characteristics were also treated with more intensive therapy irrespective of their MRD categorization: poor initial response to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    , induction failure, and those with an",
"    <span class=\"nowrap\">",
"     MLL/AF4",
"    </span>",
"    fusion transcript. At a median follow-up of four years, the estimates for event-free survival at five years were 92, 78, and 50 percent for patients with standard, intermediate, and high risk MRD, respectively. The five-year overall survival estimates for the same groups were 98, 93, and 61 percent, respectively.",
"   </p>",
"   <p>",
"    Clinical outcomes of patients with high risk MRD assigned to different treatment regimens have not yet been reported. However, the five-year event free survival rate of 50 percent compares favorably with historic controls treated with standard therapies that have relapse rates as high as 75 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/56/31625/abstract/14,20\">",
"     14,20",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H4\">",
"     'With conventional therapy'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Using MRD to minimize therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;As long-term survival in childhood ALL improves, more children experience late adverse effects including central nervous system impairment, decreased linear growth, cardiotoxicity, infertility, and an increased incidence of secondary cancers. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/44/40649?source=see_link&amp;anchor=H7#H7\">",
"     \"Overview of the outcome of acute lymphoblastic leukemia in children\", section on 'Late effects'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Given these late effects, researchers have tried to identify a group of ALL patients that may be treated with less intensive therapy without compromising survival. Ongoing trials are evaluating whether patients who demonstrate a rapid clearance of tumor cells during induction therapy resulting in no detectable MRD may be candidates for less intensive consolidation. At this point it is unknown whether the good outcomes seen in this patient group are dependent upon the use of standard induction, consolidation, and maintenance or if they may be curable with less intensive therapy.",
"   </p>",
"   <p>",
"    As an example, a multicenter randomized trial of over 3000 consecutive children and young adults (&le;25 years) with newly diagnosed ALL examined the use of MRD measurements obtained after induction and consolidation therapy to minimize maintenance therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/56/31625/abstract/33\">",
"     33",
"    </a>",
"    ]. Clinical criteria were initially used to classify the disease as standard, intermediate, or high risk, then MRD measurements following induction and before interim maintenance were used to further revise this classification. Patients with standard or intermediate clinical risk who achieved MRD negativity were randomly assigned to receive one or two delayed intensification treatments. When compared with those assigned to the standard two delayed intensification treatments, those assigned to a single intensification had a similar estimated event-free survival (94.4 versus 95.5 percent), overall survival (97.9 versus 98.5 percent), and rate of relapse (4.2 versus 2.3 percent) at five years. Our confidence in the ability of this evaluation to detect a difference in outcome, if present, is limited by the low event rate and short follow-up.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Long-term surveillance",
"    </span>",
"    &nbsp;&mdash;&nbsp;It is unknown whether interventions based upon the serial analysis of MRD after the completion of therapy will affect clinical outcomes. Theoretically, all clinically evident relapses should be preceded by the appearance of previously undetectable MRD or a rise in amount of measurable MRD [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/56/31625/abstract/34\">",
"     34",
"    </a>",
"    ]. However, the length of time between detection of potential relapse with MRD testing and the clinical detection of relapse with standard methods is not known. In addition, not all patients with detectable MRD will ultimately relapse. As such, the value of serial, quantitative measurements of MRD in long-term survivors is unknown.",
"   </p>",
"   <p>",
"    Despite the finding that the presence of residual disease following completion of combination chemotherapy or allogeneic transplant portends relapse, other studies suggest that not all patients with MRD are destined to relapse:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In one study, approximately 20 percent of patients with an MRD level greater than 10(-2) had not yet relapsed at a median follow-up of 38 months [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/56/31625/abstract/13\">",
"       13",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      MRD has been detected in bone marrow samples obtained as long as nine years following completion of therapy for ALL without clinical relapse [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/56/31625/abstract/35\">",
"       35",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A highly sensitive quantitative PCR assay demonstrated MRD in 15 of 17 children with ALL who remained in remission 2 to 35 months after completion of all treatment [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/56/31625/abstract/36\">",
"       36",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Long-term persistence of MRD without clinical relapse has also been described in patients with p210",
"      <span class=\"nowrap\">",
"       BCR/ABL",
"      </span>",
"      positive ALL and in children with t(1;19) ALL.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    It is clear that the leukemic clone can establish a prolonged \"dormancy.\" As an example, in one study, bone marrow samples obtained at relapse in 8 of 12 children who relapsed more than 10 years after the diagnosis of ALL, demonstrated the identical IgH or TCR gene rearrangement as that present in the diagnostic bone marrow specimen [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/56/31625/abstract/37\">",
"     37",
"    </a>",
"    ]. This suggests that the leukemic cells, or clonal precursors, survived for more than a decade.",
"   </p>",
"   <p>",
"    While it is unclear whether the identification of MRD should lead to subsequent therapy, the presence of a persistently positive MRD result should trigger preparation for potential disease relapse in the future. As an example, a search for potential donors may be undertaken for patients who have not yet undergone allogeneic hematopoietic cell transplantation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     MRD IN ADULTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The role of minimal residual disease (MRD) testing in adults with ALL is less well understood than in children. MRD status at various time points during and after treatment appears to have prognostic value. It is unknown whether altering therapy based on the results of MRD testing will improve morbidity and mortality.",
"   </p>",
"   <p>",
"    Ongoing clinical trials are examining the use of MRD both as a prognostic factor and as a factor in decision making to determine whether therapy intensity should be escalated or reduced in a given patient. Questions being addressed in adult populations are similar to those being addressed in children. (See",
"    <a class=\"local\" href=\"#H2\">",
"     'MRD in children'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Effect on prognosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Depending upon the method used, up to 80 percent of adults with ALL will have MRD detectable immediately following the completion of induction therapy. Multiple studies have shown that patients with detectable MRD have significantly higher relapse rates.",
"   </p>",
"   <p>",
"    MRD can be detected by polymerase chain reaction (PCR), reverse transcriptase PCR (RT-PCR), or multicolor flow cytometry. The ideal test is unknown and likely differs depending upon the ALL subtype and the clinical scenario. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/32/15880?source=see_link\">",
"     \"Detection of minimal residual disease in acute lymphoblastic leukemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     With standard therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prospective studies that have evaluated serial, quantitative measurements of residual disease in adults with ALL have demonstrated that the measurement of MRD can predict those destined to relapse and those who will remain in remission [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/56/31625/abstract/12,34,38-41\">",
"     12,34,38-41",
"    </a>",
"    ]. The following are examples of studies that have indicated that MRD positivity at various time points after the initiation of treatment is a strong factor predicting for relapse in adults with ALL:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A prospective trial of adults with standard risk ALL used tumor-specific PCR probes to measure residual disease at treatment days 11 (mid-induction I), 24 (end of induction I), and week 16 (prior to consolidation II) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/56/31625/abstract/12\">",
"       12",
"      </a>",
"      ]. MRD assessment was able to categorize 196 patients into three risk categories:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Low risk (10 percent) &mdash; No patients with MRD &lt;10(-4) at both days 11 and 24 had relapsed by three years.",
"     </li>",
"     <li>",
"      High risk (23 percent) &mdash; Of those patients with MRD &gt;10(-4) at both day 24 and week 16, 94 percent had relapsed by three years.",
"     </li>",
"     <li>",
"      Intermediate risk (67 percent) &mdash; Of those patients not meeting criteria for low or high risk MRD, 47 percent had relapsed by three years.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Another prospective study of 102 adolescent and adult patients with ALL that used multiparameter flow cytometry to define MRD based upon the percent of leukemia-associated phenotype (LAP) cells reported [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/56/31625/abstract/39\">",
"       39",
"      </a>",
"      ]:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Median relapse-free survival (RFS) times for patients in morphologic complete remission at day 35 were 16 and 42 months for patients with greater than and less than 0.05 percent LAP, respectively.",
"     </li>",
"     <li>",
"      The 12 patients with &lt;0.03 percent LAP cells by day 14 had a projected RFS rate of 90 percent at five years.",
"     </li>",
"     <li>",
"      Of those achieving morphologic complete remission after day 35, all with &gt;0.1 percent LAP cells had relapsed by two years.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A third prospective study of 132 patients with Philadelphia chromosome negative ALL used a LAP cell percentage of &ge;0.1 percent by flow cytometry to define MRD positivity for 116 eligible patients [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/56/31625/abstract/40\">",
"       40",
"      </a>",
"      ]:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Among patients with precursor B cell ALL, those with MRD &lt;0.1 percent after induction therapy had a significantly lower relapse rate (26 versus 81 percent) and higher rate of leukemia-free survival (61 versus 17 percent) at three years. This advantage could not be demonstrated for patients with T cell ALL.",
"     </li>",
"     <li>",
"      There was a nonsignificant trend towards improved clinical outcomes among those patients without MRD after consolidation therapy.",
"     </li>",
"     <li>",
"      Patients less than 35 years old who presented with a WBC count &lt;30K and a favorable immunophenotype (not pro-B or T cell) who achieved MRD negativity after a single course of induction had three-year relapse and leukemia-free survival rates of 9 and 71 percent, respectively.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Another prospective study of 580 patients with Philadelphia chromosome negative ALL who attained a cytologic complete response (CR) after two induction phases used tumor-specific PCR probes with a sensitivity of &ge;10",
"      <sup>",
"       -4",
"      </sup>",
"      to measure MRD [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/56/31625/abstract/41\">",
"       41",
"      </a>",
"      ]. MRD negativity was attained in 76 percent by week 16 after consolidation. When compared with those patients with measurable MRD, patients who attained MRD negativity had a higher rate of continuous cytologic CR (69 versus 26 percent) and overall survival (80 versus 42 percent) at five years. Among those with measurable MRD, when compared with those treated with chemotherapy alone, patients who underwent allogeneic hematopoietic cell transplantation (HCT) in first cytologic CR were more likely to retain cytologic CR at five years (66 versus 12 percent).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     In the setting of transplantation",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is a paucity of data regarding the clinical use of MRD studies before and after hematopoietic cell transplantation (HCT) in adults with ALL. Small series have demonstrated that the detection of MRD after HCT is associated with an increased risk of relapse in patients with Philadelphia chromosome negative [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/56/31625/abstract/38\">",
"     38",
"    </a>",
"    ] or positive [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/56/31625/abstract/30\">",
"     30",
"    </a>",
"    ] ALL. The role of MRD evaluation prior to allogeneic HCT is even more uncertain, with one prospective study in patients with Philadelphia chromosome positive disease failing to demonstrate a prediction of outcome [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/56/31625/abstract/42\">",
"     42",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    It is not yet known how MRD status may be used to facilitate treatment decisions in patients who have undergone or are about to undergo allogeneic HCT for ALL. As suggested by the GMALL study [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/56/31625/abstract/41\">",
"     41",
"    </a>",
"    ], patients who remain MRD positive may benefit from an early allogeneic transplant but this remains to be proven in an unbiased prospective study.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Philadelphia chromosome positive ALL",
"    </span>",
"    &nbsp;&mdash;&nbsp;The",
"    <span class=\"nowrap\">",
"     BCR/ABL",
"    </span>",
"    fusion gene associated with the Philadelphia (Ph) chromosome, t(9;22), which occurs in up to 30 percent of adults with ALL, is a marker of poor prognosis. Such patients are routinely treated with allogeneic hematopoietic cell transplantation (HCT) after remission induction.",
"   </p>",
"   <p>",
"    It is currently unclear if MRD status can be used to alter the therapy of such patients.",
"   </p>",
"   <p>",
"    RT-PCR can be used to detect and monitor the",
"    <span class=\"nowrap\">",
"     BCR/ABL",
"    </span>",
"    fusion gene [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/56/31625/abstract/30,43\">",
"     30,43",
"    </a>",
"    ]. There are two main fusion gene variants. Approximately 70 percent of patients have the p190 subtype. The p210 subtype (present in the vast majority of patients with chronic myeloid leukemia) accounts for 25 to 30 percent of ALL cases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/56/31625/abstract/44\">",
"     44",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/49/31512?source=see_link\">",
"     \"Molecular genetics of chronic myeloid leukemia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/33/40474?source=see_link&amp;anchor=H12#H12\">",
"     \"Cellular and molecular biology of chronic myeloid leukemia\", section on 'BCR-ABL1'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Detection of MRD by RT-PCR analysis of",
"    <span class=\"nowrap\">",
"     BCR/ABL",
"    </span>",
"    predicts early relapse [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/56/31625/abstract/30,43\">",
"     30,43",
"    </a>",
"    ]. In contrast, one report indicated that Ph chromosome positive ALL patients who have no detectable disease by RT-PCR after initial chemotherapy have a more favorable outcome [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/56/31625/abstract/44\">",
"     44",
"    </a>",
"    ]. Whether these patients can be cured without allogeneic HCT is unknown. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/26/3497?source=see_link&amp;anchor=H4420436#H4420436\">",
"     \"Post-remission therapy for Philadelphia chromosome positive acute lymphoblastic leukemia in adults\", section on 'Post-remission therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Several studies of MRD status following allogeneic or autologous HCT in patients with Philadelphia chromosome positive ALL suggest that MRD positivity may identify patients who are likely to relapse [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/56/31625/abstract/30,43,45,46\">",
"     30,43,45,46",
"    </a>",
"    ]. In the largest series, the relative risk for relapse was significantly higher for those patients with a detectable",
"    <span class=\"nowrap\">",
"     BCR/ABL",
"    </span>",
"    transcript following HCT, in comparison to those without detectable",
"    <span class=\"nowrap\">",
"     BCR/ABL",
"    </span>",
"    (relative risk 5.7, p = .025) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/56/31625/abstract/30\">",
"     30",
"    </a>",
"    ]. The median time from detection of a positive PCR result to clinical relapse was 94 days.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     In MLL/AF4 ALL",
"    </span>",
"    &nbsp;&mdash;&nbsp;The",
"    <span class=\"nowrap\">",
"     MLL/AF4",
"    </span>",
"    fusion gene resulting from t(4;11)(q21;q23) is associated with a poor prognosis in both adults and children with ALL. MRD testing appears to be prognostic in this group of patients. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/25/22938?source=see_link\">",
"     \"Cytogenetics in acute lymphoblastic leukemia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/5/41049?source=see_link\">",
"     \"Genetic abnormalities in hematologic and lymphoid malignancies\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A prospective analysis of quantitative RT-PCR MRD monitoring in 25 patients with the",
"    <span class=\"nowrap\">",
"     MLL/AF4",
"    </span>",
"    transcript reported that patients with continued MRD positivity and those who initially attain a clinical remission but then convert from negative to positive MRD have a high relapse rate [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/56/31625/abstract/47\">",
"     47",
"    </a>",
"    ]. In contrast, patients who remained PCR negative during the first three to six months following diagnosis appeared to enjoy prolonged disease-free survival. Further, PCR negativity following transplant is highly predictive for longer relapse-free survival [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/56/31625/abstract/48-50\">",
"     48-50",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     To escalate care",
"    </span>",
"    &nbsp;&mdash;&nbsp;Adults with ALL have a low rate of long-term survival. While a small percentage of patients may be cured with conventional therapy, the majority of patients will relapse. Intensive therapy, such as allogeneic hematopoietic cell transplantation (HCT) is associated with high rates of morbidity and mortality. Initial attempts have been made to use MRD to identify patients who require such escalated care.",
"   </p>",
"   <p>",
"    A prospective study of 142 adults with ALL who had completed consolidation therapy reported that MRD was negative, positive, or not assessable by RT-PCR in 58, 54, and 30 patients, respectively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/56/31625/abstract/51\">",
"     51",
"    </a>",
"    ]. Patients who were MRD negative were given maintenance therapy and had disease-free and overall survival rates at five years of 72 and 75 percent, respectively. Patients who were MRD positive underwent allogeneic HCT (if a donor were available) or autologous HCT (if a donor were not available) and had disease-free and overall survival rates at five years of 33 and 14 percent, respectively.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     To minimize therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Among adults with ALL, there is unlikely to be a large group of patients that may be treated with less intensive therapy without compromising survival. As such, the potential for MRD monitoring to allow for a reduction in therapy in adults is less than it is for children. (See",
"    <a class=\"local\" href=\"#H8\">",
"     'Using MRD to minimize therapy'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Surveillance",
"    </span>",
"    &nbsp;&mdash;&nbsp;It is unknown whether clinical outcomes can be improved by interventions based upon the serial analysis of MRD after the completion of therapy. While all clinically evident relapses should be preceded by the appearance of previously undetectable MRD or a rise in the amount of measurable MRD, it is unknown whether all cases that become MRD positive ultimately relapse. As such, the value of serial, quantitative measurements of MRD in long-term survivors is unknown. \"Molecular relapse\" does not always predict subsequent clinical relapse, nor does a negative result guarantee leukemia-free survival:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In cases where the disease remains dormant for years, as described above [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/56/31625/abstract/37\">",
"       37",
"      </a>",
"      ], it is possible that the leukemic clone has come under the control of an immunologic or other homeostatic mechanism.",
"     </li>",
"     <li>",
"      Cells containing a specific fusion gene transcript, such as p210",
"      <span class=\"nowrap\">",
"       BCR/ABL",
"      </span>",
"      or",
"      <span class=\"nowrap\">",
"       E2A/PBX1,",
"      </span>",
"      though members of the leukemic clone, may behave as \"preleukemic\" cells that require additional genetic mutations, perhaps acquired by a subclone of descendant cells at the time of diagnosis, in order to become fully \"leukemic\" [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/56/31625/abstract/52-54\">",
"       52-54",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      False-negative PCR results can occur with clone-specific PCR as a result of subsequent clonal evolution in IgH or TCR genes of the leukemia cells; such a change would limit the predictive power of a negative result [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/56/31625/abstract/34,35,55,56\">",
"       34,35,55,56",
"      </a>",
"      ]. This potential error might be reduced by performing flow cytometric studies concurrently with PCR [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/56/31625/abstract/57\">",
"       57",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Because leukemic blasts are considered malignant counterparts of normal, immature hematopoietic progenitor cells, they express closely related differentiation and lineage markers [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/56/31625/abstract/36\">",
"       36",
"      </a>",
"      ]. It is therefore possible that residual \"leukemic\" cells may in fact be normal hematopoietic cells. This observation is highlighted by the fact that \"disease-specific\" fusion gene products, including",
"      <span class=\"nowrap\">",
"       BCR/ABL,",
"      </span>",
"      <span class=\"nowrap\">",
"       BCL2/IgH,",
"      </span>",
"      <span class=\"nowrap\">",
"       MLL/AF4,",
"      </span>",
"      and the partial tandem duplication of MLL have been detected with highly sensitive PCR techniques in healthy individuals [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/56/31625/abstract/58-61\">",
"       58-61",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     MRD positive",
"    </span>",
"    &nbsp;&mdash;&nbsp;The long-term outcome of patients with continuous complete remission but positive MRD testing is not known. Serial quantitative measurements in such patients may be helpful, as increasing values for MRD may identify patients at a higher risk of relapse [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/56/31625/abstract/13,62-64\">",
"     13,62-64",
"    </a>",
"    ]. However, residual disease is a dynamic process, with the numbers of residual leukemic cells fluctuating over time [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/56/31625/abstract/36,65\">",
"     36,65",
"    </a>",
"    ]. Although levels of residual disease may fall below the detection limit of even highly sensitive molecular assays shortly after therapy, the leukemic cells do not necessarily disappear when the patient enters into clinical remission. They may subsequently increase until clinically overt disease recurs, or they may fall below the threshold of detection again. A \"positive\" to \"negative\" to \"positive\" pattern of PCR results is commonly seen. As such, therapeutic decisions on whether to continue therapy or begin salvage therapy cannot at present be based solely upon a single positive MRD result. However, if a positive MRD result persists, efforts should be made to prepare for potential disease relapse in the future. As an example, a search for potential donors may be undertaken for patients who have not yet undergone allogeneic hematopoietic cell transplantation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     MRD negative",
"    </span>",
"    &nbsp;&mdash;&nbsp;It is unknown whether serial testing of MRD in patients who are MRD negative after the completion of therapy may detect relapses at earlier, more curable stage. In a prospective study, 105 adult patients with standard-risk ALL who were in hematologic remission following the first year of chemotherapy and who had tested MRD negative prior to study entry, were followed with serial MRD testing for a median of 16 months [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/56/31625/abstract/66\">",
"     66",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Twenty-two of the original 105 patients relapsed after the first year of therapy. MRD was detected prior to clinical relapse in 17 of these patients (77 percent). The median interval between MRD positivity and clinical relapse was 9.5 months.",
"     </li>",
"     <li>",
"      Of the 77 patients who were consistently MRD negative, only five (6 percent) have subsequently relapsed.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?17/34/17955?source=see_link\">",
"       \"Patient information: Acute lymphoblastic leukemia (ALL) treatment in adults (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The term minimal residual disease (MRD) refers to residual leukemia cells that remain following the achievement of \"complete\" remission, but are below the limits of detection using conventional morphologic assessment. These subclinical levels of residual leukemia are thought to be responsible for relapse after initial disease response. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      While virtually all patients with ALL will attain a morphologic complete remission, up to 70 percent of children and 80 percent of adults will have MRD detectable immediately following the completion of induction therapy. Patients with detectable MRD have significantly higher relapse rates and the timing of MRD disappearance and reappearance appears to affect its prognostic value. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Prognostic value'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H11\">",
"       'Effect on prognosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      It is currently unknown whether MRD measurements can be used to modify therapy to improve clinical outcomes. Ongoing trials are evaluating the escalation of therapy intensity in MRD positive cases and the reduction of therapy intensity in MRD negative cases. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Using MRD to escalate therapy'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H16\">",
"       'To escalate care'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      It is not clear whether MRD measurement should play a role in the long-term surveillance of patients who have completed therapy. However, if a positive MRD result persists, efforts should be made to prepare for potential disease relapse in the future. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Long-term surveillance'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/56/31625/abstract/1\">",
"      Goulden NJ, Knechtli CJ, Garland RJ, et al. Minimal residual disease analysis for the prediction of relapse in children with standard-risk acute lymphoblastic leukaemia. Br J Haematol 1998; 100:235.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/56/31625/abstract/2\">",
"      Kuang S, Gu L, Dong S, et al. Long-term follow-up of minimal residual disease in childhood acute lymphoblastic leukemia patients by polymerase chain reaction analysis of multiple clone-specific or malignancy-specific gene markers. Cancer Genet Cytogenet 1996; 88:110.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/56/31625/abstract/3\">",
"      Foroni L, Coyle LA, Papaioannou M, et al. Molecular detection of minimal residual disease in adult and childhood acute lymphoblastic leukaemia reveals differences in treatment response. Leukemia 1997; 11:1732.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/56/31625/abstract/4\">",
"      Madzo J, Zuna J, Muz&iacute;kov&aacute; K, et al. Slower molecular response to treatment predicts poor outcome in patients with TEL/AML1 positive acute lymphoblastic leukemia: prospective real-time quantitative reverse transcriptase-polymerase chain reaction study. Cancer 2003; 97:105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/56/31625/abstract/5\">",
"      Steenbergen EJ, Verhagen OJ, van den Berg H, et al. Rearrangement status of the malignant cell determines type of secondary IgH rearrangement (V-replacement or V to DJ joining) in childhood B precursor acute lymphoblastic leukemia. Leukemia 1997; 11:1258.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/56/31625/abstract/6\">",
"      Brisco MJ, Condon J, Hughes E, et al. Outcome prediction in childhood acute lymphoblastic leukaemia by molecular quantification of residual disease at the end of induction. Lancet 1994; 343:196.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/56/31625/abstract/7\">",
"      Gruhn B, Hongeng S, Yi H, et al. Minimal residual disease after intensive induction therapy in childhood acute lymphoblastic leukemia predicts outcome. Leukemia 1998; 12:675.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/56/31625/abstract/8\">",
"      Wasserman R, Galili N, Ito Y, et al. Residual disease at the end of induction therapy as a predictor of relapse during therapy in childhood B-lineage acute lymphoblastic leukemia. J Clin Oncol 1992; 10:1879.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/56/31625/abstract/9\">",
"      Eckert C, Biondi A, Seeger K, et al. Prognostic value of minimal residual disease in relapsed childhood acute lymphoblastic leukaemia. Lancet 2001; 358:1239.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/56/31625/abstract/10\">",
"      Patel B, Rai L, Buck G, et al. Minimal residual disease is a significant predictor of treatment failure in non T-lineage adult acute lymphoblastic leukaemia: final results of the international trial UKALL XII/ECOG2993. Br J Haematol 2010; 148:80.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/56/31625/abstract/11\">",
"      Stow P, Key L, Chen X, et al. Clinical significance of low levels of minimal residual disease at the end of remission induction therapy in childhood acute lymphoblastic leukemia. Blood 2010; 115:4657.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/56/31625/abstract/12\">",
"      Br&uuml;ggemann M, Raff T, Flohr T, et al. Clinical significance of minimal residual disease quantification in adult patients with standard-risk acute lymphoblastic leukemia. Blood 2006; 107:1116.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/56/31625/abstract/13\">",
"      Cav&eacute; H, van der Werff ten Bosch J, Suciu S, et al. Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia. European Organization for Research and Treatment of Cancer--Childhood Leukemia Cooperative Group. N Engl J Med 1998; 339:591.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/56/31625/abstract/14\">",
"      van Dongen JJ, Seriu T, Panzer-Gr&uuml;mayer ER, et al. Prognostic value of minimal residual disease in acute lymphoblastic leukaemia in childhood. Lancet 1998; 352:1731.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/56/31625/abstract/15\">",
"      Nyvold C, Madsen HO, Ryder LP, et al. Precise quantification of minimal residual disease at day 29 allows identification of children with acute lymphoblastic leukemia and an excellent outcome. Blood 2002; 99:1253.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/56/31625/abstract/16\">",
"      Coustan-Smith E, Sancho J, Behm FG, et al. Prognostic importance of measuring early clearance of leukemic cells by flow cytometry in childhood acute lymphoblastic leukemia. Blood 2002; 100:52.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/56/31625/abstract/17\">",
"      Gameiro P, Moreira I, Yetgin S, et al. Polymerase chain reaction (PCR)- and reverse transcription PCR-based minimal residual disease detection in long-term follow-up of childhood acute lymphoblastic leukaemia. Br J Haematol 2002; 119:685.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/56/31625/abstract/18\">",
"      Zhou J, Goldwasser MA, Li A, et al. Quantitative analysis of minimal residual disease predicts relapse in children with B-lineage acute lymphoblastic leukemia in DFCI ALL Consortium Protocol 95-01. Blood 2007; 110:1607.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/56/31625/abstract/19\">",
"      Coustan-Smith E, Behm FG, Sanchez J, et al. Immunological detection of minimal residual disease in children with acute lymphoblastic leukaemia. Lancet 1998; 351:550.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/56/31625/abstract/20\">",
"      Willemse MJ, Seriu T, Hettinger K, et al. Detection of minimal residual disease identifies differences in treatment response between T-ALL and precursor B-ALL. Blood 2002; 99:4386.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/56/31625/abstract/21\">",
"      Th&ouml;rn I, Forestier E, Botling J, et al. Minimal residual disease assessment in childhood acute lymphoblastic leukaemia: a Swedish multi-centre study comparing real-time polymerase chain reaction and multicolour flow cytometry. Br J Haematol 2011; 152:743.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/56/31625/abstract/22\">",
"      Knechtli CJ, Goulden NJ, Hancock JP, et al. Minimal residual disease status before allogeneic bone marrow transplantation is an important determinant of successful outcome for children and adolescents with acute lymphoblastic leukemia. Blood 1998; 92:4072.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/56/31625/abstract/23\">",
"      Uzunel M, Mattsson J, Jaksch M, et al. The significance of graft-versus-host disease and pretransplantation minimal residual disease status to outcome after allogeneic stem cell transplantation in patients with acute lymphoblastic leukemia. Blood 2001; 98:1982.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/56/31625/abstract/24\">",
"      Leung W, Pui CH, Coustan-Smith E, et al. Detectable minimal residual disease before hematopoietic cell transplantation is prognostic but does not preclude cure for children with very-high-risk leukemia. Blood 2012; 120:468.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/56/31625/abstract/25\">",
"      Knechtli CJ, Goulden NJ, Hancock JP, et al. Minimal residual disease status as a predictor of relapse after allogeneic bone marrow transplantation for children with acute lymphoblastic leukaemia. Br J Haematol 1998; 102:860.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/56/31625/abstract/26\">",
"      Radich J, Ladne P, Gooley T. Polymerase chain reaction-based detection of minimal residual disease in acute lymphoblastic leukemia predicts relapse after allogeneic BMT. Biol Blood Marrow Transplant 1995; 1:24.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/56/31625/abstract/27\">",
"      Dominietto A, Pozzi S, Miglino M, et al. Donor lymphocyte infusions for the treatment of minimal residual disease in acute leukemia. Blood 2007; 109:5063.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/56/31625/abstract/28\">",
"      Elorza I, Palacio C, Dapena JL, et al. Relationship between minimal residual disease measured by multiparametric flow cytometry prior to allogeneic hematopoietic stem cell transplantation and outcome in children with acute lymphoblastic leukemia. Haematologica 2010; 95:936.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/56/31625/abstract/29\">",
"      Hunger SP, Fall MZ, Camitta BM, et al. E2A-PBX1 chimeric transcript status at end of consolidation is not predictive of treatment outcome in childhood acute lymphoblastic leukemias with a t(1;19)(q23;p13): a Pediatric Oncology Group study. Blood 1998; 91:1021.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/56/31625/abstract/30\">",
"      Radich J, Gehly G, Lee A, et al. Detection of bcr-abl transcripts in Philadelphia chromosome-positive acute lymphoblastic leukemia after marrow transplantation. Blood 1997; 89:2602.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/56/31625/abstract/31\">",
"      Izraeli S, Janssen JW, Haas OA, et al. Detection and clinical relevance of genetic abnormalities in pediatric acute lymphoblastic leukemia: a comparison between cytogenetic and polymerase chain reaction analyses. Leukemia 1993; 7:671.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/56/31625/abstract/32\">",
"      Conter V, Bartram CR, Valsecchi MG, et al. Molecular response to treatment redefines all prognostic factors in children and adolescents with B-cell precursor acute lymphoblastic leukemia: results in 3184 patients of the AIEOP-BFM ALL 2000 study. Blood 2010; 115:3206.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/56/31625/abstract/33\">",
"      Vora A, Goulden N, Wade R, et al. Treatment reduction for children and young adults with low-risk acute lymphoblastic leukaemia defined by minimal residual disease (UKALL 2003): a randomised controlled trial. Lancet Oncol 2013; 14:199.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/56/31625/abstract/34\">",
"      Nizet Y, Van Daele S, Lewalle P, et al. Long-term follow-up of residual disease in acute lymphoblastic leukemia patients in complete remission using clonogeneic IgH probes and the polymerase chain reaction. Blood 1993; 82:1618.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/56/31625/abstract/35\">",
"      Potter MN, Steward CG, Oakhill A. The significance of detection of minimal residual disease in childhood acute lymphoblastic leukaemia. Br J Haematol 1993; 83:412.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/56/31625/abstract/36\">",
"      Roberts WM, Estrov Z, Ouspenskaia MV, et al. Measurement of residual leukemia during remission in childhood acute lymphoblastic leukemia. N Engl J Med 1997; 336:317.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/56/31625/abstract/37\">",
"      Vora A, Frost L, Goodeve A, et al. Late relapsing childhood lymphoblastic leukemia. Blood 1998; 92:2334.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/56/31625/abstract/38\">",
"      Mortuza FY, Papaioannou M, Moreira IM, et al. Minimal residual disease tests provide an independent predictor of clinical outcome in adult acute lymphoblastic leukemia. J Clin Oncol 2002; 20:1094.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/56/31625/abstract/39\">",
"      Vidriales MB, P&eacute;rez JJ, L&oacute;pez-Berges MC, et al. Minimal residual disease in adolescent (older than 14 years) and adult acute lymphoblastic leukemias: early immunophenotypic evaluation has high clinical value. Blood 2003; 101:4695.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/56/31625/abstract/40\">",
"      Holowiecki J, Krawczyk-Kulis M, Giebel S, et al. Status of minimal residual disease after induction predicts outcome in both standard and high-risk Ph-negative adult acute lymphoblastic leukaemia. The Polish Adult Leukemia Group ALL 4-2002 MRD Study. Br J Haematol 2008; 142:227.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/56/31625/abstract/41\">",
"      G&ouml;kbuget N, Kneba M, Raff T, et al. Adult patients with acute lymphoblastic leukemia and molecular failure display a poor prognosis and are candidates for stem cell transplantation and targeted therapies. Blood 2012; 120:1868.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/56/31625/abstract/42\">",
"      Yanada M, Sugiura I, Takeuchi J, et al. Prospective monitoring of BCR-ABL1 transcript levels in patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia undergoing imatinib-combined chemotherapy. Br J Haematol 2008; 143:503.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/56/31625/abstract/43\">",
"      Gehly GB, Bryant EM, Lee AM, et al. Chimeric BCR-abl messenger RNA as a marker for minimal residual disease in patients transplanted for Philadelphia chromosome-positive acute lymphoblastic leukemia. Blood 1991; 78:458.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/56/31625/abstract/44\">",
"      Westbrook CA, Hooberman AL, Spino C, et al. Clinical significance of the BCR-ABL fusion gene in adult acute lymphoblastic leukemia: a Cancer and Leukemia Group B Study (8762). Blood 1992; 80:2983.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/56/31625/abstract/45\">",
"      Miyamura K, Tanimoto M, Morishima Y, et al. Detection of Philadelphia chromosome-positive acute lymphoblastic leukemia by polymerase chain reaction: possible eradication of minimal residual disease by marrow transplantation. Blood 1992; 79:1366.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/56/31625/abstract/46\">",
"      Preudhomme C, Henic N, Cazin B, et al. Good correlation between RT-PCR analysis and relapse in Philadelphia (Ph1)-positive acute lymphoblastic leukemia (ALL). Leukemia 1997; 11:294.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/56/31625/abstract/47\">",
"      Cimino G, Elia L, Rapanotti MC, et al. A prospective study of residual-disease monitoring of the ALL1/AF4 transcript in patients with t(4;11) acute lymphoblastic leukemia. Blood 2000; 95:96.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/56/31625/abstract/48\">",
"      Cimino G, Elia L, Rivolta A, et al. Clinical relevance of residual disease monitoring by polymerase chain reaction in patients with ALL-1/AF-4 positive-acute lymphoblastic leukaemia. Br J Haematol 1996; 92:659.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/56/31625/abstract/49\">",
"      Hilden JM, Frestedt JL, Moore RO, et al. Molecular analysis of infant acute lymphoblastic leukemia: MLL gene rearrangement and reverse transcriptase-polymerase chain reaction for t(4; 11)(q21; q23). Blood 1995; 86:3876.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/56/31625/abstract/50\">",
"      Janssen JW, Ludwig WD, Borkhardt A, et al. Pre-pre-B acute lymphoblastic leukemia: high frequency of alternatively spliced ALL1-AF4 transcripts and absence of minimal residual disease during complete remission. Blood 1994; 84:3835.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/56/31625/abstract/51\">",
"      Bassan R, Spinelli O, Oldani E, et al. Improved risk classification for risk-specific therapy based on the molecular study of minimal residual disease (MRD) in adult acute lymphoblastic leukemia (ALL). Blood 2009; 113:4153.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/56/31625/abstract/52\">",
"      Ford AM, Bennett CA, Price CM, et al. Fetal origins of the TEL-AML1 fusion gene in identical twins with leukemia. Proc Natl Acad Sci U S A 1998; 95:4584.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/56/31625/abstract/53\">",
"      Gale KB, Ford AM, Repp R, et al. Backtracking leukemia to birth: identification of clonotypic gene fusion sequences in neonatal blood spots. Proc Natl Acad Sci U S A 1997; 94:13950.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/56/31625/abstract/54\">",
"      Greaves M. Silence of the leukemic clone. N Engl J Med 1997; 336:367.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/56/31625/abstract/55\">",
"      Biondi A, Yokota S, Hansen-Hagge TE, et al. Minimal residual disease in childhood acute lymphoblastic leukemia: analysis of patients in continuous complete remission or with consecutive relapse. Leukemia 1992; 6:282.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/56/31625/abstract/56\">",
"      Szczepa��ski T, Willemse MJ, Brinkhof B, et al. Comparative analysis of Ig and TCR gene rearrangements at diagnosis and at relapse of childhood precursor-B-ALL provides improved strategies for selection of stable PCR targets for monitoring of minimal residual disease. Blood 2002; 99:2315.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/56/31625/abstract/57\">",
"      Kerst G, Kreyenberg H, Roth C, et al. Concurrent detection of minimal residual disease (MRD) in childhood acute lymphoblastic leukaemia by flow cytometry and real-time PCR. Br J Haematol 2005; 128:774.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/56/31625/abstract/58\">",
"      Biernaux C, Loos M, Sels A, et al. Detection of major bcr-abl gene expression at a very low level in blood cells of some healthy individuals. Blood 1995; 86:3118.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/56/31625/abstract/59\">",
"      D&ouml;lken G, Illerhaus G, Hirt C, Mertelsmann R. BCL-2/JH rearrangements in circulating B cells of healthy blood donors and patients with nonmalignant diseases. J Clin Oncol 1996; 14:1333.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/56/31625/abstract/60\">",
"      Schnittger S, W&ouml;rmann B, Hiddemann W, Griesinger F. Partial tandem duplications of the MLL gene are detectable in peripheral blood and bone marrow of nearly all healthy donors. Blood 1998; 92:1728.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/56/31625/abstract/61\">",
"      Uckun FM, Herman-Hatten K, Crotty ML, et al. Clinical significance of MLL-AF4 fusion transcript expression in the absence of a cytogenetically detectable t(4;11)(q21;q23) chromosomal translocation. Blood 1998; 92:810.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/56/31625/abstract/62\">",
"      Krauter J, Wattjes MP, Nagel S, et al. Real-time RT-PCR for the detection and quantification of AML1/MTG8 fusion transcripts in t(8;21)-positive AML patients. Br J Haematol 1999; 107:80.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/56/31625/abstract/63\">",
"      Muto A, Mori S, Matsushita H, et al. Serial quantification of minimal residual disease of t(8;21) acute myelogenous leukaemia with RT-competitive PCR assay. Br J Haematol 1996; 95:85.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/56/31625/abstract/64\">",
"      Tobal K, Yin JA. Monitoring of minimal residual disease by quantitative reverse transcriptase-polymerase chain reaction for AML1-MTG8 transcripts in AML-M2 with t(8; 21). Blood 1996; 88:3704.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/56/31625/abstract/65\">",
"      Estrov Z, Freedman MH. Detection of residual disease in acute lymphoblastic leukemia of childhood. Leuk Lymphoma 1999; 33:47.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/56/31625/abstract/66\">",
"      Raff T, G&ouml;kbuget N, L&uuml;schen S, et al. Molecular relapse in adult standard-risk ALL patients detected by prospective MRD monitoring during and after maintenance treatment: data from the GMALL 06/99 and 07/03 trials. Blood 2007; 109:910.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 4519 Version 11.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-183.1.191.153-6CC31590FA-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_56_31625=[""].join("\n");
var outline_f30_56_31625=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H21\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      MRD IN CHILDREN",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Prognostic value",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      - With conventional therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - In the setting of transplantation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - In E2A/PBX1",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Using MRD to escalate therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Using MRD to minimize therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Long-term surveillance",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      MRD IN ADULTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Effect on prognosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - With standard therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - In the setting of transplantation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Philadelphia chromosome positive ALL",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - In MLL/AF4 ALL",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      To escalate care",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      To minimize therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Surveillance",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - MRD positive",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - MRD negative",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/33/40474?source=related_link\">",
"      Cellular and molecular biology of chronic myeloid leukemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/25/22938?source=related_link\">",
"      Cytogenetics in acute lymphoblastic leukemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/32/15880?source=related_link\">",
"      Detection of minimal residual disease in acute lymphoblastic leukemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/5/41049?source=related_link\">",
"      Genetic abnormalities in hematologic and lymphoid malignancies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/18/33066?source=related_link\">",
"      Hematopoietic cell transplantation in chronic myeloid leukemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/49/31512?source=related_link\">",
"      Molecular genetics of chronic myeloid leukemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/44/40649?source=related_link\">",
"      Overview of the outcome of acute lymphoblastic leukemia in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?17/34/17955?source=related_link\">",
"      Patient information: Acute lymphoblastic leukemia (ALL) treatment in adults (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?3/26/3497?source=related_link\">",
"      Post-remission therapy for Philadelphia chromosome positive acute lymphoblastic leukemia in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?11/50/12073?source=related_link\">",
"      Remission criteria in acute myeloid leukemia and monitoring for residual disease",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f30_56_31626="Unipolar depression in adults and selective serotonin reuptake inhibitors (SSRIs): Pharmacology, administration, and side effects";
var content_f30_56_31626=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Unipolar depression in adults and selective serotonin reuptake inhibitors (SSRIs): Pharmacology, administration, and side effects",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?30/56/31626/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/56/31626/contributors\">",
"     Michael Hirsch, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/56/31626/contributors\">",
"     Robert J Birnbaum, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?30/56/31626/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/56/31626/contributors\">",
"     Peter P Roy-Byrne, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?30/56/31626/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/56/31626/contributors\">",
"     David Solomon, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?30/56/31626/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 9, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H399779766\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Selective serotonin reuptake inhibitors (SSRIs) are frequently used as first-line antidepressants because of their efficacy, tolerability, and general safety in overdose. In addition, SSRIs potently treat anxiety, which is often part of depressive syndromes. The SSRIs include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?12/56/13193?source=see_link\">",
"       Citalopram",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?24/56/25481?source=see_link\">",
"       Escitalopram",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?14/49/15130?source=see_link\">",
"       Fluoxetine",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?28/50/29481?source=see_link\">",
"       Fluvoxamine",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?14/50/15146?source=see_link\">",
"       Paroxetine",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?43/3/44089?source=see_link\">",
"       Sertraline",
"      </a>",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The development of antidepressant medications has proceeded through different historical phases.",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?14/49/15130?source=see_link\">",
"     Fluoxetine",
"    </a>",
"    was synthesized in 1972, and in 1987 was the first SSRI approved by the United States Food and Drug Administration for treatment of major depression [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/56/31626/abstract/1\">",
"     1",
"    </a>",
"    ]. This was followed by",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?43/3/44089?source=see_link\">",
"     sertraline",
"    </a>",
"    in 1991,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?14/50/15146?source=see_link\">",
"     paroxetine",
"    </a>",
"    in 1993,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?12/56/13193?source=see_link\">",
"     citalopram",
"    </a>",
"    in 1998, and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/56/25481?source=see_link\">",
"     escitalopram",
"    </a>",
"    in 2002.",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/50/29481?source=see_link\">",
"     Fluvoxamine",
"    </a>",
"    was never approved for use as an antidepressant in the United States, but was approved for treatment of obsessive-compulsive disorder in 1993.",
"   </p>",
"   <p>",
"    Clinicians use SSRIs to treat many other psychiatric disorders besides depression, including panic disorder, obsessive-compulsive disorder, generalized anxiety disorder, social anxiety disorder, posttraumatic stress disorder, body dysmorphic disorder, bulimia nervosa, binge eating disorder, premenstrual dysphoric disorder (premenstrual syndrome), and somatoform disorders. See appropriate topic reviews.",
"   </p>",
"   <p>",
"    The use of SSRIs for treating unipolar depression in adults is reviewed here. Sexual dysfunction associated with SSRIs, the serotonin syndrome, and management of SSRI overdose are each discussed separately. In addition, an overview of options for treating depression in adults, the use of serotonin-norepinephrine reuptake inhibitors and other antidepressants, tricyclic and tetracyclic antidepressants, monoamine oxidase inhibitors (MAOIs) antidepressants, managing treatment resistant depression, and switching and discontinuing antidepressants are discussed separately.",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?1/63/2039?source=see_link\">",
"       \"Sexual dysfunction associated with selective serotonin reuptake inhibitor (SSRI) antidepressants\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?15/63/16376?source=see_link\">",
"       \"Serotonin syndrome\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?11/26/11690?source=see_link\">",
"       \"Selective serotonin reuptake inhibitor poisoning\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?39/8/40074?source=see_link\">",
"       \"Initial treatment of depression in adults\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?5/28/5578?source=see_link\">",
"       \"Serotonin-norepinephrine reuptake inhibitors (SNRIs): Pharmacology, administration, and side effects\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?35/20/36169?source=see_link\">",
"       \"Unipolar depression in adults and tricyclic and tetracyclic drugs: Pharmacology, administration, and side effects\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?7/25/7574?source=see_link\">",
"       \"Monoamine oxidase inhibitors (MAOIs) for treating depressed adults\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?26/61/27609?source=see_link\">",
"       \"Treatment of resistant depression in adults\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?25/33/26135?source=see_link\">",
"       \"Antidepressant medication in adults: Switching and discontinuing medication\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14787857\">",
"    <span class=\"h1\">",
"     PHARMACOLOGY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25328730\">",
"    <span class=\"h2\">",
"     Structure",
"    </span>",
"    &nbsp;&mdash;&nbsp;The SSRIs vary considerably in their chemical structure. As examples, the structures of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?14/50/15146?source=see_link\">",
"     paroxetine",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/50/29481?source=see_link\">",
"     fluvoxamine",
"    </a>",
"    are unrelated to other SSRIs [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/56/31626/abstract/1,2\">",
"     1,2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25328749\">",
"    <span class=\"h3\">",
"     Citalopram and escitalopram",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?12/56/13193?source=see_link\">",
"     Citalopram",
"    </a>",
"    consists of two stereoisomers that are mirror images of each other and thus not identical in that they cannot be superimposed upon each other (similar to one&rsquo;s hands) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/56/31626/abstract/3\">",
"     3",
"    </a>",
"    ]. One of the stereoisomers, S-citalopram (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/56/25481?source=see_link\">",
"     escitalopram",
"    </a>",
"    ), more potently inhibits reuptake of serotonin compared with the other stereoisomer.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H399779781\">",
"    <span class=\"h2\">",
"     Pharmacodynamics",
"    </span>",
"    &nbsp;&mdash;&nbsp;SSRIs appear to treat depression by increasing serotonergic activity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/56/31626/abstract/4\">",
"     4",
"    </a>",
"    ]. They are selective in that they have relatively little affinity for other types of receptors.",
"   </p>",
"   <p>",
"    Serotonin (5-hydroxytryptamine or 5-HT) is an indoleamine neurotransmitter released in the brain from neurons originating in the brainstem raphe nuclei [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/56/31626/abstract/4,5\">",
"     4,5",
"    </a>",
"    ]. Serotonergic neurotransmission in the brain involves at least 14 different types of pre- and postsynaptic serotonin receptors. All SSRIs potently decrease the action of the presynaptic serotonin reuptake pump, by 60 to 80 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/56/31626/abstract/4,6\">",
"     4,6",
"    </a>",
"    ]. This increases the length of time that serotonin is available in the synapse and increases postsynaptic serotonin receptor occupancy.",
"   </p>",
"   <p>",
"    However, reuptake inhibition does not appear to be sufficient for the treatment of depression. Reuptake inhibition occurs soon after SSRIs are started, and the full therapeutic effects of SSRIs may not appear for three to eight (or more) weeks after treatment has started. The full clinical response may require additional &ldquo;downstream&rdquo; effects. As an example of one such effect, the initial increase in synaptic serotonin eventually leads to increased production of neuroprotective proteins such as brain-derived neurotrophic factor (BDNF) and Bc1-2 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/56/31626/abstract/7\">",
"     7",
"    </a>",
"    ]. In addition, treatment with an SSRI for weeks modifies the serotonergic receptors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/56/31626/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The relatively benign side effect profile of the SSRIs is due to their selectivity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/56/31626/abstract/4,8\">",
"     4,8",
"    </a>",
"    ]. None of the SSRIs significantly affect alpha-adrenergic, histaminic, or cholinergic receptors, with the exception of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?14/50/15146?source=see_link\">",
"     paroxetine",
"    </a>",
"    , which weakly antagonizes the cholinergic receptor. Side effects that occur with SSRI treatment are attributed to their effects upon serotonin receptors.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H399779788\">",
"    <span class=\"h2\">",
"     Pharmacokinetics",
"    </span>",
"    &nbsp;&mdash;&nbsp;The absorption, distribution, metabolism, and elimination of the SSRIs are well described [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/56/31626/abstract/6,9-11\">",
"     6,9-11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    SSRIs are well absorbed in the gastrointestinal tract and reach peak plasma levels within one to eight hours [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/56/31626/abstract/4,6\">",
"     4,6",
"    </a>",
"    ]. Food generally does not affect absorption. Following absorption, SSRIs bind to proteins and are widely distributed throughout the body, including the brain, because they are lipophilic.",
"   </p>",
"   <p>",
"    Metabolism and elimination occur largely in the liver [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/56/31626/abstract/6\">",
"     6",
"    </a>",
"    ]. Metabolism of each SSRI except",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/50/29481?source=see_link\">",
"     fluvoxamine",
"    </a>",
"    produces pharmacologically active metabolites [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/56/31626/abstract/2\">",
"     2",
"    </a>",
"    ]. However, only",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?14/49/15130?source=see_link\">",
"     fluoxetine",
"    </a>",
"    yields a metabolite (norfluoxetine) that potently inhibits reuptake of serotonin and has antidepressant activity.",
"   </p>",
"   <p>",
"    The elimination half-life for the SSRIs is approximately one day (ranging from about 20 to 30 hours), except for",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?14/49/15130?source=see_link\">",
"     fluoxetine",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/50/29481?source=see_link\">",
"     fluvoxamine",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/56/31626/abstract/4,9\">",
"     4,9",
"    </a>",
"    ]. The half-life for fluoxetine ranges from 1 to 3 days, and for its metabolite norfluoxetine, 4 to 16 days. Fluvoxamine has a half-life of approximately 15 hours. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H399780619\">",
"    <span class=\"h2\">",
"     Drug-drug interactions",
"    </span>",
"    &nbsp;&mdash;&nbsp;The SSRIs may inhibit hepatic cytochrome P450 enzymes that metabolize other medications, thereby causing drug-drug interactions.",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?12/56/13193?source=see_link\">",
"     Citalopram",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/56/25481?source=see_link\">",
"     escitalopram",
"    </a>",
"    inhibit liver enzymes less than other SSRIs and are thus the SSRIs of choice for situations in which drug-drug interactions are a concern [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/56/31626/abstract/6,12\">",
"     6,12",
"    </a>",
"    ].",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?43/3/44089?source=see_link\">",
"     Sertraline",
"    </a>",
"    is a reasonable alternative [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/56/31626/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The specific cytochrome enzymes that each drug and their metabolites potently or moderately inhibit are as follows [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/56/31626/abstract/6,11,12\">",
"     6,11,12",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?12/56/13193?source=see_link\">",
"       Citalopram",
"      </a>",
"      &ndash; none",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?24/56/25481?source=see_link\">",
"       Escitalopram",
"      </a>",
"      &ndash; none",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?14/49/15130?source=see_link\">",
"       Fluoxetine",
"      </a>",
"      &ndash; 2D6 (potent), 2C9, 2C19, 2B6, and 3A4",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?28/50/29481?source=see_link\">",
"       Fluvoxamine",
"      </a>",
"      &ndash; 1A2 (potent), 2C19 (potent), 2B6, 2C9, and 3A4",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?14/50/15146?source=see_link\">",
"       Paroxetine",
"      </a>",
"      &ndash; 2D6 (potent) and 2B6 (potent)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?43/3/44089?source=see_link\">",
"       Sertraline",
"      </a>",
"      &ndash; 2D6 (potent at doses &gt; 200 mg per day), 2B6, 2C9, 2C19, and 3A4",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Among the numerous drug-drug interactions that may occur with SSRIs is the interaction between",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/27/33208?source=see_link\">",
"     tamoxifen",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?14/50/15146?source=see_link\">",
"     paroxetine",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?14/49/15130?source=see_link\">",
"     fluoxetine",
"    </a>",
"    . Tamoxifen is used to treat or prevent recurrence of breast cancer, and is a prodrug that is metabolized by cytochrome P450 2D6 to the active metabolite. Although a review concluded that paroxetine and fluoxetine should not be prescribed to patients receiving tamoxifen [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/56/31626/abstract/13\">",
"     13",
"    </a>",
"    ], more recent studies indicate that the clinical significance of the drug-drug interactions is not clear (see",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/2/7210?source=see_link&amp;anchor=H6#H6\">",
"     \"Mechanisms of action of selective estrogen receptor modulators\", section on 'Tamoxifen resistance in breast cancer'",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Specific interactions of SSRIs with other medications may be determined using the drug interactions tool (Lexi-Interact Online) included in UpToDate. This tool can be accessed from the UpToDate online search page or through the individual drug information topics in the section on Drug interactions.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H399780634\">",
"    <span class=\"h1\">",
"     COMPARATIVE EFFICACY AMONG SSRIs",
"    </span>",
"    &nbsp;&mdash;&nbsp;Meta-analyses of randomized trials that compared one SSRI against another for treating major depression have generally found that the efficacy for each drug was comparable [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/56/31626/abstract/14-19\">",
"     14-19",
"    </a>",
"    ]. A few analyses found that",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/56/25481?source=see_link\">",
"     escitalopram",
"    </a>",
"    was more efficacious than",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?12/56/13193?source=see_link\">",
"     citalopram",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?43/3/44089?source=see_link\">",
"     sertraline",
"    </a>",
"    was superior to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?14/49/15130?source=see_link\">",
"     fluoxetine",
"    </a>",
"    , and citalopram superior to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?14/50/15146?source=see_link\">",
"     paroxetine",
"    </a>",
"    , but the statistically significant differences do not appear to be clinically significant [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/56/31626/abstract/3,20,21\">",
"     3,20,21",
"    </a>",
"    ]. We conclude there is no compelling evidence that one SSRI is more efficacious than another.",
"   </p>",
"   <p>",
"    Studies comparing one SSRI with another include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A systematic review and meta-analyses of 203 studies included randomized trials comparing SSRIs with other SSRIs [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/56/31626/abstract/20,22,23\">",
"       20,22,23",
"      </a>",
"      ]. The results from individual studies showed no significant differences in efficacy. In addition, results from the meta-analyses found small effects that were probably not clinically meaningful, including an analysis that compared",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?24/56/25481?source=see_link\">",
"       escitalopram",
"      </a>",
"      with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?12/56/13193?source=see_link\">",
"       citalopram",
"      </a>",
"      , and another analysis that compared",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?43/3/44089?source=see_link\">",
"       sertraline",
"      </a>",
"      with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?14/49/15130?source=see_link\">",
"       fluoxetine",
"      </a>",
"      . The investigators concluded that there is no basis for choosing one SSRI over another with regard to efficacy in major depression.",
"     </li>",
"     <li>",
"      A meta-analysis of 13 randomized trials (3879 patients with major depression) compared",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?24/56/25481?source=see_link\">",
"       escitalopram",
"      </a>",
"      with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?12/56/13193?source=see_link\">",
"       citalopram",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?14/49/15130?source=see_link\">",
"       fluoxetine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?14/50/15146?source=see_link\">",
"       paroxetine",
"      </a>",
"      , or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?43/3/44089?source=see_link\">",
"       sertraline",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/56/31626/abstract/15\">",
"       15",
"      </a>",
"      ]. Remission was comparable for patients who received escitalopram and patients who received fluoxetine, paroxetine, or sertraline. However, an analysis of 6 trials (1823 patients) that compared escitalopram with citalopram found that remission occurred in significantly more patients who received escitalopram (48 versus 38 percent). All of the individual trials were sponsored by the drug company marketing escitalopram.",
"     </li>",
"     <li>",
"      A meta-analysis of 13 randomized trials (3879 patients with major depression) that compared",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?12/56/13193?source=see_link\">",
"       citalopram",
"      </a>",
"      with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?24/56/25481?source=see_link\">",
"       escitalopram",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?14/49/15130?source=see_link\">",
"       fluoxetine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?28/50/29481?source=see_link\">",
"       fluvoxamine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?14/50/15146?source=see_link\">",
"       paroxetine",
"      </a>",
"      , or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?43/3/44089?source=see_link\">",
"       sertraline",
"      </a>",
"      found that response (improvement from baseline on the depression rating scale &ge;50 percent) occurred in significantly fewer patients who received citalopram than escitalopram (58 versus 64 percent), and significantly more patients who received citalopram than paroxetine (49 versus 39 percent) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/56/31626/abstract/19\">",
"       19",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A multiple treatments meta-analysis of 117 randomized trials (25,928 depressed patients) concluded that",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?24/56/25481?source=see_link\">",
"       escitalopram",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?43/3/44089?source=see_link\">",
"       sertraline",
"      </a>",
"      were significantly more efficacious than",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?14/49/15130?source=see_link\">",
"       fluoxetine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?28/50/29481?source=see_link\">",
"       fluvoxamine",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?14/50/15146?source=see_link\">",
"       paroxetine",
"      </a>",
"      in achieving response [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/56/31626/abstract/17\">",
"       17",
"      </a>",
"      ]. However, others believe this conclusion overstates the underlying evidence, that point estimates of most comparisons were clinically irrelevant and uncertain, and that there were several methodologic problems, including the use of indirect comparisons [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/56/31626/abstract/21\">",
"       21",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    There is no evidence that one SSRI has a faster onset of action than another.",
"   </p>",
"   <p>",
"    The comparative efficacy of different classes of antidepressants (SSRIs, serotonin-norepinephrine reuptake inhibitors, tricyclics, and monoamine oxidase inhibitors) is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/8/40074?source=see_link&amp;anchor=H18#H18\">",
"     \"Initial treatment of depression in adults\", section on 'Choice of antidepressant'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H399779802\">",
"    <span class=\"h1\">",
"     PRESCRIBING SSRIs",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treating depression with SSRIs requires use of general pharmacotherapy principles as well as knowledge about the proper dose.",
"   </p>",
"   <p>",
"    SSRIs are contraindicated in patients with hypersensitivity, as well as patients who received a monoamine oxidase inhibitor (MAOI) in the previous two weeks, because SSRIs and MAOIs can interact to cause the serotonin syndrome. In addition, clinicians should exercise caution in prescribing SSRIs with other serotonergic medications (eg,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/11/23736?source=see_link\">",
"     lithium",
"    </a>",
"    or serotonin-norepinephrine reuptake inhibitors). The serotonin syndrome is discussed separately (see",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/63/16376?source=see_link\">",
"     \"Serotonin syndrome\"",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The choice of a particular SSRI is based upon individual patient tolerance, cost, and clinician experience, because efficacy appears to be comparable. (See",
"    <a class=\"local\" href=\"#H399780634\">",
"     'Comparative efficacy among SSRIs'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H399780656\">",
"    <span class=\"h2\">",
"     General principles",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H504526\">",
"    <span class=\"h3\">",
"     Guidelines to review with patients",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prior to prescribing SSRIs, side effects, time to response, drug interactions, and stopping the medication should be discussed with patients. (See",
"    <a class=\"local\" href=\"#H399779851\">",
"     'Side effects'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Clinicians should review common side effects and the need to take the medication as prescribed rather than on an as needed basis. Patients should also be informed that although some response may occur within the first two weeks of treatment, it may take several weeks to reach full clinical effect.",
"   </p>",
"   <p>",
"    Possible drug interactions should also be reviewed, including other drugs (eg, monoamine oxidase inhibitors) that increase serotonergic activity and the possibility of the potentially fatal serotonin syndrome. (See",
"    <a class=\"local\" href=\"#H399780619\">",
"     'Drug-drug interactions'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/63/16376?source=see_link\">",
"     \"Serotonin syndrome\"",
"    </a>",
"    .) &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;",
"   </p>",
"   <p>",
"    In addition, clinicians should discuss abrupt discontinuation of SSRIs, which may precipitate dysphoria, dizziness, gastrointestinal distress, fatigue, chills, and myalgias [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/56/31626/abstract/4\">",
"     4",
"    </a>",
"    ]. This syndrome is more common with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?14/50/15146?source=see_link\">",
"     paroxetine",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/50/29481?source=see_link\">",
"     fluvoxamine",
"    </a>",
"    (which have a short half-life), and less common in",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?14/49/15130?source=see_link\">",
"     fluoxetine",
"    </a>",
"    , which has a long half-life. The discontinuation syndrome associated with suddenly stopping SSRIs is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/33/26135?source=see_link&amp;anchor=H12#H12\">",
"     \"Antidepressant medication in adults: Switching and discontinuing medication\", section on 'Discontinuation of antidepressants'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <br/>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14789327\">",
"    <span class=\"h3\">",
"     Medical tests and plasma levels",
"    </span>",
"    &nbsp;&mdash;&nbsp;No specific medical tests are required before starting an SSRI [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/56/31626/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    SSRI plasma levels are not routinely performed because they have not been shown to correlate with clinical response [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/56/31626/abstract/8,24\">",
"     8,24",
"    </a>",
"    ]. However, levels can assess adherence and whether unresponsive patients are rapid metabolizers [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/56/31626/abstract/25\">",
"     25",
"    </a>",
"    ]. Levels can also establish that it is safe to begin another serotonergic drug (eg, a monoamine oxidase inhibitor) after discontinuing an SSRI, in order to avoid the serotonin syndrome. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/63/16376?source=see_link\">",
"     \"Serotonin syndrome\"",
"    </a>",
"    .)",
"    <br/>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H399780663\">",
"    <span class=\"h3\">",
"     Response time",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many depressed patients treated with an SSRI respond within one or two weeks, while other patients require several more weeks of treatment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/56/31626/abstract/26-28\">",
"     26-28",
"    </a>",
"    ]. Severity of illness and comorbid disease may affect how quickly depressed patients respond to treatment with SSRIs.",
"   </p>",
"   <p>",
"    Time to response was evaluated in the following studies:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A meta-analysis of 28 randomized trials (5872 patients with unipolar depression) found that SSRIs begin to have a small clinically beneficial effect beyond the effect of placebo by the end of the first week of treatment [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/56/31626/abstract/26\">",
"       26",
"      </a>",
"      ]. Incremental improvement attributable to the SSRI continued at a decreasing rate for the next five weeks. A second analysis of five studies (1365 patients) showed that response (&ge; 50 percent reduction in baseline depression rating scale score) by week one was 64 percent more likely in patients who received an SSRI compared with patients who received placebo (relative risk 1.64, 95% CI 1.2-2.25).",
"     </li>",
"     <li>",
"      An open label study of 384 outpatients with major depression, treated with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?14/49/15130?source=see_link\">",
"       fluoxetine",
"      </a>",
"      for eight weeks, evaluated time to sustained response, defined as a 30 percent decrease in the baseline depression rating scale score that persisted and led to a 50 percent decrease by week eight [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/56/31626/abstract/27\">",
"       27",
"      </a>",
"      ]. Patients were not severely ill in that none of the patients had previously failed an adequate antidepressant trial during the current episode. Among the 182 patients who responded, 56 percent responded at week two, 25 percent at week four, and 9 percent at week six (the cumulative probabilities of response were thus 56, 80, and 90 percent).",
"     </li>",
"     <li>",
"      Time to response was longer in the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) trial (2876 outpatients at 41 sites), which treated patients who were more ill (more than 75 percent of the patients had recurrent or chronic depression, and most had multiple comorbid medical and psychiatric illnesses) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/56/31626/abstract/28\">",
"       28",
"      </a>",
"      ]. The average mean time to response (at least 50 percent reduction in baseline depression rating scale score) to",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?12/56/13193?source=see_link\">",
"       citalopram",
"      </a>",
"      was six weeks. Among patients who eventually responded, 56 percent did so at or after eight weeks of treatment. The average mean time to remission was seven weeks.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14788308\">",
"    <span class=\"h3\">",
"     Pregnancy",
"    </span>",
"    &nbsp;&mdash;&nbsp;It is not clearly established if SSRIs differ in their safety for use during pregnancy.",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?14/49/15130?source=see_link\">",
"     Fluoxetine",
"    </a>",
"    appears to be safe while",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?14/50/15146?source=see_link\">",
"     paroxetine",
"    </a>",
"    may be associated with an increased risk of congenital heart defects [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/56/31626/abstract/1,4\">",
"     1,4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Treatment of pregnant women with SSRIs and other antidepressants is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/0/28682?source=see_link\">",
"     \"Depression in pregnant women: Management\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H504779\">",
"    <span class=\"h2\">",
"     Administration",
"    </span>",
"    &nbsp;&mdash;&nbsp;The frequency and timing of each dose varies between SSRIs.",
"   </p>",
"   <p>",
"    The entire dose of an SSRI is generally taken once a day because the elimination half-life averages about 24 hours [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/56/31626/abstract/4\">",
"     4",
"    </a>",
"    ].",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/50/29481?source=see_link\">",
"     Fluvoxamine",
"    </a>",
"    is taken in two divided doses when the total daily dose exceeds 100mg, because it has a shorter half-life.",
"   </p>",
"   <p>",
"    Clinicians usually advise patients to take SSRIs in the morning to minimize insomnia, although there is no evidence that this side effect is related to dose timing.",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/50/29481?source=see_link\">",
"     Fluvoxamine",
"    </a>",
"    is usually taken at bedtime at doses of 100 mg or less, and patients who experience drowsiness with other SSRIs can take the drug at bedtime.",
"   </p>",
"   <p>",
"    <br/>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?43/3/44089?source=see_link\">",
"     Sertraline",
"    </a>",
"    is the only SSRI whose absorption is increased when taken with food. Although taking the other SSRIs on a full stomach will not improve absorption, it may help prevent gastrointestinal distress.",
"    <br/>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H74872026\">",
"    <span class=\"h2\">",
"     Dose",
"    </span>",
"    &nbsp;&mdash;&nbsp;We suggest starting with the lowest minimal effective dose in order to avoid side effects and slowly increasing the dose as needed. Equipotent starting doses for the SSRIs are:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?12/56/13193?source=see_link\">",
"       Citalopram",
"      </a>",
"      &ndash; 20 mg",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?24/56/25481?source=see_link\">",
"       Escitalopram",
"      </a>",
"      &ndash; 10 mg",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?14/49/15130?source=see_link\">",
"       Fluoxetine",
"      </a>",
"      &ndash; 20 mg",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?28/50/29481?source=see_link\">",
"       Fluvoxamine",
"      </a>",
"      &ndash; 50 to 100 mg",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?14/50/15146?source=see_link\">",
"       Paroxetine",
"      </a>",
"      &ndash; 20 mg",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?43/3/44089?source=see_link\">",
"       Sertraline",
"      </a>",
"      &ndash; 50 mg",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Depressed patients with a comorbid anxiety disorder may tolerate the medication better by starting with half of the suggested dose. Dose adjustments are made according to patient response, tolerability, and clinical urgency.",
"   </p>",
"   <p>",
"    Finding the effective dose involves a process of trial and error. After starting an SSRI, response should be monitored over the next four weeks. &nbsp;If there is inadequate response but good tolerability after four weeks of treatment at the recommended minimum effective dose, the dose can be slowly titrated upward. Further dose increases can generally be made at one to four week intervals as needed.",
"   </p>",
"   <p>",
"    Patients who recover from an episode of major depression should receive maintenance treatment with the full dose that successfully resolved the episode, rather than a lower dose [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/56/31626/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7700689\">",
"    <span class=\"h3\">",
"     Citalopram",
"    </span>",
"    &nbsp;&mdash;&nbsp;We suggest an initial dose of 20 mg in the morning. Older patients and those sensitive to side effects can be started at a dose of 10 mg.",
"   </p>",
"   <p>",
"    The dose range is 20 to 40 mg once per day [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/56/31626/abstract/4,8\">",
"     4,8",
"    </a>",
"    ]. The dose can be titrated up in increments of 10 or 20 mg per day, every one or four weeks. Clinicians should not prescribe",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?12/56/13193?source=see_link\">",
"     citalopram",
"    </a>",
"    at doses greater than 40 mg per day. The United States Food and Drug Administration issued a warning that citalopram causes dose-dependent QT interval prolongation, which can lead to a life-threatening cardiac arrhythmia, torsade de pointes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/56/31626/abstract/30\">",
"     30",
"    </a>",
"    ]. A subsequent warning recommended a maximum dose of 20 mg per day in patients at risk for increased serum concentrations of citalopram, including patients with [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/56/31626/abstract/31\">",
"     31",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Hepatic impairment",
"     </li>",
"     <li>",
"      Age &gt;60 years",
"     </li>",
"     <li>",
"      CYP2C19 variants that slowly metabolize",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?12/56/13193?source=see_link\">",
"       citalopram",
"      </a>",
"     </li>",
"     <li>",
"      Concomitant medications that inhibit CYP2C19. Specific interactions of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?12/56/13193?source=see_link\">",
"       citalopram",
"      </a>",
"      with other medications may be determined using the drug interactions tool (Lexi-Interact Online) included in UpToDate. This tool can be accessed from the UpToDate online search page or through the individual drug information topics in the section on Drug interactions.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Additional information about the cardiac effects of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?12/56/13193?source=see_link\">",
"     citalopram",
"    </a>",
"    and other SSRIs is discussed elsewhere in this topic. (See",
"    <a class=\"local\" href=\"#H31651631\">",
"     'Cardiac'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    A liquid concentrate formulation is available.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7700696\">",
"    <span class=\"h3\">",
"     Escitalopram",
"    </span>",
"    &nbsp;&mdash;&nbsp;We suggest an initial dose of 10 mg in the morning. Older patients and those sensitive to side effects can be started at a dose of 5 mg.",
"   </p>",
"   <p>",
"    The standard dose range is 10 to 20 mg once per day [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/56/31626/abstract/4,8\">",
"     4,8",
"    </a>",
"    ]. The dose can be titrated up in increments of 5 or 10 mg per day, after one to four weeks. Doses up to 30 mg per day have been used.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/56/25481?source=see_link\">",
"     Escitalopram",
"    </a>",
"    is a single isomer formulation of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?12/56/13193?source=see_link\">",
"     citalopram",
"    </a>",
"    , and the United States Food and Drug Administration (FDA) has issued warnings that citalopram causes dose-dependent QT interval prolongation that can lead to arrhythmias [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/56/31626/abstract/30,31\">",
"     30,31",
"    </a>",
"    ]. Although an analysis of a randomized trial by the FDA found that escitalopram also caused dose-dependent QT interval prolongation, the finding was not deemed clinically significant, and no warning was issued regarding escitalopram. Cardiac effects of escitalopram and other SSRIs and the structural relationship between escitalopram and citalopram are discussed elsewhere in this topic. (See",
"    <a class=\"local\" href=\"#H31651631\">",
"     'Cardiac'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H25328749\">",
"     'Citalopram and escitalopram'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    A liquid concentrate formulation is available.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H399781192\">",
"    <span class=\"h3\">",
"     Fluoxetine",
"    </span>",
"    &nbsp;&mdash;&nbsp;We suggest an initial dose of 20 mg in the morning. Older patients and those sensitive to side effects can be started at a dose of 10 mg.",
"   </p>",
"   <p>",
"    The standard dose range is 20 to 40 mg once per day [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/56/31626/abstract/4,8\">",
"     4,8",
"    </a>",
"    ]. The dose can be titrated up in increments of 10 or 20 mg per day, every four weeks. Doses up to 80 mg per day have been used.",
"   </p>",
"   <p>",
"    Other formulations of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?14/49/15130?source=see_link\">",
"     fluoxetine",
"    </a>",
"    are available, including a liquid concentrate. In addition, there is a 90 mg delayed release capsule taken once per week. Patients must be stabilized on fluoxetine 20mg daily prior to switching to once-weekly dosing. The manufacturer recommends waiting seven days after the last 20 mg daily dose of fluoxetine before beginning the once weekly regimen with the 90 mg delayed release formulation.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?14/49/15130?source=see_link\">",
"     Fluoxetine",
"    </a>",
"    should not be prescribed with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/27/33208?source=see_link\">",
"     tamoxifen",
"    </a>",
"    . (See",
"    <a class=\"local\" href=\"#H399780619\">",
"     'Drug-drug interactions'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7700832\">",
"    <span class=\"h3\">",
"     Fluvoxamine",
"    </span>",
"    &nbsp;&mdash;&nbsp;We suggest an initial dose of 50 mg at bedtime. Older patients and those sensitive to side effects can be started at a dose of 25 mg.",
"   </p>",
"   <p>",
"    The standard dose range is 50 to 200 mg per day [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/56/31626/abstract/4,8\">",
"     4,8",
"    </a>",
"    ]. The dose can be titrated up from the starting dose of 50 mg by increments of 25 or 50 mg per day, every several days to two weeks. When the dose exceeds 100 mg per day, it should be given in two divided doses. The two doses may be either equal, or a larger portion may be given at bedtime. The dose may be increased further by increments of 50 mg per day, every several days to two weeks. Doses up to 300 mg per day have been used.",
"   </p>",
"   <p>",
"    It is also available in an extended release formulation (100 and 150 mg) for once per day dosing at higher doses.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H399779823\">",
"    <span class=\"h3\">",
"     Paroxetine",
"    </span>",
"    &nbsp;&mdash;&nbsp;We suggest an initial dose of 20 mg in the morning. Older patients and those sensitive to side effects can be started at a dose of 10 mg.",
"   </p>",
"   <p>",
"    The standard dose range is 20 to 40 mg once per day [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/56/31626/abstract/4,8\">",
"     4,8",
"    </a>",
"    ]. The dose can be titrated up in increments of 10 or 20 mg per day, every one or four weeks. Doses up to 50 mg per day have been used.",
"   </p>",
"   <p>",
"    Other formulations of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?14/50/15146?source=see_link\">",
"     paroxetine",
"    </a>",
"    are available, including a liquid concentrate. In addition, there is an enteric coated, controlled-release formulation. It may cause less nausea than the immediate release formulation for patients who are experiencing this adverse effect; otherwise, there is no compelling reason to change from one formulation to the other. The controlled-release formulation is less bioavailable, thus, a 12.5 mg dose of the controlled release formulation is equivalent to 10 mg of regular release paroxetine. The recommended starting dose of the controlled-release formulation is 25",
"    <span class=\"nowrap\">",
"     mg/day;",
"    </span>",
"    the maximum dose is 75",
"    <span class=\"nowrap\">",
"     mg/day.",
"    </span>",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?14/50/15146?source=see_link\">",
"     Paroxetine",
"    </a>",
"    should not be prescribed with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/27/33208?source=see_link\">",
"     tamoxifen",
"    </a>",
"    . (See",
"    <a class=\"local\" href=\"#H399780619\">",
"     'Drug-drug interactions'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7700895\">",
"    <span class=\"h3\">",
"     Sertraline",
"    </span>",
"    &nbsp;&mdash;&nbsp;We suggest an initial dose of 50 mg in the morning. Older patients and those sensitive to side effects can be started at a dose of 25 mg.",
"   </p>",
"   <p>",
"    The standard dose range is 50 to 150 or 200 mg once per day [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/56/31626/abstract/4,8\">",
"     4,8",
"    </a>",
"    ]. &nbsp;The dose can be titrated up in increments of 25 or 50 mg per day, every one to four weeks. Doses up to 300 mg per day have been used.",
"   </p>",
"   <p>",
"    A liquid concentrate formulation is available.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?43/3/44089?source=see_link\">",
"     Sertraline",
"    </a>",
"    reaches its peak plasma concentration sooner when taken with food [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/56/31626/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H399779851\">",
"    <span class=\"h1\">",
"     SIDE EFFECTS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H399780694\">",
"    <span class=\"h2\">",
"     Overview",
"    </span>",
"    &nbsp;&mdash;&nbsp;The SSRIs tend to have similar side effect profiles [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/56/31626/abstract/4\">",
"     4",
"    </a>",
"    ]. However, certain SSRIs may be more likely to cause specific side effects (",
"    <a class=\"graphic graphic_table graphicRef62488 \" href=\"mobipreview.htm?37/46/38639\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/56/31626/abstract/33\">",
"     33",
"    </a>",
"    ]. Thus, some patients who cannot tolerate one SSRI may do well with another [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/56/31626/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The SSRIs are often first-line treatment for depression because they are better tolerated than tricyclics or monoamine oxidase inhibitors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/56/31626/abstract/4,8,33,34\">",
"     4,8,33,34",
"    </a>",
"    ]. In three-arm randomized trials, discontinuation because of an adverse event was typically lowest for placebo, intermediate for the SSRI, and highest for the tricyclic (5 to 10 versus 10 to 20 versus 30 to 35 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/56/31626/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Nevertheless, SSRIs often cause adverse side effects. A telephone survey of 401 patients treated with an SSRI for major depression found that 55 percent suffered at least one bothersome side effect during the first three months of treatment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/56/31626/abstract/34\">",
"     34",
"    </a>",
"    ]. The incidence of each bothersome side effect was:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Sexual dysfunction &ndash; 17 percent",
"     </li>",
"     <li>",
"      Drowsiness &ndash; 17 percent",
"     </li>",
"     <li>",
"      Weight gain &ndash; 12 percent",
"     </li>",
"     <li>",
"      Insomnia &ndash; 11 percent",
"     </li>",
"     <li>",
"      Anxiety &ndash; 11 percent",
"     </li>",
"     <li>",
"      Dizziness &ndash; 11 percent",
"     </li>",
"     <li>",
"      Headache &ndash; 10 percent",
"     </li>",
"     <li>",
"      Dry mouth &ndash; 7 percent",
"     </li>",
"     <li>",
"      Blurred vision &ndash; 6 percent",
"     </li>",
"     <li>",
"      Nausea &ndash; 6 percent",
"     </li>",
"     <li>",
"      Rash or itching &ndash; 6 percent",
"     </li>",
"     <li>",
"      Tremor &ndash; 5 percent",
"     </li>",
"     <li>",
"      Constipation &ndash; 5 percent",
"     </li>",
"     <li>",
"      Stomach upset &ndash; 3 percent",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Some patients on SSRIs describe asthenia, a type of daytime sedation associated with malaise, diminished mental energy, or emotional blunting [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/56/31626/abstract/33\">",
"     33",
"    </a>",
"    ]. Other side effects include diaphoresis, diarrhea, hyperprolactinemia, and syndrome of inappropriate antidiuretic hormone (SIADH) and hyponatremia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/56/31626/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Observational studies suggest that SSRIs may be associated with movement disorders, including akathisia, dyskinesia, dystonia, parkinsonism, tremor, and tardive dyskinesia; bruxism has also been reported [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/56/31626/abstract/35-37\">",
"     35-37",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p>",
"    While any SSRI can cause side effects, there are a few general trends in side effect frequency [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/56/31626/abstract/16,33\">",
"     16,33",
"    </a>",
"    ]. Nausea and sedation may be more likely to occur with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?14/50/15146?source=see_link\">",
"     paroxetine",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/50/29481?source=see_link\">",
"     fluvoxamine",
"    </a>",
"    , diarrhea with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?43/3/44089?source=see_link\">",
"     sertraline",
"    </a>",
"    , and activation may be more likely to occur with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?14/49/15130?source=see_link\">",
"     fluoxetine",
"    </a>",
"    and sertraline.",
"   </p>",
"   <p>",
"    <br/>",
"    For many patients, side effects persist even after three months of treatment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/56/31626/abstract/34\">",
"     34",
"    </a>",
"    ]. Reducing the dose may help alleviate the problem if the dose was previously titrated up. Dividing the dose during the day may also help.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H399780701\">",
"    <span class=\"h2\">",
"     Suicide risk",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is no clear evidence that treating depressed patients with SSRIs, or antidepressants in general, increases or decreases risk of suicidality (suicidal ideation, preparatory act, attempt, or death) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/56/31626/abstract/38,39\">",
"     38,39",
"    </a>",
"    ]. However, there may be an age-specific effect of antidepressants upon suicidality. Antidepressants in general may raise the risk of suicidality in patients age 18 to 24 years, have no effect upon patients age 25 to 30 years, and may lower the risk in patients 31 years and older. It is also important to note that untreated depression may lead to suicidality.",
"   </p>",
"   <p>",
"    Suicidal ideation and behavior in adults and the potential effect of SSRIs on suicidal ideation and behavior in adults and children are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/8/10377?source=see_link\">",
"     \"Suicidal ideation and behavior in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/48/43783?source=see_link\">",
"     \"Effect of antidepressants on suicide risk in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/23/15736?source=see_link\">",
"     \"Effect of antidepressants on suicide risk in children and adolescents\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31651631\">",
"    <span class=\"h2\">",
"     Cardiac",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?12/56/13193?source=see_link\">",
"     Citalopram",
"    </a>",
"    causes dose-dependent QT interval prolongation, which can lead to a life-threatening cardiac arrhythmia, torsade de pointes (a form of polymorphic ventricular tachycardia) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/56/31626/abstract/30,31\">",
"     30,31",
"    </a>",
"    ]. An analysis by the United States Food and Drug Administration (FDA) of a randomized trial (N = 119) found that the maximum mean prolongation in the individually corrected QT intervals was longer for citalopram 60 mg per day (18.5 milliseconds, 90% CI 16.0-21.0) compared to 20 mg per day (8.5 milliseconds, 90% CI 6.2-10.8). Thus, clinicians should not prescribe citalopram at doses greater than 40 mg per day. In addition, citalopram should be avoided in patients with congenital long QT syndrome, persistent corrected QT measurements &gt;500 milliseconds, bradycardia, hypokalemia, hypomagnesemia, recent myocardial infarction, or uncompensated heart failure, as well as patients taking other drugs that prolong the QT interval.",
"   </p>",
"   <p>",
"    Additional support for the FDA warning comes from a retrospective study of 38,397 patients with an antidepressant prescription and subsequent electrocardiogram documented in the medical record [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/56/31626/abstract/40\">",
"     40",
"    </a>",
"    ]. The analyses, which adjusted for potential confounding factors (eg, general medical comorbidity, concurrent first-generation antipsychotic, or history of myocardial infarction), found a modest association between increasing doses of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?12/56/13193?source=see_link\">",
"     citalopram",
"    </a>",
"    and corrected QT interval prolongation.",
"   </p>",
"   <p>",
"    Some authorities disagree with our recommendation to avoid prescribing",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?12/56/13193?source=see_link\">",
"     citalopram",
"    </a>",
"    at doses greater than 40 mg per day, based upon a review that found no cases of citalopram induced sudden cardiac death among patients who were taking up to 60 mg per day of citalopram and were free of identified risk factors for QT prolongation and torsade de pointes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/56/31626/abstract/41\">",
"     41",
"    </a>",
"    ]. Additional information about dosing citalopram is discussed elsewhere in this topic. (See",
"    <a class=\"local\" href=\"#H7700689\">",
"     'Citalopram'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/56/25481?source=see_link\">",
"     Escitalopram",
"    </a>",
"    , the single isomer formulation of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?12/56/13193?source=see_link\">",
"     citalopram",
"    </a>",
"    , may also prolong the corrected QT interval [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/56/31626/abstract/40\">",
"     40",
"    </a>",
"    ]. In a randomized trial (N = 113), the FDA found that the maximum mean prolongation in the individually corrected QT intervals was longer for escitalopram 30 mg per day (10.7 milliseconds, 90% CI 8.7-12.7) compared to 10 mg per day (4.5 milliseconds, 90% CI 2.5-6.4); however, the FDA concluded that the finding was not clinically significant and did not justify a warning. (See",
"    <a class=\"local\" href=\"#H7700696\">",
"     'Escitalopram'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Other SSRIs have been associated with QT prolongation, but appear to be unlikely to cause serious arrhythmia when used in usual recommended doses and in patients without other risk factors. Risk factors for a serious arrhythmia due to drug-induced QTc prolongation include baseline QT prolongation, underlying heart disease (particularly heart failure, myocardial infarction, and left ventricular hypertrophy), bradycardia, electrolyte derangements (especially hypokalemia and hypomagnesemia), concurrent use of more than one drug that can prolong the QT interval, female gender, and advanced age (eg, &gt;60 years). SSRI drug interactions that may place a patient at elevated risk due to QTc prolongation can be determined with the Lexi-Interact program included with UpToDate.",
"   </p>",
"   <p>",
"    The acquired long QT syndrome and torsade de pointes are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/55/23418?source=see_link\">",
"     \"Acquired long QT syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    An internet resource with updated lists of specific drugs that prolong the QT interval is available at the University of Arizona Center for Education and Research on Therapeutics website (",
"    <a class=\"external\" href=\"file://www.torsades.org/\">",
"     www.torsades.org",
"    </a>",
"    or",
"    <a class=\"external\" href=\"file://www.qtdrugs.org/\">",
"     www.qtdrugs.org",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H367753\">",
"    <span class=\"h2\">",
"     Overdose",
"    </span>",
"    &nbsp;&mdash;&nbsp;A single-substance SSRI overdose rarely causes death or serious sequelae [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/56/31626/abstract/42-44\">",
"     42-44",
"    </a>",
"    ]. Overdoses of up to 30 times the usual daily dose typically produce minor or no symptoms, while larger ingestions may cause drowsiness, tremor, and gastrointestinal distress. In addition, overdoses may lead to the serotonin syndrome. Nearly all fatalities from SSRI overdoses involve extremely large doses or co-ingestion of other substances [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/56/31626/abstract/45\">",
"     45",
"    </a>",
"    ]. The toxicity and management of SSRI overdoses and the serotonin syndrome are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/26/11690?source=see_link\">",
"     \"Selective serotonin reuptake inhibitor poisoning\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/63/16376?source=see_link\">",
"     \"Serotonin syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H516881\">",
"    <span class=\"h2\">",
"     Serotonin syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;Serotonin syndrome is a potentially lethal condition caused by overstimulation of central and peripheral serotonin receptors. It typically results from an interaction between multiple medications that increase serotonergic neurotransmission (",
"    <a class=\"graphic graphic_table graphicRef64604 \" href=\"mobipreview.htm?42/19/43324\">",
"     table 2",
"    </a>",
"    ). However, the syndrome can occur after initiating or increasing a single serotonergic drug. Clinical features include anxiety, agitation, delirium, diaphoresis, tachycardia, hypertension, hyperthermia, gastrointestinal distress, tremor, muscle rigidity, myoclonus, and hyperreflexia. It is not known whether SSRIs differ in their likelihood to cause this syndrome.",
"   </p>",
"   <p>",
"    The clinical features, diagnosis, treatment, and prevention of serotonin syndrome are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/63/16376?source=see_link\">",
"     \"Serotonin syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H399780708\">",
"    <span class=\"h2\">",
"     Sexual dysfunction and infertility",
"    </span>",
"    &nbsp;&mdash;&nbsp;SSRIs reduce libido in women and men, cause anorgasmia in women and erectile dysfunction in men, and increase ejaculation latency in men, beyond the sexual dysfunction associated with depression itself [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/56/31626/abstract/1-4,46\">",
"     1-4,46",
"    </a>",
"    ]. As an example, the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) study found that among 1473 patients treated with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?12/56/13193?source=see_link\">",
"     citalopram",
"    </a>",
"    , 54 percent reported decreased libido [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/56/31626/abstract/47\">",
"     47",
"    </a>",
"    ]. Sexual dysfunction is dose-dependent and does not appear to diminish over time. Some observational studies suggest that sexual side effects are more common with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?14/50/15146?source=see_link\">",
"     paroxetine",
"    </a>",
"    and less common with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?14/49/15130?source=see_link\">",
"     fluoxetine",
"    </a>",
"    , but results are inconsistent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/56/31626/abstract/1,48-50\">",
"     1,48-50",
"    </a>",
"    ]. Options for managing SSRI-induced sexual dysfunction are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/63/2039?source=see_link\">",
"     \"Sexual dysfunction associated with selective serotonin reuptake inhibitor (SSRI) antidepressants\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In addition, SSRIs may interfere with male fertility. A study evaluated DNA integrity, which correlates with fertility and pregnancy outcomes, in semen samples from healthy male volunteers [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/56/31626/abstract/51\">",
"     51",
"    </a>",
"    ]. Abnormal levels of DNA fragmentation were significantly more frequent after four weeks of daily",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?14/50/15146?source=see_link\">",
"     paroxetine",
"    </a>",
"    , compared with baseline (50 versus 10 percent, OR 9).",
"    <br/>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H399780715\">",
"    <span class=\"h2\">",
"     Weight change",
"    </span>",
"    &nbsp;&mdash;&nbsp;The effect of SSRIs upon weight depends upon the specific medication prescribed and the length of treatment. Short-term treatment for two to three months with SSRIs usually causes little or no weight change [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/56/31626/abstract/52-58\">",
"     52-58",
"    </a>",
"    ]. However, short-term therapy is not clinically appropriate for most patients.",
"   </p>",
"   <p>",
"    Treatment with SSRIs for longer periods of time may result in weight gain. However, in some cases it is not clear if this is a true medication side effect or the result of recovery from depression and the reversal of undesired weight loss. The evidence suggests that",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?14/49/15130?source=see_link\">",
"     fluoxetine",
"    </a>",
"    may be the least problematic SSRI with regard to undesired weight gain and that",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?14/50/15146?source=see_link\">",
"     paroxetine",
"    </a>",
"    may the most problematic. Studies lasting between 6 and 30 months have reported the following weight effects:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?14/49/15130?source=see_link\">",
"       Fluoxetine",
"      </a>",
"      leads to small weight changes ranging from a loss of 0.2 percent of body weight at baseline [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/56/31626/abstract/59\">",
"       59",
"      </a>",
"      ] to a gain of 0.9 percent [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/56/31626/abstract/52\">",
"       52",
"      </a>",
"      ]. A randomized trial showed a mean weight gain of 3.0 kg (6.6 lb) for fluoxetine, compared to 3.2 kg (7.0 lb) for placebo [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/56/31626/abstract/53\">",
"       53",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?12/56/13193?source=see_link\">",
"       Citalopram",
"      </a>",
"      leads to weight changes ranging from none [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/56/31626/abstract/60\">",
"       60",
"      </a>",
"      ] to a gain of 2.5 percent of baseline body weight [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/56/31626/abstract/52\">",
"       52",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?28/50/29481?source=see_link\">",
"       Fluvoxamine",
"      </a>",
"      leads to weight gain of 2.6 percent of baseline body weight [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/56/31626/abstract/52\">",
"       52",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?14/50/15146?source=see_link\">",
"       Paroxetine",
"      </a>",
"      leads to weight gain in 6 percent of patients [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/56/31626/abstract/61\">",
"       61",
"      </a>",
"      ], ranging from 1.6 to 3.6 percent of baseline body weight [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/56/31626/abstract/52,59\">",
"       52,59",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?43/3/44089?source=see_link\">",
"       Sertraline",
"      </a>",
"      leads to weight gain ranging from 1.0 to 1.6 percent of baseline body weight [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/56/31626/abstract/52,59\">",
"       52,59",
"      </a>",
"      ]. A randomized trial showed a mean weight gain of 1.5 kg (3.3 lb) for sertraline, compared to 1.8 kg (4.0 lb) for placebo [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/56/31626/abstract/62\">",
"       62",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Most studies have evaluated patients suffering from major depressive disorder. It is not clear whether weight change caused by SSRIs differs according to different demographic profiles such as age or sex.",
"   </p>",
"   <p>",
"    A review found that weight gain during treatment with SSRIs may be due to remission of major depression, improved appetite, increased carbohydrate craving, and changes in serotonin 2C receptor activity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/56/31626/abstract/63\">",
"     63",
"    </a>",
"    ]. In addition, weight gain during SSRI treatment is significantly related to poor appetite at the beginning of treatment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/56/31626/abstract/53\">",
"     53",
"    </a>",
"    ]. Additionally, there may be a genetic component involving polymorphisms in the catechol-O-methyltransferase gene [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/56/31626/abstract/64\">",
"     64",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Weight gain due to long-term treatment with SSRIs may lead to diabetes mellitus. A nested case-control study of patients with depression found that use of moderate to high daily doses of SSRIs for periods greater than 24 months was associated with a significant two-fold increased risk of developing diabetes mellitus, compared to not using antidepressants (incidence rate ratio: 2.06, 95% CI 1.20-3.52) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/56/31626/abstract/65\">",
"     65",
"    </a>",
"    ]. Analysis of individual antidepressants found an increased risk estimate for",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?14/50/15146?source=see_link\">",
"     paroxetine",
"    </a>",
"    (incidence rate ratio: 1.33, 95% CI 1.02-1.73), suggesting the possibility that the increased risk for SSRIs might have been primarily due to paroxetine.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12543449\">",
"    <span class=\"h2\">",
"     Bleeding",
"    </span>",
"    &nbsp;&mdash;&nbsp;Based upon observational studies, SSRIs may increase the risk of abnormal bleeding [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/56/31626/abstract/66-68\">",
"     66-68",
"    </a>",
"    ]. Observed complications include stroke, upper gastrointestinal bleeding, and intraoperative bleeding, as well as more minor problems such as easy bruising, petechiae and purpura, epistaxis, and hematomas [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/56/31626/abstract/69-72\">",
"     69-72",
"    </a>",
"    ]. There is no indication that any specific SSRI is more strongly associated with abnormal bleeding. In addition, the risk of bleeding may be amplified in patients who are taking other medications that can cause bleeding, such as nonsteroidal antiinflammatory drugs (eg,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?15/38/15978?source=see_link\">",
"     ibuprofen",
"    </a>",
"    , or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?42/43/43705?source=see_link\">",
"     naproxen",
"    </a>",
"    ) or anticoagulants (eg,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/9/34969?source=see_link\">",
"     clopidogrel",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/56/31626/abstract/68\">",
"     68",
"    </a>",
"    ]. As an example, a retrospective cohort study (N = 27,058) found that the risk of bleeding was significantly increased in patients taking an SSRI plus aspirin compared with aspirin alone, and in patients taking an SSRI, aspirin, plus clopidogrel compared with aspirin plus clopidogrel [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/56/31626/abstract/73\">",
"     73",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Other evidence that shows an association between SSRIs and abnormal bleeding includes the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A meta-analysis of 16 observational studies (N = 506,411) found that the risk of intracranial hemorrhage was elevated in patients who received SSRIs compared to controls who did not (RR 1.72, 95% CI 1.16-2.55); heterogeneity across studies was small to moderate [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/56/31626/abstract/74\">",
"       74",
"      </a>",
"      ]. In a separate analysis, the risk of brain hemorrhage was elevated by the combination of SSRIs and anticoagulants, compared with anticoagulants alone (RR 1.56, 95% CI 1.33-1.83). However, the clinical significance of these findings is not clear; SSRI use was associated with a trend toward a protective effect against subarachnoid hemorrhage (RR 0.62, 95% CI 0.38-1.01). In addition, the absolute risk of any stroke in patients using SSRIs was thought to be very low [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/56/31626/abstract/74,75\">",
"       74,75",
"      </a>",
"      ]; based upon the meta-analysis, it was estimated that SSRIs may lead to one additional intracerebral hemorrhage for every 10,000 patients treated for one year.",
"     </li>",
"     <li>",
"      An observational study found that among 1321 cases of upper gastrointestinal bleeding, 5.3 percent used SSRIs, compared to 3.0 percent of the 10,000 matched controls with no bleeding (adjusted OR 1.6, 95% CI 1.2-2.1) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/56/31626/abstract/67\">",
"       67",
"      </a>",
"      ]. This was consistent with the results of a pooled analysis of 14 heterogeneous observational studies that found SSRIs were associated with an increased risk of bleeding (OR of 1.7, 95% CI 1.4-2.0) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/56/31626/abstract/76\">",
"       76",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The biological plausibility of the association between SSRIs and increased bleeding is supported by the finding that SSRIs can decrease intraplatelet serotonin concentrations, which may affect platelet aggregation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/56/31626/abstract/77,78\">",
"     77,78",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H399780736\">",
"    <span class=\"h2\">",
"     Bone fractures",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many observational studies have found an association between SSRI use and bone fractures, which is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/21/9562?source=see_link&amp;anchor=H17#H17\">",
"     \"Drugs that affect bone metabolism\", section on 'Antidepressants'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1030505\">",
"    <span class=\"h2\">",
"     Issues in breast cancer",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although concerns have been raised that",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?14/50/15146?source=see_link\">",
"     paroxetine",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?14/49/15130?source=see_link\">",
"     fluoxetine",
"    </a>",
"    may interact with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/27/33208?source=see_link\">",
"     tamoxifen",
"    </a>",
"    and interfere with tamoxifen treatment of breast cancer, the clinical significance of the drug-drug interactions is not clear. Nevertheless, we prefer to avoid using CPY2D6 inhibitors with tamoxifen if alternative strategies are available (see",
"    <a class=\"local\" href=\"#H399780619\">",
"     'Drug-drug interactions'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/2/7210?source=see_link&amp;anchor=H6#H6\">",
"     \"Mechanisms of action of selective estrogen receptor modulators\", section on 'Tamoxifen resistance in breast cancer'",
"    </a>",
"    ). &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5th to 6th grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10th to 12th grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?6/21/6483?source=see_link\">",
"       \"Patient information: Reducing the costs of medicines (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?21/24/21894?source=see_link\">",
"       \"Patient information: Depression treatment options for adults (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?19/41/20116?source=see_link\">",
"       \"Patient information: Depression in adults (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?31/61/32726?source=see_link\">",
"       \"Patient information: Reducing the costs of medicines (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The National Institute of Mental Health also has educational material on the use of antidepressants, including SSRIs, entitled, \"What medications are used to treat depression?\" that is available online at the website",
"    <a class=\"external\" href=\"file://www.nimh.nih.gov/health/publications/mental-health-medications/what-medications-are-used-to-treat-depression.shtml\">",
"     file://www.nimh.nih.gov/health/publications/mental-health-medications/what-medications-are-used-to-treat-depression.shtml",
"    </a>",
"    . Material explaining the symptoms, causes, and treatment for depression is also available in a booklet entitled \"Depression\" that is available online at the website",
"    <a class=\"external\" href=\"file://www.nimh.nih.gov/health/publications/depression/index.shtml\">",
"     file://www.nimh.nih.gov/health/publications/depression/index.shtml",
"    </a>",
"    . Both publications can also be obtained through a toll-free number, 866-615-6464. The web site also provides references, summaries of study results in language intended for the lay public, and information about clinical trials currently recruiting patients.",
"   </p>",
"   <p>",
"    The Depression and Bipolar Support Alliance (",
"    <a class=\"external\" href=\"file://www.dbsalliance.org/\">",
"     file://www.dbsalliance.org",
"    </a>",
"    or 800-826-3632) is a national organization whose mission is to educate members about depression and how to cope with it. Other functions include increasing public awareness of the illness and advocating for more research and services. The organization is administered and maintained by patients and family members, and has local chapters.",
"   </p>",
"   <p>",
"    The National Alliance on Mental Illness (",
"    <a class=\"external\" href=\"file://www.nami.org/\">",
"     file://www.nami.org",
"    </a>",
"    or 800-950-6264) is a similarly structured organization devoted to providing education, support, and advocacy for patients with any mental illness. Depression is one of their priorities.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H399779858\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Selective serotonin reuptake inhibitors (SSRIs) are frequently used as first-line antidepressants because of their efficacy, tolerability, and general safety in overdose. The six commonly available SSRIs are",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?12/56/13193?source=see_link\">",
"       citalopram",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?24/56/25481?source=see_link\">",
"       escitalopram",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?14/49/15130?source=see_link\">",
"       fluoxetine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?28/50/29481?source=see_link\">",
"       fluvoxamine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?14/50/15146?source=see_link\">",
"       paroxetine",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?43/3/44089?source=see_link\">",
"       sertraline",
"      </a>",
"      . (See",
"      <a class=\"local\" href=\"#H399779766\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      SSRIs inhibit the serotonin reuptake pump and increase postsynaptic serotonin receptor occupancy. This initial action may cause subsequent changes involved in treating depression. SSRIs are selective in that they have relatively little affinity for other types of receptors. (See",
"      <a class=\"local\" href=\"#H399779781\">",
"       'Pharmacodynamics'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The SSRIs may inhibit hepatic cytochrome P450 enzymes that metabolize other medications and cause drug-drug interactions.",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?12/56/13193?source=see_link\">",
"       Citalopram",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?24/56/25481?source=see_link\">",
"       escitalopram",
"      </a>",
"      inhibit liver enzymes less than other SSRIs and are thus the SSRIs of choice for situations in which drug-drug interactions are a concern. (See",
"      <a class=\"local\" href=\"#H399780619\">",
"       'Drug-drug interactions'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      There is no compelling evidence that one SSRI is more efficacious than another. Although a few analyses have found that",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?24/56/25481?source=see_link\">",
"       escitalopram",
"      </a>",
"      may possibly be more efficacious than",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?12/56/13193?source=see_link\">",
"       citalopram",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?43/3/44089?source=see_link\">",
"       sertraline",
"      </a>",
"      may possibly be more efficacious than",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?14/49/15130?source=see_link\">",
"       fluoxetine",
"      </a>",
"      , there are questions about the clinical significance of the statistically significant differences that were observed. (See",
"      <a class=\"local\" href=\"#H399780634\">",
"       'Comparative efficacy among SSRIs'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The choice of a particular SSRI is based upon cost, individual patient tolerance, and clinician experience, because efficacy appears to be comparable. (See",
"      <a class=\"local\" href=\"#H399780634\">",
"       'Comparative efficacy among SSRIs'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      SSRIs should generally be started at their minimal effective dose:",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?12/56/13193?source=see_link\">",
"       citalopram",
"      </a>",
"      20 mg,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?24/56/25481?source=see_link\">",
"       escitalopram",
"      </a>",
"      10 mg,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?14/49/15130?source=see_link\">",
"       fluoxetine",
"      </a>",
"      20 mg,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?28/50/29481?source=see_link\">",
"       fluvoxamine",
"      </a>",
"      50 mg,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?14/50/15146?source=see_link\">",
"       paroxetine",
"      </a>",
"      20 mg, and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?43/3/44089?source=see_link\">",
"       sertraline",
"      </a>",
"      50 mg. A process of trial and error is used to find the effective dose. Dose adjustments are made according to patient response, tolerability, and clinical urgency. Clinicians should not prescribe citalopram at doses that exceed 40 mg per day because of dose-dependent QT interval prolongation. In addition, the dose should not exceed 20 mg per day in patients with risk factors for increased serum concentrations of citalopram, including hepatic impairment, age &gt;60 years, CYP2C19 variants that slowly metabolize citalopram, and concomitant medications that inhibit CYP2C19. (See",
"      <a class=\"local\" href=\"#H74872026\">",
"       'Dose'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H31651631\">",
"       'Cardiac'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Common SSRI side effects include sexual dysfunction, drowsiness, weight gain, insomnia, anxiety, dizziness, headache, and dry mouth. In addition, observational studies suggest SSRIs may increase the risk of diabetes, abnormal bleeding, and bone loss. (See",
"      <a class=\"local\" href=\"#H399779851\">",
"       'Side effects'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Ehmke, CJ, Nemeroff, CB. Paroxetine. In: The American Psychiatric Publishing Textbook of Psychopharmacology, 4th ed, American Psychiatric Publishing, Inc, Washington, DC 2009. p.321.",
"    </li>",
"    <li>",
"     Aboujaoude, E, Koran, LM. Fluvoxamine. In: The American Psychiatric Publishing Textbook of Psychopharmacology, 4th ed, American Psychiatric Publishing, Inc, Washington, DC 2009. p.353.",
"    </li>",
"    <li>",
"     Roseboom, PH, Kalin, NH. Citalopram and s-cialopram. In: The American Psychiatric Publishing Textbook of Psychopharmacology, 4th ed, American Psychiatric Publishing, Inc, Washington, DC 2009. p.363.",
"    </li>",
"    <li>",
"     Zahajszky, J, Rosenbaum, JF, Tollefson, GD. Fluoxetine. In: American Psychiatric Publishing Textbook of Psychopharmacology, 4th ed, American Psychiatric Publishing, Inc, Washington, DC 2009. p.289.",
"    </li>",
"    <li>",
"     Aghajanian, G. Serotonin. In: Neuropsychopharmacology: The Fifth Generation of Progress: An Official Publication of the American College of Neuropsychopharmacology, Davis, KL, Charney, D, Coyle, JT, Nemeroff, C (Eds), Lippincott Williams &amp; Wilkins, New York 2002. p.15.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/56/31626/abstract/6\">",
"      Preskorn SH. Clinically relevant pharmacology of selective serotonin reuptake inhibitors. An overview with emphasis on pharmacokinetics and effects on oxidative drug metabolism. Clin Pharmacokinet 1997; 32 Suppl 1:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/56/31626/abstract/7\">",
"      Krishnan V, Nestler EJ. The molecular neurobiology of depression. Nature 2008; 455:894.",
"     </a>",
"    </li>",
"    <li>",
"     Labbate, LA, Fava, M, Rosenbaum, JF, et, al. Drugs for the treatment of depression. In: Handbook of Psychiatric Drug Therapy, 6th ed, Lippincott Williams &amp; Wilkins, Philadelphia, PA 2010. p.54.",
"    </li>",
"    <li>",
"     MedicinesComplete [Internet database]. Pharmaceutical Press, London, 2010 file://www.medicinescomplete.com (Accessed on September 28, 2010).",
"    </li>",
"    <li>",
"     DRUGDEX&reg; System [Internet database]. Greenwood Village, CO, Thomson Reuters (Healthcare) Inc, 2002-2010. (Accessed September 28, 2010).",
"    </li>",
"    <li>",
"     Wynn, GH, Sandson, N, Muniz, J. Psychiatry. In: Clinical Manual of Drug Interaction Principles for Medical Practice, Wynn, GH, Oesterheld, JR, Cozza, KL, Armstrong, SC (Eds), American Psychiatric Publishing, Inc, Washington, D.C. 2009. p.423.",
"    </li>",
"    <li>",
"     Treatment Guidelines from The Medical Letter. The Medical Letter, Volume 8, (Issue 93), May, 2010, p. 35.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/56/31626/abstract/13\">",
"      Desmarais JE, Looper KJ. Interactions between tamoxifen and antidepressants via cytochrome P450 2D6. J Clin Psychiatry 2009; 70:1688.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/56/31626/abstract/14\">",
"      Kennedy SH, Andersen HF, Thase ME. Escitalopram in the treatment of major depressive disorder: a meta-analysis. Curr Med Res Opin 2009; 25:161.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/56/31626/abstract/15\">",
"      Cipriani A, Santilli C, Furukawa TA, et al. Escitalopram versus other antidepressive agents for depression. Cochrane Database Syst Rev 2009; :CD006532.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/56/31626/abstract/16\">",
"      Cipriani A, La Ferla T, Furukawa TA, et al. Sertraline versus other antidepressive agents for depression. Cochrane Database Syst Rev 2010; :CD006117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/56/31626/abstract/17\">",
"      Cipriani A, Furukawa TA, Salanti G, et al. Comparative efficacy and acceptability of 12 new-generation antidepressants: a multiple-treatments meta-analysis. Lancet 2009; 373:746.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/56/31626/abstract/18\">",
"      Omori IM, Watanabe N, Nakagawa A, et al. Fluvoxamine versus other anti-depressive agents for depression. Cochrane Database Syst Rev 2010; :CD006114.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/56/31626/abstract/19\">",
"      Cipriani A, Purgato M, Furukawa TA, et al. Citalopram versus other anti-depressive agents for depression. Cochrane Database Syst Rev 2012; 7:CD006534.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/56/31626/abstract/20\">",
"      Qaseem A, Snow V, Denberg TD, et al. Using second-generation antidepressants to treat depressive disorders: a clinical practice guideline from the American College of Physicians. Ann Intern Med 2008; 149:725.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/56/31626/abstract/21\">",
"      Gartlehner G, Gaynes BN. Are all antidepressants equal? Evid Based Ment Health 2009; 12:98.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/56/31626/abstract/22\">",
"      Gartlehner G, Gaynes BN, Hansen RA, et al. Comparative benefits and harms of second-generation antidepressants: background paper for the American College of Physicians. Ann Intern Med 2008; 149:734.",
"     </a>",
"    </li>",
"    <li>",
"     Gartlehner, G, Hansen, RA, Thieda, P et al. Comparative Effectiveness of Second-Generation Antidepressants in the Pharmacologic Treatment of Adults Depression. Comparative Effectiveness Review No. 7-EHC007-EF. Rockville, MD: Agency for Healthcare Research and Quality, 2007. www.effectivehealthcare.ahrq.gov/reports/final.cfm (Accessed on October 04, 2010).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/56/31626/abstract/24\">",
"      Rasmussen BB, Br&oslash;sen K. Is therapeutic drug monitoring a case for optimizing clinical outcome and avoiding interactions of the selective serotonin reuptake inhibitors? Ther Drug Monit 2000; 22:143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/56/31626/abstract/25\">",
"      Baumann P, Hiemke C, Ulrich S, et al. The AGNP-TDM expert group consensus guidelines: therapeutic drug monitoring in psychiatry. Pharmacopsychiatry 2004; 37:243.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/56/31626/abstract/26\">",
"      Taylor MJ, Freemantle N, Geddes JR, Bhagwagar Z. Early onset of selective serotonin reuptake inhibitor antidepressant action: systematic review and meta-analysis. Arch Gen Psychiatry 2006; 63:1217.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/56/31626/abstract/27\">",
"      Nierenberg AA, Farabaugh AH, Alpert JE, et al. Timing of onset of antidepressant response with fluoxetine treatment. Am J Psychiatry 2000; 157:1423.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/56/31626/abstract/28\">",
"      Trivedi MH, Rush AJ, Wisniewski SR, et al. Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice. Am J Psychiatry 2006; 163:28.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/56/31626/abstract/29\">",
"      Frank E, Kupfer DJ, Perel JM, et al. Comparison of full-dose versus half-dose pharmacotherapy in the maintenance treatment of recurrent depression. J Affect Disord 1993; 27:139.",
"     </a>",
"    </li>",
"    <li>",
"     FDA Drug Safety Communication: Abnormal heart rhythms associated with high doses of Celexa (citalopram hydrobromide). file://www.fda.gov/Drugs/DrugSafety/ucm269086.htm (Accessed on August 25, 2011).",
"    </li>",
"    <li>",
"     FDA Drug Safety Communication: Revised recommendations for Celexa (citalopram hydrobromide) related to a potential risk of abnormal heart rhythms with high doses file://www.fda.gov/Drugs/DrugSafety/ucm297391.htm (Accessed on March 28, 2012).",
"    </li>",
"    <li>",
"     Block, DR, Yonkers, KA, Carpenter, LL. Sertraline. In: The American Psychiatric Publishing Textbook of Psychopharmacology, 4th, Schatzberg, AF, Nemeroff, CB (Eds), American Psychiatric Publishing, Inc, Washington, D.C. 2009. p.307.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/56/31626/abstract/33\">",
"      Nierenberg AA, Ostacher MJ, Huffman JC, et al. A brief review of antidepressant efficacy, effectiveness, indications, and usage for major depressive disorder. J Occup Environ Med 2008; 50:428.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/56/31626/abstract/34\">",
"      Hu XH, Bull SA, Hunkeler EM, et al. Incidence and duration of side effects and those rated as bothersome with selective serotonin reuptake inhibitor treatment for depression: patient report versus physician estimate. J Clin Psychiatry 2004; 65:959.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/56/31626/abstract/35\">",
"      Jimenez-Jimenez, FJ, Molina, JA. Extrapyramidal symptoms associated with selective serotonin reuptake inhibitors. CNS Drugs 2000; 14:367.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/56/31626/abstract/36\">",
"      Gerber PE, Lynd LD. Selective serotonin-reuptake inhibitor-induced movement disorders. Ann Pharmacother 1998; 32:692.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/56/31626/abstract/37\">",
"      Ak M, Gulsun M, Uzun O, Gumus HO. Bruxism associated with serotonin reuptake inhibitors: two cases. J Clin Psychopharmacol 2009; 29:620.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/56/31626/abstract/38\">",
"      Leon AC. The revised warning for antidepressants and suicidality: unveiling the black box of statistical analyses. Am J Psychiatry 2007; 164:1786.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/56/31626/abstract/39\">",
"      Friedman RA, Leon AC. Expanding the black box - depression, antidepressants, and the risk of suicide. N Engl J Med 2007; 356:2343.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/56/31626/abstract/40\">",
"      Castro VM, Clements CC, Murphy SN, et al. QT interval and antidepressant use: a cross sectional study of electronic health records. BMJ 2013; 346:f288.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/56/31626/abstract/41\">",
"      Vieweg WV, Hasnain M, Howland RH, et al. Citalopram, QTc interval prolongation, and torsade de pointes. How should we apply the recent FDA ruling? Am J Med 2012; 125:859.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/56/31626/abstract/42\">",
"      Barbey JT, Roose SP. SSRI safety in overdose. J Clin Psychiatry 1998; 59 Suppl 15:42.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/56/31626/abstract/43\">",
"      Graudins A, Dowsett RP, Liddle C. The toxicity of antidepressant poisoning: is it changing? A comparative study of cyclic and newer serotonin-specific antidepressants. Emerg Med (Fremantle) 2002; 14:440.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/56/31626/abstract/44\">",
"      Mason J, Freemantle N, Eccles M. Fatal toxicity associated with antidepressant use in primary care. Br J Gen Pract 2000; 50:366.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/56/31626/abstract/45\">",
"      Muzyk AJ, Jakel RJ, Preud'homme X. Serotonin syndrome after a massive overdose of controlled-release paroxetine. Psychosomatics 2010; 51:437.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/56/31626/abstract/46\">",
"      Clayton AH. Recognition and assessment of sexual dysfunction associated with depression. J Clin Psychiatry 2001; 62 Suppl 3:5.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/56/31626/abstract/47\">",
"      Perlis RH, Laje G, Smoller JW, et al. Genetic and clinical predictors of sexual dysfunction in citalopram-treated depressed patients. Neuropsychopharmacology 2009; 34:1819.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/56/31626/abstract/48\">",
"      Clayton AH, Pradko JF, Croft HA, et al. Prevalence of sexual dysfunction among newer antidepressants. J Clin Psychiatry 2002; 63:357.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/56/31626/abstract/49\">",
"      Ferguson JM. The effects of antidepressants on sexual functioning in depressed patients: a review. J Clin Psychiatry 2001; 62 Suppl 3:22.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/56/31626/abstract/50\">",
"      Montejo AL, Llorca G, Izquierdo JA, Rico-Villademoros F. Incidence of sexual dysfunction associated with antidepressant agents: a prospective multicenter study of 1022 outpatients. Spanish Working Group for the Study of Psychotropic-Related Sexual Dysfunction. J Clin Psychiatry 2001; 62 Suppl 3:10.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/56/31626/abstract/51\">",
"      Tanrikut C, Feldman AS, Altemus M, et al. Adverse effect of paroxetine on sperm. Fertil Steril 2010; 94:1021.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/56/31626/abstract/52\">",
"      Maina G, Albert U, Salvi V, Bogetto F. Weight gain during long-term treatment of obsessive-compulsive disorder: a prospective comparison between serotonin reuptake inhibitors. J Clin Psychiatry 2004; 65:1365.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/56/31626/abstract/53\">",
"      Michelson D, Amsterdam JD, Quitkin FM, et al. Changes in weight during a 1-year trial of fluoxetine. Am J Psychiatry 1999; 156:1170.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/56/31626/abstract/54\">",
"      Croft H, Settle E Jr, Houser T, et al. A placebo-controlled comparison of the antidepressant efficacy and effects on sexual functioning of sustained-release bupropion and sertraline. Clin Ther 1999; 21:643.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/56/31626/abstract/55\">",
"      Uher R, Farmer A, Henigsberg N, et al. Adverse reactions to antidepressants. Br J Psychiatry 2009; 195:202.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/56/31626/abstract/56\">",
"      de Jonghe F, Ravelli DP, Tuynman-Qua H. A randomized, double-blind study of fluoxetine and maprotiline in the treatment of major depression. Pharmacopsychiatry 1991; 24:62.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/56/31626/abstract/57\">",
"      Wade A, Michael Lemming O, Bang Hedegaard K. Escitalopram 10 mg/day is effective and well tolerated in a placebo-controlled study in depression in primary care. Int Clin Psychopharmacol 2002; 17:95.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/56/31626/abstract/58\">",
"      Lepola UM, Loft H, Reines EH. Escitalopram (10-20 mg/day) is effective and well tolerated in a placebo-controlled study in depression in primary care. Int Clin Psychopharmacol 2003; 18:211.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/56/31626/abstract/59\">",
"      Fava M, Judge R, Hoog SL, et al. Fluoxetine versus sertraline and paroxetine in major depressive disorder: changes in weight with long-term treatment. J Clin Psychiatry 2000; 61:863.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/56/31626/abstract/60\">",
"      Hochstrasser B, Isaksen PM, Koponen H, et al. Prophylactic effect of citalopram in unipolar, recurrent depression: placebo-controlled study of maintenance therapy. Br J Psychiatry 2001; 178:304.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/56/31626/abstract/61\">",
"      Lecrubier Y, Judge R. Long-term evaluation of paroxetine, clomipramine and placebo in panic disorder. Collaborative Paroxetine Panic Study Investigators. Acta Psychiatr Scand 1997; 95:153.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/56/31626/abstract/62\">",
"      Doogan DP, Caillard V. Sertraline in the prevention of depression. Br J Psychiatry 1992; 160:217.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/56/31626/abstract/63\">",
"      Fava M. Weight gain and antidepressants. J Clin Psychiatry 2000; 61 Suppl 11:37.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/56/31626/abstract/64\">",
"      Secher A, Bukh J, Bock C, et al. Antidepressive-drug-induced bodyweight gain is associated with polymorphisms in genes coding for COMT and TPH1. Int Clin Psychopharmacol 2009; 24:199.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/56/31626/abstract/65\">",
"      Andersohn F, Schade R, Suissa S, Garbe E. Long-term use of antidepressants for depressive disorders and the risk of diabetes mellitus. Am J Psychiatry 2009; 166:591.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/56/31626/abstract/66\">",
"      de Abajo FJ, Rodr&iacute;guez LA, Montero D. Association between selective serotonin reuptake inhibitors and upper gastrointestinal bleeding: population based case-control study. BMJ 1999; 319:1106.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/56/31626/abstract/67\">",
"      de Abajo FJ, Garc&iacute;a-Rodr&iacute;guez LA. Risk of upper gastrointestinal tract bleeding associated with selective serotonin reuptake inhibitors and venlafaxine therapy: interaction with nonsteroidal anti-inflammatory drugs and effect of acid-suppressing agents. Arch Gen Psychiatry 2008; 65:795.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/56/31626/abstract/68\">",
"      Schalekamp T, Klungel OH, Souverein PC, de Boer A. Increased bleeding risk with concurrent use of selective serotonin reuptake inhibitors and coumarins. Arch Intern Med 2008; 168:180.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/56/31626/abstract/69\">",
"      Serebruany VL. Selective serotonin reuptake inhibitors and increased bleeding risk: are we missing something? Am J Med 2006; 119:113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/56/31626/abstract/70\">",
"      Krasowska D, Szymanek M, Schwartz RA, My��li��ski W. Cutaneous effects of the most commonly used antidepressant medication, the selective serotonin reuptake inhibitors. J Am Acad Dermatol 2007; 56:848.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/56/31626/abstract/71\">",
"      Opatrny L, Delaney JA, Suissa S. Gastro-intestinal haemorrhage risks of selective serotonin receptor antagonist therapy: a new look. Br J Clin Pharmacol 2008; 66:76.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/56/31626/abstract/72\">",
"      Movig KL, Janssen MW, de Waal Malefijt J, et al. Relationship of serotonergic antidepressants and need for blood transfusion in orthopedic surgical patients. Arch Intern Med 2003; 163:2354.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/56/31626/abstract/73\">",
"      Labos C, Dasgupta K, Nedjar H, et al. Risk of bleeding associated with combined use of selective serotonin reuptake inhibitors and antiplatelet therapy following acute myocardial infarction. CMAJ 2011; 183:1835.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/56/31626/abstract/74\">",
"      Hackam DG, Mrkobrada M. Selective serotonin reuptake inhibitors and brain hemorrhage: a meta-analysis. Neurology 2012; 79:1862.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/56/31626/abstract/75\">",
"      McGrath ER, O'Donnell MJ. Estimating treatment effects in observational studies. Neurology 2012; 79:1844.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/56/31626/abstract/76\">",
"      de Abajo FJ. Effects of selective serotonin reuptake inhibitors on platelet function: mechanisms, clinical outcomes and implications for use in elderly patients. Drugs Aging 2011; 28:345.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/56/31626/abstract/77\">",
"      Li N, Wall&eacute;n NH, Ladjevardi M, Hjemdahl P. Effects of serotonin on platelet activation in whole blood. Blood Coagul Fibrinolysis 1997; 8:517.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/56/31626/abstract/78\">",
"      Hergovich N, Aigner M, Eichler HG, et al. Paroxetine decreases platelet serotonin storage and platelet function in human beings. Clin Pharmacol Ther 2000; 68:435.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 14675 Version 24.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1005-83.177.194.223-A277839E2F-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_56_31626=[""].join("\n");
var outline_f30_56_31626=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H399779858\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H399779766\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14787857\">",
"      PHARMACOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25328730\">",
"      Structure",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H25328749\">",
"      - Citalopram and escitalopram",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H399779781\">",
"      Pharmacodynamics",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H399779788\">",
"      Pharmacokinetics",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H399780619\">",
"      Drug-drug interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H399780634\">",
"      COMPARATIVE EFFICACY AMONG SSRIs",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H399779802\">",
"      PRESCRIBING SSRIs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H399780656\">",
"      General principles",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H504526\">",
"      - Guidelines to review with patients",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14789327\">",
"      - Medical tests and plasma levels",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H399780663\">",
"      - Response time",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14788308\">",
"      - Pregnancy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H504779\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H74872026\">",
"      Dose",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7700689\">",
"      - Citalopram",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7700696\">",
"      - Escitalopram",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H399781192\">",
"      - Fluoxetine",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7700832\">",
"      - Fluvoxamine",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H399779823\">",
"      - Paroxetine",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7700895\">",
"      - Sertraline",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H399779851\">",
"      SIDE EFFECTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H399780694\">",
"      Overview",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H399780701\">",
"      Suicide risk",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H31651631\">",
"      Cardiac",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H367753\">",
"      Overdose",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H516881\">",
"      Serotonin syndrome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H399780708\">",
"      Sexual dysfunction and infertility",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H399780715\">",
"      Weight change",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12543449\">",
"      Bleeding",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H399780736\">",
"      Bone fractures",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1030505\">",
"      Issues in breast cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H399779858\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PSYCH/14675\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PSYCH/14675|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?37/46/38639\" title=\"table 1\">",
"      Side effects antidepressants",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?42/19/43324\" title=\"table 2\">",
"      Serotonin syndrome drugs",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/55/23418?source=related_link\">",
"      Acquired long QT syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/33/26135?source=related_link\">",
"      Antidepressant medication in adults: Switching and discontinuing medication",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/0/28682?source=related_link\">",
"      Depression in pregnant women: Management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?9/21/9562?source=related_link\">",
"      Drugs that affect bone metabolism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/48/43783?source=related_link\">",
"      Effect of antidepressants on suicide risk in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/23/15736?source=related_link\">",
"      Effect of antidepressants on suicide risk in children and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/8/40074?source=related_link\">",
"      Initial treatment of depression in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?7/2/7210?source=related_link\">",
"      Mechanisms of action of selective estrogen receptor modulators",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?7/25/7574?source=related_link\">",
"      Monoamine oxidase inhibitors (MAOIs) for treating depressed adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?19/41/20116?source=related_link\">",
"      Patient information: Depression in adults (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?21/24/21894?source=related_link\">",
"      Patient information: Depression treatment options for adults (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?31/61/32726?source=related_link\">",
"      Patient information: Reducing the costs of medicines (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?6/21/6483?source=related_link\">",
"      Patient information: Reducing the costs of medicines (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?11/26/11690?source=related_link\">",
"      Selective serotonin reuptake inhibitor poisoning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/63/16376?source=related_link\">",
"      Serotonin syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?5/28/5578?source=related_link\">",
"      Serotonin-norepinephrine reuptake inhibitors (SNRIs): Pharmacology, administration, and side effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?1/63/2039?source=related_link\">",
"      Sexual dysfunction associated with selective serotonin reuptake inhibitor (SSRI) antidepressants",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/8/10377?source=related_link\">",
"      Suicidal ideation and behavior in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/61/27609?source=related_link\">",
"      Treatment of resistant depression in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/20/36169?source=related_link\">",
"      Unipolar depression in adults and tricyclic and tetracyclic drugs: Pharmacology, administration, and side effects",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f30_56_31627="Risk of recurrent systemic reaction after VIT";
var content_f30_56_31627=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ALLRG%2F66059&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ALLRG%2F66059&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Risk of recurrent systemic allergic reaction after stopping venom immunotherapy",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Elevated in:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Adults compared to children",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Patients allergic to honey bee venom compared to those with vespid venom allergy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Patients with severe pretreatment systemic allergic reactions (SARs)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Patients with SARs during VIT to treatment injections or re-stings",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        VIT duration less than three years, compared with five or more years",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Elevated baseline serum tryptase",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Mastocytosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Persistent high sensitivity on intradermal skin testing or in vitro testing for venom-specific IgE",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Not influenced by:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Sex",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Atopy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Venom-specific IgG level at discontinuation of VIT",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Diminished if:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Skin tests and venom-specific IgE negative at discontinuation of VIT",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     SAR: systemic allergic reaction; VIT: venom immunotherapy.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_56_31627=[""].join("\n");
var outline_f30_56_31627=null;
var title_f30_56_31628="Therapies for acromegaly";
var content_f30_56_31628=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F55079&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=9\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F55079&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=9\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Comparison of treatments for acromegaly",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1\" colspan=\"1\" rowspan=\"2\">",
"       &nbsp;",
"      </td>",
"      <td class=\"subtitle1\" colspan=\"2\" rowspan=\"1\">",
"       Surgery",
"      </td>",
"      <td class=\"subtitle1\" colspan=\"1\" rowspan=\"2\">",
"       Radiotherapy",
"      </td>",
"      <td class=\"subtitle1\" colspan=\"1\" rowspan=\"2\">",
"       Octreotide, lanreotide",
"      </td>",
"      <td class=\"subtitle1\" colspan=\"1\" rowspan=\"2\">",
"       Cabergoline",
"      </td>",
"      <td class=\"subtitle1\" colspan=\"1\" rowspan=\"2\">",
"       Pegvisomant",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2\">",
"       Microadenoma",
"      </td>",
"      <td class=\"subtitle2\" colspan=\"1\">",
"       Macroadenoma",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Normal IGF-1",
"      </td>",
"      <td>",
"       80-90 percent",
"      </td>",
"      <td>",
"       40 percent",
"      </td>",
"      <td>",
"       50 percent at 10 yrs",
"      </td>",
"      <td>",
"       50 percent",
"      </td>",
"      <td>",
"       40 percent",
"      </td>",
"      <td>",
"       95 percent",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Adenoma shrinkage",
"      </td>",
"      <td>",
"       95 percent",
"      </td>",
"      <td>",
"       70 percent",
"      </td>",
"      <td>",
"       95 percent",
"      </td>",
"      <td>",
"       50 percent",
"      </td>",
"      <td>",
"       No data",
"      </td>",
"      <td>",
"       Not expected",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Advantages",
"      </td>",
"      <td>",
"       Potential cure reduction",
"      </td>",
"      <td>",
"       Rapid size reduction",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       Oral administration",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Disadvantages",
"      </td>",
"      <td>",
"       <p>",
"        Recurrence:",
"       </p>",
"       <p>",
"        5-10 percent",
"       </p>",
"      </td>",
"      <td>",
"       Regrowth of adenoma",
"      </td>",
"      <td>",
"       Slow",
"      </td>",
"      <td>",
"       Injection",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       Injection",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1_start\" colspan=\"7\" rowspan=\"1\">",
"       Complications",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       Hypopituitarism",
"      </td>",
"      <td class=\"sublist_other\">",
"       Rare",
"      </td>",
"      <td class=\"sublist_other\">",
"       15 percent",
"      </td>",
"      <td class=\"sublist_other\">",
"       50 percent at 10 yrs",
"      </td>",
"      <td class=\"sublist_other\">",
"       None",
"      </td>",
"      <td class=\"sublist_other\">",
"       None",
"      </td>",
"      <td class=\"sublist_other\">",
"       None",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       Other",
"      </td>",
"      <td class=\"sublist_other\">",
"       Diabetes insipidus, 5 percent",
"      </td>",
"      <td class=\"sublist_other\">",
"       Diabetes insipidus, 10 percent",
"      </td>",
"      <td class=\"sublist_other\">",
"       Neurological deficits",
"      </td>",
"      <td class=\"sublist_other\">",
"       GI symptoms, gallstones",
"      </td>",
"      <td class=\"sublist_other\">",
"       Nausea, lassitude",
"      </td>",
"      <td class=\"sublist_other\">",
"       Elevated liver enzymes",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    A summary of the advantages, disadvantages, and complications of different treatments of acromegaly.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_56_31628=[""].join("\n");
var outline_f30_56_31628=null;
var title_f30_56_31629="ETT HR recovery prognosis";
var content_f30_56_31629=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F57524&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F57524&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Heart rate recovery after exercise predicts mortality",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 430px; height: 292px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    In a study of 2428 patients without known heart disease, an abnormal value for the recovery of heart rate, defined as a reduction of &le;12 beats per minute (bpm) from the heart rate at peak exercise, was associated with an increased risk of death. Circles represent the relative risk of death for each of the quintiles as compared with the fifth quintile which had the lowest risk of death; red lines represent the 95 percent confidence interval.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Cole CR, Blackstone EH, Pashkow FJ, et al. N Engl J Med 1999; 341:1351",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_56_31629=[""].join("\n");
var outline_f30_56_31629=null;
var title_f30_56_31630="Benign gastric ulcer UGI";
var content_f30_56_31630=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F76712&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F76712&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Acute gastric ulcer",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 309px; height: 252px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This image from an upper GI series demonstrates a small ulcer crater (arrow) with smooth folds radiating into the center of the ulcer. This feature suggests benignity, which was confirmed by biopsy. The patient responded to conventional antiulcer therapy.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Jonathan Kruskal, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_56_31630=[""].join("\n");
var outline_f30_56_31630=null;
var title_f30_56_31631="Port sites for vaginal hysterectomy";
var content_f30_56_31631=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F58323&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F58323&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Port sites for vaginal hysterectomy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 378px; height: 504px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     5: 5mm trocar; 12: 12mm trocar.",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Thomas Lyons, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_56_31631=[""].join("\n");
var outline_f30_56_31631=null;
